SMILES,Conditions,Name,NCT_Number,Phases,Status,Gender,Age,Funded Bys,Study Designs,Locations,Patent_id,CPC,Gender_code_0,Gender_code_1,Gender_code_2,Gender_code_3,Age_code_0,Age_code_1,Age_code_2,Age_code_3,Age_code_4,Age_code_5,Allocation_Type_0,Allocation_Type_1,Allocation_Type_2,Allocation_Type_3,Intervention_Model_0,Intervention_Model_1,Intervention_Model_2,Intervention_Model_3,Intervention_Model_4,Intervention_Model_5,Country_0,Country_1,Country_2,Country_3,Country_4,Country_5,Funder_Type_0,Funder_Type_1,Funder_Type_2,Funder_Type_3,Funder_Type_4,Funder_Type_5,claims_#,Duration,Patent_#,PCT_code_0,PCT_code_1,CPC_code_0,CPC_code_2,CPC_code_3,CPC_code_4,CPC_code_5,PCT_code_2,CPC_code_1,logP,MW,PSA,HBA,HBD,Rings,Polarizability,Refractivity,Bond_#,Bioavailability_0,Bioavailability_1,Bioavailability_2,ECFP4.1,ECFP4.2,ECFP4.3,ECFP4.4,ECFP4.5,ECFP4.6,ECFP4.7,ECFP4.8,ECFP4.9,ECFP4.10,ECFP4.11,ECFP4.12,ECFP4.13,ECFP4.14,ECFP4.15,ECFP4.16,ECFP4.17,ECFP4.18,ECFP4.19,ECFP4.20,ECFP4.21,ECFP4.22,ECFP4.23,ECFP4.24,ECFP4.25,ECFP4.26,ECFP4.27,ECFP4.28,ECFP4.29,ECFP4.30,ECFP4.31,ECFP4.32,ECFP4.33,ECFP4.34,ECFP4.35,ECFP4.36,ECFP4.37,ECFP4.38,ECFP4.39,ECFP4.40,ECFP4.41,ECFP4.42,ECFP4.43,ECFP4.44,ECFP4.45,ECFP4.46,ECFP4.47,ECFP4.48,ECFP4.49,ECFP4.50,ECFP4.51,ECFP4.52,ECFP4.53,ECFP4.54,ECFP4.55,ECFP4.56,ECFP4.57,ECFP4.58,ECFP4.59,ECFP4.60,ECFP4.61,ECFP4.62,ECFP4.63,ECFP4.64,ECFP4.65,ECFP4.66,ECFP4.67,ECFP4.68,ECFP4.69,ECFP4.70,ECFP4.71,ECFP4.72,ECFP4.73,ECFP4.74,ECFP4.75,ECFP4.76,ECFP4.77,ECFP4.78,ECFP4.79,ECFP4.80,ECFP4.81,ECFP4.82,ECFP4.83,ECFP4.84,ECFP4.85,ECFP4.86,ECFP4.87,ECFP4.88,ECFP4.89,ECFP4.90,ECFP4.91,ECFP4.92,ECFP4.93,ECFP4.94,ECFP4.95,ECFP4.96,ECFP4.97,ECFP4.98,ECFP4.99,ECFP4.100,ECFP4.101,ECFP4.102,ECFP4.103,ECFP4.104,ECFP4.105,ECFP4.106,ECFP4.107,ECFP4.108,ECFP4.109,ECFP4.110,ECFP4.111,ECFP4.112,ECFP4.113,ECFP4.114,ECFP4.115,ECFP4.116,ECFP4.117,ECFP4.118,ECFP4.119,ECFP4.120,ECFP4.121,ECFP4.122,ECFP4.123,ECFP4.124,ECFP4.125,ECFP4.126,ECFP4.127,ECFP4.128
CC(=O)[O-],BURN,_ACETATE,NCT01413620,Phase 1,Recruiting,All,"6 Months to 85 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Shriners Hospitals for Children, Galveston, Texas, United States",,,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O,BREAST NEOPLASM,_GOSERELIN,NCT01723774,Phase 2,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama, Birmingham, Alabama, United States|Mayo Clinic - Scottsdale, Scottsdale, Arizona, United States|Mayo Clinic - Rochester, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Baylor College of Medicine, Houston, Texas, United States",7118552.0,A61M5/326,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,20.0,67.8453356331752,776.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.3,1269.4105,495.89,18.0,17.0,6.0,131.22,325.84,33.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0
C[C@]12CC[C@@H]3c4ccc(O)cc4C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@H]3[C@@H]1CC[C@@H]2O,NEOPLASMS,_FULVESTRANT,NCT02530411,Phase 2,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Royal Bournemouth Hospital, Bournemouth, Dorset, United Kingdom|Royal Devon and Exeter Hospital, Exeter, England, United Kingdom|Royal Cornwall Hospital, Truro, Cornwall, England, United Kingdom|Velindre Cancer Center, Velindre Hospital, Cardiff, Wales, United Kingdom|Royal United Hospital Bath, Bath, United Kingdom",6774122,5,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,0.0,1.0,0.0,0.0,9.0,43.007043265775394,1402.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.54,606.78,57.53,3.0,2.0,4.0,65.88,155.34,15.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1,NEOPLASMS,_VANDETANIB,NCT02530411,Phase 2,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Royal Bournemouth Hospital, Bournemouth, Dorset, United Kingdom|Royal Devon and Exeter Hospital, Exeter, England, United Kingdom|Royal Cornwall Hospital, Truro, Cornwall, England, United Kingdom|Velindre Cancer Center, Velindre Hospital, Cardiff, Wales, United Kingdom|Royal United Hospital Bath, Bath, United Kingdom",RE42353,C07D401/12,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,0.0,1.0,0.0,0.0,18.0,163.518758085381,548.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.01,475.35400000000004,59.51,6.0,1.0,4.0,47.1,118.63,6.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,SYSTEMIC LUPUS ERYTHEMATOSUS,_PREDNISONE,NCT03492255,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Rheumatology Division of Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, Sao Paulo, Brazil|Hospital das Clinicas da Faculdade de Medicina da USP, São Paulo, Brazil",6488960,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
O=P1(N(CCCl)CCCl)NCCCO1,SYSTEMIC LUPUS ERYTHEMATOSUS,_CYCLOPHOSPHAMIDE,NCT03492255,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Rheumatology Division of Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, Sao Paulo, Brazil|Hospital das Clinicas da Faculdade de Medicina da USP, São Paulo, Brazil",3987166,7,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,SYSTEMIC LUPUS ERYTHEMATOSUS,_METHYLPREDNISOLONE,NCT03492255,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Rheumatology Division of Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, Sao Paulo, Brazil|Hospital das Clinicas da Faculdade de Medicina da USP, São Paulo, Brazil",3962414,A61F9/0017,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,SYSTEMIC LUPUS ERYTHEMATOSUS,_MYCOPHENOLATE_MOFETIL,NCT03492255,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Rheumatology Division of Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, Sao Paulo, Brazil|Hospital das Clinicas da Faculdade de Medicina da USP, São Paulo, Brazil",5543408,C07D307/88,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,20.041479291155802,259.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.17,433.4947,94.53,6.0,1.0,3.0,45.54,117.1,10.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,SOFT TISSUE SARCOMA,_DOCETAXEL,NCT03449901,Phase 2,Recruiting,All,"10 Years and older   (Child, Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford Medicine, Palo Alto, California, United States|Sarcoma Oncology Center, Santa Monica, California, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Columbia University Medical Center, New York, New York, United States",4814470,C07D305/14,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,6.0,20.238608595659002,3874.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.59,807.8792,224.45,10.0,5.0,6.0,82.15,203.9,13.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,SOFT TISSUE SARCOMA,_GEMCITABINE,NCT03449901,Phase 2,Recruiting,All,"10 Years and older   (Child, Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford Medicine, Palo Alto, California, United States|Sarcoma Oncology Center, Santa Monica, California, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Columbia University Medical Center, New York, New York, United States",4808614.0,C07D317/30,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,14.0,20.8628513932524,1700.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.14,263.1981,108.38,6.0,3.0,2.0,21.45,53.25,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
N=C(N)NCCC[C@H](N)C(=O)O,SOFT TISSUE SARCOMA,_ARGININE,NCT03449901,Phase 2,Recruiting,All,"10 Years and older   (Child, Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford Medicine, Palo Alto, California, United States|Sarcoma Oncology Center, Santa Monica, California, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Columbia University Medical Center, New York, New York, United States",4271152.0,C07K14/672,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,10.0,15.376085751247402,163.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-3.5,174.201,125.22,6.0,5.0,0.0,17.8,53.92,5.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,BREAST CANCER,_NIRAPARIB,NCT02826512,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Antoni van Leeuwenhoek, Amsterdam, Netherlands|Deventer ziekenhuis, Deventer, Netherlands|Erasmus Medical Center Cancer Institute, Rotterdam, Netherlands",8859562,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,1.0,122.71299205322399,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.45,320.39599999999996,72.94,3.0,2.0,4.0,36.41,94.92,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,BREAST CANCER,_ENZALUTAMIDE,NCT02955394,Phase 2,Recruiting,Female,"18 Years to 101 Years   (Adult, Older Adult)",Other|U.S. Fed,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Colorado, Aurora, Colorado, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|West Cancer Center, Germantown, Tennessee, United States",7709517,C07D233/70,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,13.0,47.6395819216,3.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.75,464.436,76.44,3.0,1.0,3.0,42.71,113.48,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,BREAST CANCER,_METHOTREXATE,NCT02897700,Phase 1,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ganzhou City People's Hospital, Ganzhou, Jiangxi, China|China-Japan Union Hospital, Jilin University, Changchun, Jilin, China|Shanghai 10th People's Hospital, Tongji University School of Medicine, Shanghai, China",6746429,A61M5/2425,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
O=c1[nH]cc(F)c(=O)[nH]1,BREAST CANCER,_FLUOROURACIL,NCT02897700,Phase 1,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ganzhou City People's Hospital, Ganzhou, Jiangxi, China|China-Japan Union Hospital, Jilin University, Changchun, Jilin, China|Shanghai 10th People's Hospital, Tongji University School of Medicine, Shanghai, China",6670335,A61K8/06,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,20.0,33.8405306063779,2.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.58,130.0772,58.2,2.0,2.0,1.0,9.46,26.17,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,LYMPHEDEMA,_TACROLIMUS,NCT04390685,Phase 1|Phase 2,Recruiting,Female,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Sydvestjysk Sygehus, Esbjerg, Denmark|Department of Plastic and Reconstructive Surgery, Odense, Denmark|Sygehus Lillebælt Vejle, Vejle, Denmark",5260301,4,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0
CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1,BREAST NEOPLASM,_RIBOCICLIB,NCT03283384,Phase 2,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, Netherlands|Ziekenhuisgroep Twente, Almelo, Netherlands|Ziekenhuis Amstelland, Amstelveen, Netherlands|Nederlands Kanker Instituut - Antoni van Leeuwenhoek, Amsterdam, Netherlands|Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands|Gelre Ziekenhuizen, Apeldoorn, Netherlands|Amphia Ziekenhuis, Breda, Netherlands|Stichting Reinier Haga Groep (Reinier de Graaf Gasthuis), Delft, Netherlands|Haaglanden Medisch Centrum, Den Haag, Netherlands|HAGA Ziekenhuis, Den Haag, Netherlands|Stichting Deventer Ziekenhuisgroep, Deventer, Netherlands|Catharina Ziekenhuis, Eindhoven, Netherlands|Maxima Medisch Centrum, Eindhoven, Netherlands|Groene Hart Ziekenhuis, Gouda, Netherlands|Spaarne Gasthuis, Haarlem, Netherlands|Ziekenhuis St. Jansdal, Harderwijk, Netherlands|Tergooi Ziekenhuizen, Hilversum, Netherlands|Westfriesgasthuis, Hoorn, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Academisch Ziekenhuis Maastricht, Maastricht, Netherlands|Canisius-Wilhelmina Ziekenhuis, Nijmegen, Netherlands|Laurentius Ziekenhuis, Roermond, Netherlands|Bravis Ziekenhuis, Roosendaal, Netherlands|Antonius Ziekenhuis, Sneek, Netherlands|Ziekenhuis Rivierenland, Tiel, Netherlands|Elisabeth Tweesteden Ziekenhuis, Tilburg, Netherlands|VieCuri Medisch Centrum, Venlo, Netherlands|Streekziekenhuis Koningin Beatrix, Winterswijk, Netherlands|Isala, Zwolle, Netherlands",8324225,5,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,9.0,66.3997207334852,15.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.5,434.548,91.21,7.0,2.0,5.0,49.13,125.59,5.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,GASTROINTESTINAL STROMAL TUMORS,_PACLITAXEL,NCT03944304,Phase 2,Recruiting,All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Asan Medical Center, Seoul, Korea, Republic of",5439686,A61K47/6925,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,17.0,29.4708310232242,5311.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.2,853.9061,221.29,10.0,4.0,7.0,87.17,218.29,14.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1,BREAST NEOPLASM,_ENTINOSTAT,NCT03280563,Phase 1|Phase 2,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|UCSF Helen Diller Family CCC, San Francisco, California, United States|Stanford Cancer Institute, Stanford, California, United States|Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, United States|Wellness Oncology and Hematology - Main Office, West Hills, California, United States|Yale University School Of Medicine; Yale Cancer Center, Trumbull, Connecticut, United States|Northwest Georgia Oncology Centers PC - Marietta, Marietta, Georgia, United States|Rush University Medical Center - Chicago, Chicago, Illinois, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|University of Michigan, Ann Arbor, Michigan, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Providence Cancer Center, Portland, Oregon, United States|UPMC Pinnacle Health System, Harrisburg, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Univ of Pittsburgh Sch of Med; Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Houston Methodist Hospital; Department of Pharmacy, Houston, Texas, United States|Northwest Medical Specialties, PLLC; Research Department, Tacoma, Washington, United States|Rambam Medical Center, Haifa, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Rabin Medical Center-Beilinson Campus; Davidof Institute, Petach Tikva, Israel|Sheba Medical Center, Ramat Gan, Israel|Tel Aviv Sourasky Medical Center; Pharmacy, Tel Aviv, Israel|National Cancer Center, Goyang-si, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|University of Ulsan College of Medicine - Asan Medical Center, Seoul, Korea, Republic of",WO-2004058234-A2,0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,51.0,32.7488,59.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.07,376.416,106.34,4.0,3.0,3.0,39.39,108.29,7.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0
CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1,BREAST NEOPLASM,_ABEMACICLIB,NCT03280563,Phase 1|Phase 2,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|UCSF Helen Diller Family CCC, San Francisco, California, United States|Stanford Cancer Institute, Stanford, California, United States|Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, United States|Wellness Oncology and Hematology - Main Office, West Hills, California, United States|Yale University School Of Medicine; Yale Cancer Center, Trumbull, Connecticut, United States|Northwest Georgia Oncology Centers PC - Marietta, Marietta, Georgia, United States|Rush University Medical Center - Chicago, Chicago, Illinois, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|University of Michigan, Ann Arbor, Michigan, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Providence Cancer Center, Portland, Oregon, United States|UPMC Pinnacle Health System, Harrisburg, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Univ of Pittsburgh Sch of Med; Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Houston Methodist Hospital; Department of Pharmacy, Houston, Texas, United States|Northwest Medical Specialties, PLLC; Research Department, Tacoma, Washington, United States|Rambam Medical Center, Haifa, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Rabin Medical Center-Beilinson Campus; Davidof Institute, Petach Tikva, Israel|Sheba Medical Center, Ramat Gan, Israel|Tel Aviv Sourasky Medical Center; Pharmacy, Tel Aviv, Israel|National Cancer Center, Goyang-si, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|University of Ulsan College of Medicine - Asan Medical Center, Seoul, Korea, Republic of",7855211,C07D401/14,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,23.0,12.189161995112801,5.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.25,506.606,75.0,7.0,1.0,5.0,54.75,141.26,7.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O,OSTEOARTHRITIS,_VANCOMYCIN,NCT04075526,Not Applicable,Recruiting,All,"18 Years to 100 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Eisenhower Health, Rancho Mirage, California, United States|Cleveland Clinic Florida, Weston, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston Medical Center, Boston, Massachusetts, United States|New England Baptist Hospital, Boston, Massachusetts, United States|New York University Dept of Orthopeadic Surgery, New York, New York, United States|Hospital for Special Surgery, New York, New York, United States|Mount Sinai Hospital, New York, New York, United States|Columbia, New York, New York, United States|Cleveland Clinic Ohio, Cleveland, Ohio, United States|Inova Mount Vernon Hospital, Alexandria, Virginia, United States",10188697,A61K9/08,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,26.0,38.768763218957204,1648.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.11,1449.254,530.49,24.0,19.0,10.0,138.7,346.61,13.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
S=P(N1CC1)(N1CC1)N1CC1,BREAST CANCER,_THIOTEPA,NCT01646034,Phase 3,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"NKI-AVL, Amsterdam, Netherlands",4766149,7,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,27.532392862276396,109.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.17,189.218,9.03,3.0,0.0,3.0,18.23,50.72,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,DIABETIC FOOT,_DEXAMETHASONE,NCT03871049,Not Applicable,Recruiting,All,"20 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Assiut University Hospital, Assiut, Egypt",6284804,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,DIABETIC FOOT,_BUPIVACAINE,NCT03871049,Not Applicable,Recruiting,All,"20 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Assiut University Hospital, Assiut, Egypt",8182835.0,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1,GASTROINTESTINAL STROMAL TUMORS,_ANLOTINIB,NCT04106024,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Beijing Cancer Hospital, Beijing, Beijing, China",8148532,C07D239/88,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,6.0,49.315181009877,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.7,407.445,82.39,4.0,2.0,5.0,42.95,110.65,6.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0
NC(=O)CC[C@H](N)C(=O)O,BURN,_GLUTAMINE,NCT00985205,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Arizona Burn Center at Maricopa Medical Center, Phoenix, Arizona, United States|Southern California Regional Burn Ctr at LAC & USC Med. Ctr., Los Angeles, California, United States|Shriners Hospitals for Children Northern California, Sacramento, California, United States|Department of Anesthesiology, University of Colorado, Aurora, Colorado, United States|Connecticut Burn Center, Bridgeport, Connecticut, United States|The Burn Center at Washington Hospital Center, Washington, District of Columbia, United States|Shands Burn Center at the University of Florida, Gainesville, Florida, United States|University of South Florida/Tampa Gen. Hosp. Reg. Burn Center, FL, Tampa, Florida, United States|Joseph M Still Burn Center, Augusta, Georgia, United States|Department of Surgery University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|Mercy Hospital St. Louis, Saint Louis, Missouri, United States|CHI St.Elizabeth Regional Burn Center, Lincoln, Nebraska, United States|The Nebraska Medical Center, Omaha, Nebraska, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Akron's Children's Hospital, Paul & Carol David Foundation, Akron, Ohio, United States|The Ohio State University Wexnar Medical Center, Columbus, Ohio, United States|Legacy Emmanuel Hospital & Health Center, Portland, Oregon, United States|The Western Pennsylvania Hospital Burn Center, Pittsburgh, Pennsylvania, United States|The University of Tennessee Health Science Center, Memphis, Tennessee, United States|University of Texas Southwestern, Dallas, Texas, United States|JBSA Fort Sam Houston, Fort Sam Houston, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|Memorial Hermann/UTHSC, Houston, Texas, United States|Harbourview Medical Center, Seattle, Washington, United States|Columbia-St. Mary's, Milwaukee, Wi, Milwaukee, Wisconsin, United States|Ghent University Hospital, Ghent, Belgium|University Hospital of Liège, Liège, Belgium|Calgary Firefighters' Burn Unit, Calgary, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|Health Sciences Centre Burn Unit, Winnipeg, Winnipeg, Manitoba, Canada|HHS/Hamilton Firefighters Burn Unit, Hamilton, Ontario, Canada|Ross Tilley Burn Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|CHUM/Centre des Grands Brules, Montreal, Quebec, Canada|HEJ/Centre des Grands Brules, Quebec, Canada|Instituto Tecnologico de Santo Domingo, Santo Domingo, Dominican Republic|RWTH Aachen University, Aachen, North Rhine-Westphalia, Germany|Hospital Central ""Dr. Ignacio Morones Prieto, San Luis Potosi, San Luis Potosí, Mexico|Hospital Civil Fray Antonio Alcalde, Guadalajara, Mexico|Centro Nacional de Quemaduras y Cirugia Reconstructiva, Asunción, Paraguay|Hospital Universitario La Fe, Valencia, Spain|Uppsala University Hospital, Uppsala, Sweden|University Hospitals Birmingham NHS Foundation Trust, Birmingham, Edgbaston, United Kingdom|St Helens & Knowsley Teaching Hospitals, Liverpool, England, United Kingdom|Chelsea and Westminster Hospital, London, England, United Kingdom|Newcastle upon Tyne Hospitals, Newcastle Upon Tyne, England, United Kingdom",5288703.0,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,13.0,16.5260066941826,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.3,146.1445,106.41,4.0,3.0,0.0,13.87,33.11,4.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,BREAST CANCER,_SUNITINIB,NCT02790580,Phase 2,Recruiting,Female,"18 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National University Hospital, Singapore, Singapore, Singapore",6573293,C07D403/06,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,29.0,27.532392862276396,773.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.24,398.4738,77.23,3.0,3.0,3.0,44.32,116.27,7.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,GASTROINTESTINAL STROMAL TUMORS,_SUNITINIB,NCT03673501,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic Scottsdale, Scottsdale, Arizona, United States|University of California San Diego Medical Center, La Jolla, California, United States|UCLA Hematology Oncology Center - Main Site, Los Angeles, California, United States|Stanford Medicine, Stanford, California, United States|University of Colorado Hospital - Anschutz Cancer Pavillion, Aurora, Colorado, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Smilow Cancer Hospital at Yale, New Haven, Connecticut, United States|Washington Cancer Institute at MedStar Washington Hospital Center, Washington, District of Columbia, United States|Mayo Clinic Florida, Jacksonville, Florida, United States|Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States|Orlando Health UF Health Cancer Center, Orlando, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Georgia Cancer Specialists, Sandy Springs, Georgia, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|IU Simon Cancer Center, Indianapolis, Indiana, United States|University of Iowa Hospital and Clinics, Iowa City, Iowa, United States|Norton Cancer Institute, Audubon Hospital Campus, Louisville, Kentucky, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|University of Minnesota Medical Center-Fairview, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine - Siteman Cancer Center, Saint Louis, Missouri, United States|Rutgers Cancer Institute, New Brunswick, New Jersey, United States|Montefiore Medical Center-Montefiore Medical Park, Bronx, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|The Monter Cancer Center, Lake Success, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States|University of Toledo, Toledo, Ohio, United States|Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Oregon Health & Science University Center for Health and Healing, Portland, Oregon, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Henry-Joyce Cancer Clinic, Nashville, Tennessee, United States|Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Emily Couric Clinical Cancer Center, Charlottesville, Virginia, United States|Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia, United States|University of Washington Medical Center, Seattle, Washington, United States|Froedtert Hospital-Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Sanatorio Allende, Córdoba, Cordoba, Argentina|Instituto Medicao Especializado Alexander Fleming, Buenos Aires, Argentina|Border Medical Oncology Research Unit, Albury, New South Wales, Australia|Prince of Wales Hospital, Randwick, New South Wales, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Ashford Cancer Centre Research, Kurralta Park, South Australia, Australia|Ashford Cancer Centre Research, Kurralta Park, South Australia, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Princess Alexandara Hospital, Woolloongabba, Australia|Institut Jules Bordet, Bruxelles, Belgium|UZ Leuven, Leuven, Belgium|Cross Cancer Institute, Edmonton, Alberta, Canada|CancerCare Manitoba, Winnipeg, Manitoba, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Hopital Maisonneuve-Rosemont, Québec, Canada|Clinica San Carlos de Apoquindo Red Salud UC Christs, Santiago, Chile|Fakultni nemocnice v Motole, Prague, Czechia|Institut Bergonnié, Bordeaux, France|Centre Georges François Leclerc, Dijon, France|Centre Oscar Lambret, Lille Cedex, France|Centre Léon Bérard, Lyon, France|Hopital La Timone, Marseille, France|IPC, Marseille, France|IGR, Paris, France|CHU Poitiers-Hopital la Miletrie, Poitiers, France|ICO - Site René Gauducheau, Saint Herblain, France|HELIOS Klinikum Berlin-Buch, Berlin, Germany|Technische Universitat Dresden, Dresden, Germany|West German Cancer Center, Essen, Germany|Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, Hungary|Debreceni Egyetem, Debrecen, Hungary|Shamir Medical Center (Assaf Harofeh), Be'er Ya'akov, Israel|Rabin Medical Cente, Petah Tikva, Israel|Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel|Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi, Bologna, Italy|stituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori, Meldola, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy|IOV - Istituto Oncologico Veneto IRCCS, Padova, Italy|Universita degli Studi di Palermo, Palermo, Italy|Università Campus Bio-Medico di Roma, Rome, Italy|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Ajou University Hospital, Suwon, Korea, Republic of|Antoni van Leeuwenhoek, Amsterdam, Netherlands|The Netherlands Cancer Institute, Amsterdam, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Leiden University Medical Centre, Leiden, Netherlands|Oslo University Hospital, Oslo, Norway|Centrum Onkologii-Instytut im. M. Sklodowskiej Curie, Warsaw, Poland|National Cancer Centre, Singapore, Singapore|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital de Basurto, Bilbao, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Clinico San Carlos, Madrid, Spain|Hospital Universitario HM Madrid Sanchinarro, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Clinico Universitario Virgen de la Victoria, Malaga, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Instituto Valenciano de Oncología,, Valencia, Spain|Complejo Hospitalario Universitario de Vigo, Vigo, Spain|Karolinska universitetssjukhuset, Solna, Sweden|Centre Hospitalier Universitaire Vaudois, Fondation du Centre Pluridisciplinaire d'Oncologi, Lausanne, Switzerland|Universitaetsspital Zuerich, Klinik fuer Onkologie, Zurich, Switzerland|Chang Gung Memorial Hospital, Linkou, Taoyuan County, Taiwan|Kaohsiung Chang Gung Memorial Hospital,, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Chen Kung University Hospital, Tainan, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|St James's University Hospital, Leeds, United Kingdom|Royal Marsden Hospital - Fulham, London, United Kingdom|University College London Hospitals, London, United Kingdom|Weston Park Hospital, Sheffield, United Kingdom",6573293,C07D403/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,29.0,27.532392862276396,773.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.24,398.4738,77.23,3.0,3.0,3.0,44.32,116.27,7.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0
COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,SYSTEMIC LUPUS ERYTHEMATOSUS,_CURCUMIN,NCT03953261,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Loma Linda University, Loma Linda, California, United States",4138212,C09B61/00,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,14.0,17.905911825704802,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.62,368.3799,93.06,6.0,2.0,2.0,38.12,103.81,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0
COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,BREAST CANCER,_CURCUMIN,NCT03980509,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Medical University of South Carolina, Charleston, South Carolina, United States",4138212,C09B61/00,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,14.0,17.905911825704802,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.62,368.3799,93.06,6.0,2.0,2.0,38.12,103.81,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0
Cc1c(C)c2c(c(C)c1O)CC[C@@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)O2,BREAST CANCER,_VITAMIN_E,NCT04463459,Not Applicable,Recruiting,Female,"30 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"BSMMU, Dhaka, Bangladesh",3932634.0,0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,2.0,13.1090987494609,9855.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,8.84,430.7061,29.46,2.0,1.0,2.0,55.29,135.37,12.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0
CN(C)C(=N)NC(=N)N,BREAST CANCER,_METFORMIN,NCT04559308,Phase 2,Recruiting,Female,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Beni-suef university, Banī Suwayf, Egypt",6288095.0,4,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CN(C)C(=N)NC(=N)N,RHEUMATOID ARTHRITIS,_METFORMIN,NCT04068246,Early Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Faculty of Pharmacy, Sadat City, Egypt",6288095.0,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,BREAST CANCER,_ATORVASTATIN,NCT02958852,Phase 2,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Lund University Hospital, Department of Oncology, Lund, Sweden",4681893,C07D405/06,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
CC(C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)O)C(C)C,RHEUMATOID ARTHRITIS,_ANGIOTENSIN,NCT03770702,Phase 3,Recruiting,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sherief Abd-Elsalam, Tanta, Egypt",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,RHEUMATOID ARTHRITIS,_MONTELUKAST,NCT03770923,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sherief Abd-Elsalam, Tanta, Egypt",8007830.0,A61K9/1623,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
Cc1cncc(CN2CCC(=C3c4ccc(Cl)cc4CCc4cccnc43)CC2)c1,RHEUMATOID ARTHRITIS,_RUPATADINE,NCT03770923,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sherief Abd-Elsalam, Tanta, Egypt",5407941,C07D401/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,23.0312737427873,128.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.82,415.97,29.02,3.0,0.0,5.0,46.98,133.83,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,BREAST CANCER,_MIDAZOLAM,NCT04172220,Not Applicable,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, PN, Italy",8217033,5,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,21.0,37.68455204418978,189.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.89,325.767,30.18,2.0,0.0,4.0,32.7,99.43,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0
CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1,WILSON DISEASE,_BUPROPION,NCT04526210,Phase 1,Enrolling by invitation,All,18 Years to 50 Years   (Adult),Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Clinical Trial Site, Austin, Texas, United States",5358970,1,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,17.0,14.423294112815402,185.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.28,239.74099999999999,29.1,2.0,1.0,1.0,25.93,67.7,4.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1.Cl,WILSON DISEASE,_BUPROPION_HYDROCHLORIDE,NCT04526210,Phase 1,Enrolling by invitation,All,18 Years to 50 Years   (Adult),Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Clinical Trial Site, Austin, Texas, United States",RE33994,1,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,1.0,35.3190003901517,98.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
COC(=O)CCc1ccc(OCC(O)CNC(C)C)cc1,DIABETIC FOOT ULCER,_ESMOLOL,NCT03998436,Phase 3,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M.S. Ramaiah Medical College and Hospital, Bangalore, Karnataka, India|Deenanath Mangeshkar Hospital and Research Center, Pune, Maharashtra, India|Chellaram Diabetes Institute, Pune, Maharashtra, India|M.V. Hospital for Diabetes Pvt Ltd, Chennai, Tamilnadu, India|Madras Diabetes Research Foundation, Chennai, Tamilnadu, India|Sri Ramachandra Hospital, Chennai, Tamilnadu, India|Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India|Maharaja Agrasen Hospital, New Delhi, India",6310094.0,2,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,9.0,9.56077126840386,564.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.02,295.374,67.79,4.0,2.0,1.0,33.68,81.05,10.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0
COC(=O)CCc1ccc(OCC(O)CNC(C)C)cc1.Cl,DIABETIC FOOT ULCER,_ESMOLOL_HYDROCHLORIDE,NCT03998436,Phase 3,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M.S. Ramaiah Medical College and Hospital, Bangalore, Karnataka, India|Deenanath Mangeshkar Hospital and Research Center, Pune, Maharashtra, India|Chellaram Diabetes Institute, Pune, Maharashtra, India|M.V. Hospital for Diabetes Pvt Ltd, Chennai, Tamilnadu, India|Madras Diabetes Research Foundation, Chennai, Tamilnadu, India|Sri Ramachandra Hospital, Chennai, Tamilnadu, India|Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India|Maharaja Agrasen Hospital, New Delhi, India",6310094,2,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,9.0,9.56077126840386,155.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,BREAST CANCER,_DEXMEDETOMIDINE,NCT03109990,Not Applicable,Recruiting,Female,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Renji hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, Shanghai, China",5344840,4,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,WILSON DISEASE,_CELECOXIB,NCT04526197,Phase 1,Enrolling by invitation,All,18 Years to 50 Years   (Adult),Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Clinical Trial Site, Austin, Texas, United States",5972986.0,4,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0
COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,BREAST CANCER,_LENVATINIB,NCT03168074,Phase 2,Recruiting,Female,"18 Years to 99 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Nationa University Hospital, Singapore, Singapore",7253286,4,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,15.0,51.6478777798312,65.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.03,426.86,115.57,4.0,3.0,4.0,42.29,112.21,6.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,BREAST CANCER,_VENETOCLAX,NCT04298918,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Yale Cancer Center, New Haven, Connecticut, United States|Dana Farber Cancer Inst., Boston, Massachusetts, United States|Washington University; Division of Oncology, Saint Louis, Missouri, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|SCRI-Tennessee Oncology, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States|Kinghorn Cancer Centre; St Vincents Hospital, Darlinghurst, New South Wales, Australia|Peter MacCallum Cancer Center, East Melbourne, Victoria, Australia|St John of God Hospital; Bendat Cancer Centre, Subiaco, Western Australia, Australia|Hospital Araujo Jorge; Departamento de Ginecologia E Mama, Goiania, GO, Brazil|Hospital Perola Byington, Sao Paulo, SP, Brazil|Masarykův onkologický ústav; Klinika komplexní onkologické péče, Brno, Czechia|Fakultni Nemocnice Hradec Kralove; Dept of Radiotherapy & Oncology, Hradec Kralove, Czechia|Fakultni nemocnice Olomouc; Onkologicka klinika, Olomouc, Czechia|Fakultni nemocnice Kralovske Vinohrady; Radioterapeuticka a onkologicka klinika, Praha 10, Czechia|Fakultni Poliklinika Vseobecne Fakultni Niemocnice; Onkologicka Klinika, Praha 2, Czechia|Thomayerova nemocnice; Onkologicka klinika 1. LF UK A TN, Praha 4 - Krc, Czechia|Honvédelmi Minisztérium Állami Egészségügyi Központ; Onkológiai Osztály; Pharmacy, Budapest, Hungary|Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz; Onkoradiológia, Nyíregyháza, Hungary|Pécsi Tudományegyetem; Klinikai Központ Onkoterápiás Intézet, Pécs, Hungary|Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet; Megyei Onkologiai Kozpont, Szolnok, Hungary|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy|IOV - Istituto Oncologico Veneto IRCCS, Padova, Veneto, Italy|Kyungpook National University Medical Center, Daegu, Korea, Republic of|National Cancer Center, Goyang-si, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Seoul St Mary's Hospital, Seoul, Korea, Republic of|Szpital Specjalistyczny Podkarpacki Ośrodek Onkologiczny, Brzozów, Poland|Szpital Morski im. PCK; Poradnia Onkologiczna, Gdynia, Poland|PRATIA MCM Kraków, Kraków, Poland|Centrum Terapii Wspolczesnej J.M.Jasnorzewska Spolka Komandytowo-Akcyjna, Lodz, Poland|Neuromed, Lublin, Poland|SP ZOZ MSWiA z WARMINSKO-MAZURSKIM CENTRUM ONKOLOGII; CLINICAL ONCOLOGY, CLINICAL IMMUNOLOGY, Olsztyn, Poland|MRUKMED Lekarz Beata Madej-Mruk i Partner Spolka Partnerska Oddzial nr 1 w Rzeszowie, Rzeszow, Poland|Examen sp, Skórzewo, Poland|Narodowy Inst.Onkologii im.Sklodowskiej-Curie Panstw.Inst.Bad; Klinika Nowtw.Piersi i Chir.Rekonstr, Warszawa, Poland|Dolnośląskie Centrum Onkologii; Oddział Onkologii Klinicznej i Chemioterapii, Wrocław, Poland|Hospital Universitari Vall d'Hebron; Oncology, Barcelona, Spain|Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia, Spain|Chulalongkorn Hospital; Medical Oncology, Bangkok, Thailand|Rajavithi Hospital; Division of Medical Oncology, Bangkok, Thailand|Songklanagarind Hospital; Department of Oncology, Songkhla, Thailand",8546399,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,24.0,40.214378118647204,25.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.92,868.45,172.03,10.0,3.0,8.0,93.95,238.59,12.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,BREAST NEOPLASM,_NERATINIB,NCT01670877,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry|U.S. Fed,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama Cancer Center, Birmingham, Alabama, United States|Mayo Clinic, Phoenix, Arizona, United States|University of Southern California Keck School of Medicine, Los Angeles, California, United States|Stanford Medicine Cancer Institute, Stanford, California, United States|University of Miami Hospital and Clinics, Miami, Florida, United States|Northwestern University - Feinberg School of Medicine, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Dana-Farber Cancer Institute, Harvard University, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|St. Luke's Cancer Institute, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of North Carolina at Chapel Hill (Lineberger Comprehensive Cancer Center), Chapel Hill, North Carolina, United States|Duke Cancer Institute at Duke University Medical Center, Durham, North Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Baylor College of Medicine, Houston, Texas, United States|BC Cancer Agency, Vancouver, British Columbia, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada",6288082,C07D215/48,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,0.0,0.0,0.0,0.0,1.0,15.0,23.589806772212896,58.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.72,557.05,112.4,8.0,2.0,4.0,58.1,157.29,11.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0
CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1,BREAST CANCER,_ABEMACICLIB,NCT04565054,Phase 3,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Praxis für interdisziplinäre Onkologie & Hämatologie, Freiburg, Baden-Württemberg, Germany|Brustzentrum, LMU Klinikum, Ludwig-Maximilians-Universität,, Muenchen, Bayern, Germany|Brustzentrum Niederrhein, Johanniter Bethesda Krankenhaus, Moenchengladbach, NRW, Germany",7855211,C07D401/14,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,23.0,12.189161995112801,5.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.25,506.606,75.0,7.0,1.0,5.0,54.75,141.26,7.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
CN(C)C(=N)N=C(N)N.Cl,BREAST CANCER,_METFORMIN_HYDROCHLORIDE,NCT04170465,Phase 2,Recruiting,Female,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Damanhour University, Beheira, Egypt",,,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1,BREAST NEOPLASM,_DECITABINE,NCT03295552,Phase 2,Recruiting,Female,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China",5654333,1,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,30.0,25.988213310334892,1199.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.0,228.2053,120.74,7.0,3.0,2.0,21.15,50.68,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,BREAST CANCER,_DICLOFENAC,NCT04511832,Not Applicable,Recruiting,All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,"China Medical University Hospital, Taichung, Taiwan",6407079,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,35.0,163.551612969465,1298.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.98,296.149,49.33,3.0,2.0,2.0,27.93,75.46,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0
Cc1nnc(SCC2=C(C(=O)O)N3C(=O)[C@@H](NC(=O)Cn4cnnn4)[C@H]3SC2)s1,BREAST NEOPLASM,_CEFAZOLIN,NCT03742908,Not Applicable,Recruiting,Female,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China",3937655,C12Q1/18,0.0,1.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,13.0,21.8484979157682,879.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.4,454.50699999999995,156.09,9.0,2.0,4.0,41.44,119.86,7.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,BREAST CANCER,_CARVEDILOL,NCT03879629,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic, Phoenix, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States",6022562,A61K9/5026,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,14.0,51.7464424320827,334.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.05,406.4742,75.74,5.0,3.0,4.0,45.03,115.64,10.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,CESAREAN SECTION,_BUPIVACAINE,NCT03498118,Not Applicable,Recruiting,Female,18 Years to 40 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,"AswanUH, Aswan, Egypt",8182835.0,1,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,PSORIASIS,_TRIAMCINOLONE,NCT04117919,Phase 2,Recruiting,All,"20 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"No. 91, Xueshi Rd., North Dist., Taichung City 404, Taiwan (R.O.C.), Taichung, Taiwan",5976573,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314,POSTOPERATIVE COMPLICATIONS,_NALBUPHINE,NCT03470077,Phase 2,Recruiting,All,3 Years to 8 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Assiut University Hospital, Assiut, Egypt",4237140,4,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,18.5301546232982,597.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.0,357.4434,73.16,5.0,3.0,6.0,38.59,97.0,2.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0
CN(C)C(=O)Oc1cccc([N+](C)(C)C)c1,BURN,_NEOSTIGMINE,NCT03513406,Phase 3,Recruiting,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Kansas Medical Center, Kansas City, Kansas, United States",4439427,6,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,20.0,17.281669028111402,79.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,-1.6,223.2915,29.54,1.0,0.0,1.0,25.08,75.28,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0
O=C(O)CCSC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]4[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]5[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]6[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]7[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]8[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]9[C@@H](CSCCC(=O)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O,BURN,_SUGAMMADEX,NCT03513406,Phase 3,Recruiting,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Kansas Medical Center, Kansas City, Kansas, United States",7265099,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,3.0,84.8970204726996,4.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.69,2002.12,769.76,48.0,24.0,9.0,189.62,432.64,40.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
C[N+]1(C)CCC(OC(=O)C(O)(c2ccccc2)C2CCCC2)C1.[Br-],BURN,_GLYCOPYRROLATE,NCT03513406,Phase 3,Recruiting,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Kansas Medical Center, Kansas City, Kansas, United States",4824676,A61K9/7023,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,26.3496170352573,464.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
Cn1ncnc1[C@H]1c2n[nH]c(=O)c3cc(F)cc(c23)N[C@@H]1c1ccc(F)cc1,BREAST CANCER,_TALAZOPARIB,NCT04039230,Phase 1|Phase 2,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States",8012976,5,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,5.0,25.331115628657603,10.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.93,380.35900000000004,84.2,5.0,2.0,5.0,35.82,111.27,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0
CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,BREAST CANCER,_MEGESTROL_ACETATE,NCT03306472,Phase 2,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom",5145684.0,B82Y5/00,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,20.0,19.450091377646306,2187.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.71,384.51599999999996,60.44,3.0,0.0,4.0,43.51,108.66,3.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
CC(C)=CCC/C(C)=C/CC/C(C)=C/CCC1(C)CCc2cc(O)ccc2O1,BREAST CANCER,_TOCOTRIENOL,NCT03855423,Not Applicable,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"University of Malaya Medical Center, Kuala Lumpur, Malaysia",US-20070293449-A1,A61K9/1272 ,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,25.0,32.7488,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.68,382.5787,29.46,2.0,1.0,2.0,48.12,122.8,9.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
CN1CCN2c3ncccc3Cc3ccccc3C2C1,BREAST CANCER,_MIRTAZAPINE,NCT02336750,Phase 3,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Fudan University Cancer Hospital, Shanghai, China",5178878.0,A61K9/0056,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,166.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.9,265.3529,19.37,3.0,0.0,4.0,30.35,82.66,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0
CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1,GASTROINTESTINAL STROMAL TUMORS,_AXITINIB,NCT04258956,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Maria Sklodowska-Curie National Research Institue of Oncology, Warsaw, Poland",6534524,C07D401/14,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,14.0,16.7231359986858,54.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.17,386.47,70.67,3.0,2.0,4.0,42.58,115.14,5.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1,BREAST CANCER,_CHLORHEXIDINE,NCT02395614,Not Applicable,Recruiting,Female,"18 Years to 81 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Vanderbilt University Medical Center, Nashville, Tennessee, United States",5538353,A45D34/04,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,20.0,10.940676399926,1621.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.71,505.44699999999995,167.58,10.0,10.0,2.0,54.6,181.71,9.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1,DIABETIC FOOT ULCER,_CHLORHEXIDINE,NCT03503370,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",U.S. Fed,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD, Baltimore, Maryland, United States",5538353,A45D34/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,20.0,10.940676399926,1621.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.71,505.44699999999995,167.58,10.0,10.0,2.0,54.6,181.71,9.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,GOUT ATTACK,_BETAMETHASONE,NCT04306653,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital of Patras, PAtras, Achaia, Greece",6126920.0,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.6906096634427,1325.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.81,102.49,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1,BREAST CANCER,_RUCAPARIB,NCT03911453,Early Phase 1,Recruiting,All,"21 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Arizona Cancer Center, Tucson, Arizona, United States",6495541,2,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,5.0,35.2204357379001,20.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.39,323.371,56.92,2.0,3.0,4.0,35.19,92.91,3.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0
C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,PSORIATIC ARTHRITIS,_TOFACITINIB,NCT03486457,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China|Anhui Provincial Hospital, Hefei, Anhui, China|The First Affiliated Hospital of Anhui Medical University/Rheumatology Department, Hefei, Anhui, China|Peking University First Hospital, Beijing, Beijing, China|Peking Union Medical College Hospital, Beijing, Beijing, China|The First Affiliated Hospital of Army Medical University, PLA, Chongqing, Chongqing, China|The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China|The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China|Guangzhou First People's Hospital, Guangzhou, Guangdong, China|Guangdong Second Provincial General Hospital, Guangzhou, Guangdong, China|The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, China|The Third Hospital of Hebei Medical University, Rheumatology and Immunology Department, Shijiazhuang, Hebei, China|Rheumatology Department, The first Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China|The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China|Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China|Xiangya Hospital Central South University, Changsha, Hunan, China|The Second Xiangya Hospital of Central South University, Changsha, Hunan, China|Zhuzhou Central Hospital, Zhuzhou, Hunan, China|The First Affiliated Hospital of Baotou Medical College, Baotou, Inner Mongolia, China|Department of Rheumatology, The First People's Hospital of Changzhou, Changzhou, Jiangsu, China|Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China|Jiangsu Province Hospital, Nanjing, Jiangsu, China|Affiliated Hospital of Nantong University, Nantong, Jiangsu, China|Department of Rheumatology ,The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China|Department of Rheumatology, Northern Jiangsu People's Hospital, Yangzhou, Jiangsu, China|Jiu Jiang No.1 People's Hospital, Jiujiang, Jiangxi, China|Pingxiang People's Hospital, Pingxiang, Jiangxi, China|The First hospital of Jilin University, Changchun, Jilin, China|Linyi People's Hospital, Linyi, Shandong, China|Zhongshan Hospital Fudan University, Shanghai, Shanghai, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China|Department of Rheumatology and Immunology,West China Hospital，Sichuan University, Chengdu, Sichuan, China|Tianjin Medical University General Hospital, Rheumatology and Immunology Department, Tianjin, Tianjin, China|First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China|Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China|The First Affiliated Hosptial of Wenzhou Medical University, Wenzhou, Zhejiang, China|Peking Union Medical College Hospital, Beijing, China|Rheumatology and Immunology Department, Xuanwu Hospital Capital Medical University, Beijing, China|Huashan Hospital, Fudan University, Shanghai, China|Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China",7301023,C07D487/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,1.0,66.1697365448982,52.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.58,312.3696,88.91,5.0,1.0,3.0,32.65,87.8,3.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1,SYSTEMIC LUPUS ERYTHEMATOSUS,_BARICITINIB,NCT03843125,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Achieve Clinical Research, LLC, Birmingham, Alabama, United States|University of Alabama at Birmingham, Birmingham, Alabama, United States|Arizona Arthritis & Rheumatology Associates, P. C., Gilbert, Arizona, United States|Arizona Arthritis & Rheumatology Research, PLLC, Glendale, Arizona, United States|Arizona Arthritis & Rheumatology Research, Phoenix, Arizona, United States|Arizona Arthritis & Rheumatology Associates, P. C., Tucson, Arizona, United States|University of Arizona, Tucson, Arizona, United States|Wallace Rheumatic Studies Center, Beverly Hills, California, United States|Medvin Clinical Research - Weidmann, Covina, California, United States|St. Joseph Heritage Medical Group, Fullerton, California, United States|MD Medical Corporation, Hemet, California, United States|University of California - San Diego, La Jolla, California, United States|UCLA Medical Center, Los Angeles, California, United States|ACRC Studies, Poway, California, United States|Office: Dr Robin K Dore, Tustin, California, United States|Inland Rheumatology & Osteoporosis Medical Group, Upland, California, United States|Medvin Clinical Research - Weidmann, Whittier, California, United States|Denver Arthritis Clinic - Lowry, Denver, Colorado, United States|New England Research Associates, Bridgeport, Connecticut, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Clinical Research of West Florida, Clearwater, Florida, United States|UF Health-Jacksonville, Jacksonville, Florida, United States|Lakes Research, LLC, Miami Lakes, Florida, United States|Omega Research Metro West, LLC, Orlando, Florida, United States|Millennium Research, Ormond Beach, Florida, United States|Integral Rheumatology & Immunology Specialists, Plantation, Florida, United States|Clinical Research of West Florida, Inc., Tampa, Florida, United States|ForCare Clinical Research, Tampa, Florida, United States|Tampa Medical Group, P.A., Tampa, Florida, United States|Piedmont Healthcare, Atlanta, Georgia, United States|Emory University, Atlanta, Georgia, United States|Arthritis & Rheumatology of Georgia, Atlanta, Georgia, United States|Atlanta Center for Clinical Research, Atlanta, Georgia, United States|North Georgia Rheumatology, PC, Lawrenceville, Georgia, United States|St Luke's Clinic - Intermountain Orthopaedics, Boise, Idaho, United States|University of Chicago Duchosis Ctr Advanced Medicine (DCAM), Chicago, Illinois, United States|Orthoillinois, Rockford, Illinois, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Arthritis Center of Lexington, Lexington, Kentucky, United States|Johns Hopkins Asthma and Allergy Center, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Tufts Medical Center, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Clinical Research Institute of Michigan, LLC, Clinton Township, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Advanced Rheumatology, PC, Lansing, Michigan, United States|St. Paul Rheumatology, PA, Eagan, Minnesota, United States|University of Minnesota Medical School, Minneapolis, Minnesota, United States|North MS Medical Clinics, Inc., Tupelo, Mississippi, United States|SLUcare Rheumatology, Saint Louis, Missouri, United States|St. Louis Rheumatology, Saint Louis, Missouri, United States|Glacier View Research Institute, Kalispell, Montana, United States|Allied Clinical Research, Reno, Nevada, United States|Albuquerque Center for Rheumatology, Albuquerque, New Mexico, United States|Albuquerque Clinical Trials, Inc., Albuquerque, New Mexico, United States|Arthritis and Osteoporosis Associates of New Mexico, Las Cruces, New Mexico, United States|SUNY Health Science Center, Brooklyn, New York, United States|St. Lawrence Health System, Canton, New York, United States|Northwell Health, Great Neck, New York, United States|The Feinstein Institute for Medical Research, Manhasset, New York, United States|Columbia University Medical Center, New York, New York, United States|NYU Langone, New York, New York, United States|Buffalo Rheumatology, Orchard Park, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Joint and Muscle Medical Care, Charlotte, North Carolina, United States|Box Arthritis & Rheumatology of the Carolinas, PLLC, Charlotte, North Carolina, United States|Medication Management, LLC, Greensboro, North Carolina, United States|PMG Research of Wilmington, Wilmington, North Carolina, United States|Cincinnati Rheumatic Disease Study Group, Cincinnati, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Paramount Medical Research, Middleburg Heights, Ohio, United States|Arthritis & Rheumatology Center of Oklahoma PLLC, Oklahoma City, Oklahoma, United States|Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States|East Penn Rheumatology Associates, Bethlehem, Pennsylvania, United States|UPMC Lupus Center of Excellence, Pittsburgh, Pennsylvania, United States|Clinical Research Center of Reading,LLC, Wyomissing, Pennsylvania, United States|Articularis Healthcare d/b/a/ Low Country Rheumatology, PA, North Charleston, South Carolina, United States|Eagle Medical, Crossville, Tennessee, United States|West Tennessee Research Institute, Jackson, Tennessee, United States|Amarillo Center for Clinical Research, Amarillo, Texas, United States|Accurate Clinical Management, Baytown, Texas, United States|Dr. Dhiman Basu Private Practice, Colleyville, Texas, United States|Metroplex Clinical Research Center, Dallas, Texas, United States|Precision Comprehensive Clinical Research Solutions, Fort Worth, Texas, United States|Rheumatology Center of Houston, Houston, Texas, United States|Southwest Rheumatology, P.A., Mesquite, Texas, United States|University of Texas Health Science Center - San Antonio, San Antonio, Texas, United States|Arthritis Clinic Of Central Texas, San Marcos, Texas, United States|Advanced Rheumatology of Houston, The Woodlands, Texas, United States|Clear Lake Specialties, Webster, Texas, United States|Arthritis Clinic of Northern VA, P.C., Arlington, Virginia, United States|Spectrum Medical Inc., Danville, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Swedish Medical Center, Seattle, Washington, United States|Aurora Rheumatology, Franklin, Wisconsin, United States|Rheumatic Disease Center, Glendale, Wisconsin, United States|Froedtert Memorial Lutheran Hospital, Milwaukee, Wisconsin, United States|Aprillus Asistencia e Investigacion - Servicio de neurologia, Caba, Buenos Aires, Argentina|DOM Centro de Reumatologia, Ciudad de Buenos Aires, Buenos Aires, Argentina|Framingham Centro Medico, La Plata, Buenos Aires, Argentina|CER Instituto Medico, Quilmes, Buenos Aires, Argentina|Instituto de Investigaciones Clinicas Quilmes, Quilmes, Buenos Aires, Argentina|Sanatorio Británico, Rosario, Santa Fe, Argentina|Centro Medico Privado de Reumatologia, SAN M. DE Tucuman, Tucuman, Argentina|Centro de Educación Médica e Investigaciones Clínicas ""Norberto Quirno"" (CEMIC), Buenos Aires, Argentina|Sanatorio Guemes Cardiocirugia, Ciudad Autonoma Buenos Aires, Argentina|Clinica Adventista de Belgrano, Ciudad Autonoma Buenos Aires, Argentina|IR Medical Center S.A. Instituto de Reumatologia, Mendoza, Argentina|Optimus Clinical Research, Kogarah, New South Wales, Australia|The Rheumatology Research Unit Sunshine Coast, Maroochydore, Queensland, Australia|Emeritus Research, Camberwell, Victoria, Australia|Monash Health, Clayton, Victoria, Australia|St Vincents Hospital Melbourne, Fitzroy, Victoria, Australia|Griffith University, Southport, Australia|Ordensklinikum Linz GmbH Elisabethinen, Linz, Oberösterreich, Austria|Medizinische Universität Graz, Graz, Austria|Medizinische Universität Wien, Wien, Austria|Krankenhaus Hietzing, Wien, Austria|UZ Leuven, Leuven, Vlaams Brabant, Belgium|Cliniques Universitaires Saint-Luc, Brussels, Belgium|Centre Hospitalier Universitaire Sart Tilman, Liege, Belgium|SER - Serviços Especializados em Reumatologia da Bahia S/S - ME, Salvador, Bahia, Brazil|Santa Casa de Misericordia de Belo Horizonte, Belo Horizonte, MG, Brazil|Centro de Estudos em Terapias Inovadoras-CETI, Curitiba, Paraná, Brazil|EDUMED - Educação em Saúde Ltda., Curitiba, Paraná, Brazil|Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|LMK Serviços Médicos S/S, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital de Clinicas UNICAMP, Campinas, SP, Brazil|Oncovida- Centro de Onco-Hematologia de Mato Grosso, Cuiaba, Brazil|CIP - Centro Internacional de Pesquisa, Goiás, Brazil|Hospital Alemao Oswaldo Cruz, Sao Paulo, Brazil|Clinical Research Chile SpA, Valdivia, Los Ríos, Chile|Quantum Research Santiago, Santiago, Región Metropolitana, Chile|Clinica Alemana de Osorno, Osorno, Chile|Sociedad Medica Del Aparato Locomotor SA, Santiago, Chile|Prosalud y cia. Ltda., Santiago, Chile|CINVEC- Estudos Clínicos Quinta Región Limitada, Vina del Mar, Chile|First affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China|First Affiliated Hospital of the Harbin Medical University, Harbin, Heilongjiang, China|Wuhan Union Hospital, Wuhan, Hubei, China|Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China|China-Japan Union Hospital, CJUH., Changchun, Jilin, China|Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China|Ningbo First Hospital, Ningbo, Zhejiang, China|Peking University First Hospital, Beijing, China|Beijing Peking Union Medical College Hospital, Beijing, China|Shanghai Huashan Hospital Affil to Fu Dan University, Shanghai, China|China Medical University (CMU) - First Affiliated Hospital, Shenyang, China|The First Affliated Hospital of Soochow University, Suzhou Shi, China|Tianjin Medical University General Hospital, Tianjin, China|People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China|HPTU-El Hospital con alma Pablo Tobon Uribe, Medellin, Antioquia, Colombia|Clinica de la Costa, Barranquilla, Atlantico, Colombia|Circaribe SAS, Barranquilla, Atlántico, Colombia|Idearg S.A.S., Bogota, Cundinamarca, Colombia|Centro Integral de Reumatologia e Inmunologia, Bogotá, Cundinamarca, Colombia|Instituto de Reumatologia, Bogota, Distrito Capital De Bogota, Colombia|Servimed S.A.S., Bucaramanga, Santander, Colombia|Medicity SAS, Bucaramanga, Santander, Colombia|Clinica De Artritis Temprana, Cali, Valle Del Cauca, Colombia|Centro de Medicina Interna, Cali, Valle Del Cauca, Colombia|Preventive Care Ltdac, Chia, Colombia|Clinical Hospital Center Rijeka, Rijeka, Croatia|University Hospital Split, Split, Croatia|Klinicka Bolnica Dubrava, Zagreb, Croatia|Revmatologie.s.r.o., Brno, Czechia|Fakultni Nemocnice Olomouc, Olomouc, Czechia|ARTHROHELP s.r.o., Pardubice, Czechia|VFN a 1 LF University Karlovy, Praha 2, Czechia|Revmatologicky ustav, Praha 2, Czechia|CHRU Brest - Hopital Cavale Blanche, Brest Cedex, Finistère, France|Centre hospitalier universitaire Pellegrin, Bordeaux, France|CHRU Lille - Hopital Claude Huriez, Lille Cedex, France|Hopital Européen, Marseille, France|CHU Montpellier Lapeyronie Hospital, Montpellier, France|Centre hospitalier universitaire de Haut Leveque, Pessac Cedex, France|Hôpital de HautePierre, Strasbourg, France|Universitätsklinikum Freiburg, Freiburg, Baden-Württemberg, Germany|Universitätsklinikum Heidelberg, Heidelberg, Baden-Württemberg, Germany|Universitätsklinikum Tübingen, Tübingen, Baden-Württemberg, Germany|Klinikum der Universität München, München, Bayern, Germany|Universitätsklinikum Würzburg A. ö. R., Würzburg, Bayern, Germany|Universitätsklinikum Köln, Köln, Nordrhein-Westfalen, Germany|Universitätsklinikum Münster, Münster, Nordrhein-Westfalen, Germany|Universitatsmedizin der Johannes Gutenberg-Universitat Mainz, Mainz, Rheinland-Pfalz, Germany|Universitätsklinikum Carl Gustav Carus, Dresden, Sachsen, Germany|Universitatsklinikum Leipzig, Leipzig, Sachsen, Germany|Universitätsklinikum Jena, Jena, Thüringen, Germany|Charité Campus Virchow-Klinikum, Berlin, Germany|Immanuel Krankenhaus Rheuma Klinik Berlin Buch, Berlin, Germany|Schlosspark Klinik, Berlin, Germany|Gen Hospital of Athens G Gennimatas, Athens, Attiki, Greece|University General Hospital of Heraklion, Heraklion, Crete, Greece|Regional General University Hospital of Larissa, Larissa, Greece|Kianous Stavros, Thessaloniki, Greece|Gen. Hosp. of Thessaloniki ""Hippokration"", Thessaloniki, Greece|Bekes Megyei Pandy Kalman Korhaz, Gyula, Bekes, Hungary|Budai Irgalmasrendi Korhaz, Budapest, Hungary|Qualiclinic Kft, Budapest, Hungary|Del-pesti Centrumkorhaz - Orszagos Hematologiai es Infektologiai Intezet, Budapest, Hungary|Debreceni Egyetem Orvos-es Egészsegtudomanyi Centrum, Debrecen, Hungary|Debreceni Egyetem Klinikai Kozpont, Debrecen, Hungary|Pecsi Tudomanyegyetem Klinikai Kozpont, Pecs, Hungary|Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont I. Belgyogyaszati Klinika, Szeged, Hungary|Vita Verum Egeszsegugyi Szolgaltato Bt, Székesfehérvár, Hungary|Vital Medical Center, Veszprem, Hungary|Krishna Institute of Medical Sciences Ltd., Hyderabad, Andhra Pradesh, India|Panchshil Hospital, Ahmedabad, Gujarat, India|CIMS Hospital Private Limited, Ahmedabad, Gujarat, India|NHL Municipal Medical College & VS General Hospital, Ahmedabad, Gujarat, India|Shree Giriraj Hospital, Rajkot, Gujarat, India|Nirmal Hospital Private Limited, Surat, Gujarat, India|Sterling Hospital, Vadodara, Gujarat, India|St. John Medical College & Hospital, Bangalore, Karnataka, India|Chanre Rheumatology & Immunology Center & Research, Bangalore, Karnataka, India|Sushruta Multispecialty Hospital & Research Center Pvt Ltd, Hubli, Karnataka, India|Kasturba Medical College Hospital, Mangalore, Mangalore, Karna, India|Jasleen Hospital, Nagpur, Maharashtra, India|Synexus Affiliate - Sujata Birla Hospital & Medical Research Center, Nashik, Maharashtra, India|Fortis Escorts Hospital, Jaipur, Rajasthan, India|Post Graduate Institute of Medical Education & Research, Chandigarh, India|Carmel Hospital, Haifa, Israel|Hadassah Medical Center, Jerusalem, Israel|Meir Medical Center, Kfar Saba, Israel|Rabin Medical Center, Petach Tikva, Israel|Sheba Medical Center, Ramat Gan, Israel|IRCCS Ospedale Policlinico San Martino, Genova, Italy|Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico, Milano, Italy|Azienda Ospedaliera Universitaria Policlinico de Modena, Modena, Italy|Azienda Ospedaliera - Universitaria Pisana, Pisa, Italy|Azienda Policlinico Umberto I, Roma, Italy|Azienda Ospedaliera Santa Maria Della Misericordia, Udine, Italy|University of Occupational and Enviromental Health, Kitakyushu, Fukuoka, Japan|Hiroshima University Hospital, Hiroshima-shi, Hiroshima-ken, Japan|National Hospital Organization Asahikawa Medical Center, Asahikawa, Hokkaido, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, Japan|Jp Red Cross Society Himeji Hp, Himeji, Hyogo, Japan|Kobe University Hospital, Kobe, Hyogo, Japan|Kagawa University Hospital, Kita-gun, Kagawa, Japan|Tohoku University Hospital, Sendai-shi, Miyagi, Japan|Tomishiro Central Hospital, Tomigusuku, Okinawa, Japan|Seirei Hamamatsu General Hospital, Hamamatsu, Shizuoka, Japan|Juntendo University Hospital, Bunkyo-ku, Tokyo, Japan|Nippon Medical School Hospital, Bunkyo-Ku, Tokyo, Japan|St. Lukes International Hospital, Chuo-Ku, Tokyo, Japan|Toho University Ohashi Med C, Meguro-ku, Tokyo, Japan|Showa University Hospital, Shinagawa-ku, Tokyo, Japan|Keio University Hospital, Shinjuku-Ku, Tokyo, Japan|National Hospital Organization Kyushu Medical Center, Fukuoka, Japan|Hamanomachi Hospital, Fukuoka, Japan|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Kyung Pook National University Hospital, Daegu, Korea, Korea, Republic of|Chungnam National University Hospital, Daejeon, Korea, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Korea, Republic of|Hanyang University Medical Center, Seoul, Korea, Korea, Republic of|Asan Medical Center, Seoul, Korea, Korea, Republic of|Seoul St. Mary's Hospital, Seoul, Korea, Korea, Republic of|Dr. Alberto Esteban Bazzoni Ruiz, Torreon, Coahuila, Mexico|Hospital Angeles Lindavista, Mexico city, DF, Mexico|Clinica para el Diagnostico y Tratamiento de la Enfermedades, Mexico City, Distrito Federal, Mexico|Morales Vargas Centro de Investigacion, S.C., Leon, Guanajuato, Mexico|Centro Integral en Reumatologia SA de CV, Guadalajara, Jalisco, Mexico|Clinica en Investigación en Reumatologia y Obesidad S.C., Guadalajara, Jalisco, Mexico|Centro de Estudios de Investigacion Metabolicos y Cardiovasculares, Guadalajara, Jalisco, Mexico|Investigación Biomédica para el Desarrollo de Fármacos S.A. de C.V., Zapopan, Jalisco, Mexico|Centro de Alta Especialidad Reumatologia Inv del Potosi SC, San Luis Potosi, SLP, Mexico|Consultorio Jose Luis Garcia Figueroa, Villahermosa, Tabasco, Mexico|Köhler & Milstein Research, Merida, Yucatan, Mexico|Centro Peninsular de Investigacion S.C.P, Merida, Yucatán, Mexico|Cemdeicy S.C.P., Merida, Yucatán, Mexico|Centro de Investigación y Tratamiento Reumatológico S.C, Ciudad De México, Mexico|Centro Medico Dalinde, Mexico City, Mexico|Oaxaca Site Management Organization SC, Oaxaca, Mexico|Zuyderland MC, Sittard - Geleen, Limburg, Netherlands|Vrije Universiteit Medisch Centrum Amsterdam, Amsterdam, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Medische Centrum Leeuwarden, Leeuwarden, Netherlands|Mary Mediatrix Medical Center, Lipa, Batangas, Philippines|Cebu Doctors Hospital, Cebu City, Cebu, Philippines|Southern Philippines Medical Center, Davao, Davao Del Norte, Philippines|Makati Medical Center, Makati, Luzon, Philippines|St. Luke's Medical Center, Quezon City, Luzon, Philippines|Angeles University Foundation and Medical Center, Angeles City, Pampanga, Philippines|Chong Hua Medical Arts Center, Cebu, Philippines|Niepubliczny Zaklad Opieki Zdrowotnej Biogenes Sp. z o.o., Wroclaw, Dolnoslaskie, Poland|Medycyna Kliniczna, Warszawa, Mazowieckie, Poland|Gabinet Internistyczno- Reumatologiczny Piotr Adrian Klimiuk, Bialystok, Podlaskie, Poland|Zespol Poradni Specjalistycznych REUMED, Lublin, Polska, Poland|Ambulatorium Barbara Bazela, Elblag, Warminsko-Mazurki, Poland|Szpital Uniwersytecki Nr 2 w Bydgoszczy, Klinika Reumatologii i Ukladowych Chorob Tkanki Lacznej, Bydgoszcz, Poland|Centrum Medyczne Pratia Katowice, Katowice, Poland|MCM Krakow - PRATIA - PPDS, Krakow, Poland|Centrum Medyczne Plejady, Krakow, Poland|NZOZ Lecznica MAK-MED s.c., Nadarzyn, Poland|Twoja Przychodnia Centrum Medyczne Nowa Sol, Nowa Sol, Poland|Klinika Reumatologii i Rehabilitacji, Poznan, Poland|Klinika Reumatologii, Chorob Wewnetrznych i Geriatrii PUM, Szczecin, Poland|""REUMATIKA - Centrum Reumatologii"" NZOZ, Warszawa, Poland|Centrum Medyczne AMED, Warszawa, Poland|Napoca Emergency Clinical County Hospital, Napoca, Cluj, Romania|Craiova Emergency Clinical County Hospital, Craiova, Dolj, Romania|C.M.D.T.A. Neomed, Brasov, Romania|SANA Medical Center, Bucharest, Romania|Spitalul Clinic Sf Maria Bucuresti, Bucuresti, Romania|Spitalul Clinic Sf Maria Bucuresti, Bucuresti, Romania|Spitalul Clinic ""Dr. Ioan Cantacuzino"", Bucuresti, Romania|Spitalul Euroclinic, Bucureti, Romania|LLC MK Med, St. Petersburg, Saint Petersburg, Russian Federation|Chelyabinsk Regional Clinical Hospital, Chelyabinsk, Russian Federation|City Hospital # 7, Kazan, Russian Federation|V.A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation|Russian National Research Medical University n.a. N.I.Pirogov, Moscow, Russian Federation|City Clinical Hospital 1 named after N.I. Pirogov, Moscow, Russian Federation|Moscow State University of Medicine and Dentistry n.a. Evdokimov, Moscow, Russian Federation|Research Institute of Clinical Immunology, Novosibirsk, Russian Federation|Institute of Cytology and Genetics of Siberian Branch of Russian Academy of Medical Sciences, Novosibirsk, Russian Federation|Regional Hospital - Omsk, Omsk, Russian Federation|Orenburg State Medical Academy of Roszdrav, Orenburg, Russian Federation|Kursk Regional Clinical Hospital, Rursk, Russian Federation|Ryazan State Medical University, Ryazan, Russian Federation|Russian Medical Military Academy n.a. S.M. Kirov, Saint Petersburg, Russian Federation|Departmental Hospital at Smolensk Station ""rzhd"" JSC, Smolensk, Russian Federation|Kuvatov Republican Clinical Hospital, Ufa, Russian Federation|LLC Medical Center Zdorovaya Semiya, Zonova, Russian Federation|Clinical Center of Serbia, Belgrade, Serbia|Clinical Center of Serbia, Belgrade, Serbia|Institute of Rheumatology, Belgrade, Serbia|Institute of Rheumatology, Belgrade, Serbia|Institute of Rheumatology, Belgrade, Serbia|Military Medical Academy, Belgrade, Serbia|Institute for Treatment and Rehabilitation Niska Banja, Niska Banja, Serbia|Clinical Center of Vojvodina, Novi Sad, Serbia|Suite 509 Umhlanga Netcare Medical Centre, Umhlanga, Durban, South Africa|Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, Guateng, South Africa|Vincent Pallotti Hospital, Cape Town, Western Cape, South Africa|Panorama Medical Centre, Cape Town, Western Cape, South Africa|Winelands Medical Research Centre, Stellenbosch, Western Cape, South Africa|Suite 209A Jakaranda Hospital, Pretoria, South Africa|University Of Pretoria, Pretoria, South Africa|Hospital Marina Baixa, La Vila Joiosa, Alicante, Spain|Corporacion Sanitaria Parc Tauli, Sabadell, Barcelona, Spain|Hospital De Fuenlabrada, Fuenlabrada, Madrid, Spain|Hospital do Meixoeiro, Vigo, Pontevedra, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Corporació Sanitària Clínic, Barcelona, Spain|Hospital Quiron Infanta Luisa, Sevilla, Spain|Universitätsspital Basel, Basel, Basel Stadt, Switzerland|Cantonal Hospital St.Gallen, st.Gallen, Sankt Gallen, Switzerland|Buddhist Tzu-Chi General Hospital, Dalin Township, Taiwan|Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|Chang Gung Memorial Hospital - Kaohsiung Branch, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|Chi-Mei Medical Center, Tainan City, Taiwan|Taipei Medical University Hospital, Taipei City, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital - Linkou, Taoyuan City, Taiwan|Maidstone Hospital, Maidstone, Kent, United Kingdom|Whipps Cross University Hospital, Leytonstone, London, United Kingdom|St George's Hospital, Tooting, London, United Kingdom|Guys/St. Thomas Hospital, London, Surrey, United Kingdom|Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust, Doncaster, United Kingdom|Leeds Teaching Hospital, Leeds, United Kingdom",8158616,C07D487/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,3.0,37.257438551099604,12.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.08,371.42,120.56,6.0,1.0,4.0,36.72,105.55,4.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)O)c2ccc3ccccc3c21,RHEUMATOID ARTHRITIS,_INDOCYANINE_GREEN,NCT02680067,Phase 1,Recruiting,All,"18 Years to 89 Years   (Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"University of Rochester, Rochester, New York, United States",6915154,A61B5/0261,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,11.0,58.7773876260292,7.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.26,753.99,114.99,7.0,2.0,6.0,87.2,231.13,14.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
CC(=O)C(=O)O,BREAST CANCER,_PYRUVATE,NCT03121989,Phase 1,Recruiting,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Screening,"Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-0.38,88.0621,54.37,3.0,1.0,0.0,7.31,17.99,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0
C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1,BREAST CANCER,_PACRITINIB,NCT04520269,Phase 1|Phase 2,Recruiting,All,"21 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National University Hospital, Singapore, Singapore",WO-2010068181-A1,A61P35/00,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,17.0,32.7488,7.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.78,472.589,68.74,7.0,1.0,5.0,52.32,139.43,4.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
CN(C)CCC=C1c2ccccc2COc2ccccc21,BREAST CANCER,_DOXEPIN,NCT02447211,Phase 2,Recruiting,Female,"21 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Isfahan University of Medical Sciences, Isfahan, Iran, Islamic Republic of",6211229,5,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,31.0,13.5033573584673,975.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.08,279.3761,12.47,2.0,0.0,3.0,32.47,98.24,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
Cc1cc(Nc2cc(N)ncn2)c(=O)n2c1C(=O)NC21CCCCC1,BREAST CANCER,_TOMIVOSERTIB,NCT04261218,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cross Cancer Institute, Edmonton, Alberta, Canada|British Columbia Cancer Vancouver, Vancouver, British Columbia, Canada|Jewish General Hospital, Montreal, Quebec, Canada",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.53,340.38699999999994,113.24,6.0,3.0,4.0,35.86,97.64,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0
CC(=O)N[C@@H]1C(O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(=O)O)O[C@@H](OC2[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]2NC(C)=O)[C@H](O)[C@H]1O,"PAIN, POSTOPERATIVE",_HYALURONIC_ACID,NCT03814707,Not Applicable,Recruiting,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Faculty of Dental Medicine - Cairo University -, Giza, Egypt",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-1.8,776.6486,399.71,23.0,14.0,4.0,70.56,155.1,12.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0
Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1,BREAST CANCER,_ALPELISIB,NCT03056755,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Mayo Clinic (Arizona), Phoenix, Arizona, United States|Kaiser Permanente Medical Group Kaiser Permanente-Moanalua M.C, Anaheim, California, United States|Beverly Hills Cancer Center, Beverly Hills, California, United States|USC Norris Cancer Center, Los Angeles, California, United States|University of Calif Irvine Medical Center, Orange, California, United States|Kaiser Permanente Southern California, San Diego, California, United States|University of California, San Francisco, San Francisco, California, United States|Cancer Research Collaboration, Inc, Santa Ana, California, United States|Yale University Yale Cancer Center, New Haven, Connecticut, United States|Miami Cancer Center at Mercy Hospital, Miami, Florida, United States|Advent Health Cancer Institute, Orlando, Florida, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kansas Cancer Center, Kansas City, Kansas, United States|University of Louisville Hospital/James Brown Cancer Ctr. SC, Louisville, Kentucky, United States|Mercy Medical Center, Baltimore, Maryland, United States|Greater Baltimore Medical Center Cancer Center, Baltimore, Maryland, United States|Holy Cross Hospital Pharmacy, Silver Spring, Maryland, United States|Massachusetts General Hospital Neuroendocrine Unit, Boston, Massachusetts, United States|Lahey Clinic, Burlington, Massachusetts, United States|Josephine Ford Cancer Institute, Detroit, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|St Vincent Frontier Cancer Center, Billings, Montana, United States|New Mexico Cancer Care Alliance, Albuquerque, New Mexico, United States|Memorial Sloane Kettering Cancer Center, New York, New York, United States|University Hospitals of Cleveland Seidman Cancer Center, Cleveland, Ohio, United States|Texas Oncology Charles A. Sammons Cancer Ctr, Dallas, Texas, United States|Texas Oncology P A SC-3, Dallas, Texas, United States|Texas Oncology Houston Memorial City, Houston, Texas, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Texas Oncology P A Plano East, Plano, Texas, United States|Cancer Care Centers of South Texas HOAST CCC of So. TX- San Antonio(2), San Antonio, Texas, United States|UT Health San Antonio, San Antonio, Texas, United States|Virginia Oncology Associates SC, Norfolk, Virginia, United States|Northwest Medical Specialists, Tacoma, Washington, United States|Wenatchee Valley Medical Center, Wenatchee, Washington, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Rosario, Sante Fe, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, La Rioja, Argentina|Novartis Investigative Site, San Juan, Argentina|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Halifax, Nova Scotia, Canada|Novartis Investigative Site, Kitchener, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Temuco, Araucania, Chile|Novartis Investigative Site, Santiago, Chile|Novartis Investigative Site, Santiago, Chile|Novartis Investigative Site, Copenhagen, Denmark|Novartis Investigative Site, Odense C, Denmark|Novartis Investigative Site, Vejle, Denmark|Novartis Investigative Site, Nice Cedex 2, Alpes Maritimes, France|Novartis Investigative Site, Saint-Cloud, Hauts De Seine, France|Novartis Investigative Site, Bordeaux, France|Novartis Investigative Site, Caen Cedex, France|Novartis Investigative Site, Lille Cedex, France|Novartis Investigative Site, Lyon, France|Novartis Investigative Site, Montpellier Cedex 5, France|Novartis Investigative Site, Saint Herblain cedex, France|Novartis Investigative Site, Strasbourg Cedex, France|Novartis Investigative Site, Toulouse Cedex 9, France|Novartis Investigative Site, Augsburg, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Kiel, Germany|Novartis Investigative Site, Ravensburg, Germany|Novartis Investigative Site, Troisdorf, Germany|Novartis Investigative Site, Tübingen, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Kolkata, West Bengal, India|Novartis Investigative Site, Delhi, India|Novartis Investigative Site, Kfar Saba, Israel|Novartis Investigative Site, Petach Tikva, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Rehovot, Israel|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Ancona, AN, Italy|Novartis Investigative Site, Bergamo, BG, Italy|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Bologna, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Osaka-city, Osaka, Japan|Novartis Investigative Site, Suita city, Osaka, Japan|Novartis Investigative Site, Bunkyo ku, Tokyo, Japan|Novartis Investigative Site, Koto ku, Tokyo, Japan|Novartis Investigative Site, Shinjuku-ku, Tokyo, Japan|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Mexico D F, Distrito Federal, Mexico|Novartis Investigative Site, Jalisco, Mexico|Novartis Investigative Site, Maastricht, AZ, Netherlands|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Malaga, Andalucia, Spain|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Salamanca, Castilla Y Leon, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Hospitalet de LLobregat, Catalunya, Spain|Novartis Investigative Site, Castellon, Comunidad Valenciana, Spain|Novartis Investigative Site, San Sebastian, Pais Vasco, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Tainan, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Sutton, Surrey, United Kingdom|Novartis Investigative Site, Edinburgh, United Kingdom|Novartis Investigative Site, Leicester, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Nottingham, United Kingdom",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,5.0,34.431918519887475,2.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.76,441.47,101.21,4.0,2.0,3.0,42.75,105.85,5.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12,SYSTEMIC LUPUS ERYTHEMATOSUS,_UPADACITINIB,NCT04451772,Phase 2,Recruiting,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Wallace Rheumatic Studies Ctr /ID# 224374, Beverly Hills, California, United States|Valerius Med Grp & Res Ctr /ID# 223922, Los Alamitos, California, United States|Beth Israel Deaconess Medical Center /ID# 222505, Boston, Massachusetts, United States|June DO, PC /ID# 221841, Lansing, Michigan, United States|STAT Research, Inc. /ID# 221840, Vandalia, Ohio, United States|Tekton Research, Inc. /ID# 224411, Austin, Texas, United States|Aprillus Asistencia e Investig /ID# 221890, Capital Federal, Buenos Aires, Argentina|Hospital Interzonal Gral Agudos San Martin /ID# 221893, La Plata, Buenos Aires, Argentina|CER Instituto Medico /ID# 223175, Quilmes, Buenos Aires, Argentina|Fundacion Respirar /ID# 223174, Ciudad Autonoma Buenos Aires, Ciuadad Autonoma De Buenos Aires, Argentina|Centro Medico Privado/Reuma /ID# 221888, San Miguel de Tucuman, Ciuadad Autonoma De Buenos Aires, Argentina|Instituto CAICI SRL /ID# 221892, Rosario, Santa Fe, Argentina|Hospital Militar Central Ciruj /ID# 222569, Buenos Aires, Argentina|Hospital Cordoba /ID# 221894, Cordoba, Argentina|Investigaciones Clin Tucuman /ID# 221889, San Miguel de Tucuman, Argentina|Centro de Enfermedades del Hígado y Aparato Digestivo /ID# 221891, Santa Fe, Argentina|MHAT Kaspela /ID# 223360, Plovdiv, Bulgaria|UMHAT Sv. Ivan Rilski /ID# 223358, Sofia, Bulgaria|UMHAT Sv. Ivan Rilski /ID# 223359, Sofia, Bulgaria|Anhui Provincial Hospital /ID# 222854, Hefei, Anhui, China|Xiangya Hospital Central South University /ID# 222850, Changsha, Hunan, China|Huashan Hospital of Fudan University /ID# 222929, Shanghai, Shanghai, China|People's Hospital of Xinjiang /ID# 222928, Urumqi, China|Vrije Universiteit Medisch Centrum /ID# 221776, Amsterdam, Netherlands|Leids Universitair Medisch Centrum /ID# 221774, Leiden, Netherlands|Universitair Medisch Centrum Utrecht /ID# 221775, Utrecht, Netherlands|GCM Medical Group, PSC /ID# 224394, San Juan, Puerto Rico|Mindful Medical Research /ID# 222513, San Juan, Puerto Rico|Hospital Universitario A Coruña - CHUAC /ID# 221993, A Coruña, A Coruna, Spain|Hospital Universitario Basurto /ID# 221999, Bilbao, Spain|Hospital Universitario de Galdakao /ID# 221996, Galdakao, Spain|Hospital Universitario 12 de Octubre /ID# 221994, Madrid, Spain|Hospital Universitario Virgen de Valme /ID# 221997, Sevilla, Spain|Hospital Universitario y Politecnico La Fe /ID# 221998, Valencia, Spain|HUA - Txagorritxu /ID# 221992, Vitoria, Spain|China Medical University Hosp /ID# 221747, Taichung City, Taichung, Taiwan|National Taiwan Univ Hosp /ID# 221745, Taipei City, Taipei, Taiwan|Taichung Veterans General Hosp /ID# 221748, Taichung City, Taiwan|Taipei Veterans General Hosp /ID# 221746, Taipei City, Taiwan|Linkou Chang Gung Memorial Ho /ID# 222469, Taoyuan City, Taiwan",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,53.0,68.53528819893633,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.57,380.375,78.32,3.0,2.0,4.0,36.09,93.03,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,METASTATIC BREAST CANCER,_GEMCITABINE,NCT03901339,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"HonorHealth Research Institute, Avondale, Arizona, United States|Arizona Oncology Associates, PC, Tucson, Arizona, United States|Highlands Oncology Group, Fayetteville, Arkansas, United States|University of California, San Diego Moores Cancer Center, La Jolla, California, United States|Los Angeles Hematology Oncology Medical Group, Los Angeles, California, United States|UCLA Department of Medicine - Hematology/Oncology, Los Angeles, California, United States|University of California, Irvine Medical Center-Chao Family Comprehensive Cancer Center, Orange, California, United States|Southern California Permanente Medical Group, San Diego, California, United States|UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Rocky Mountain Cancer Centers, Aurora, Colorado, United States|University of Colorado, Aurora, Colorado, United States|Yale University Cancer Center, New Haven, Connecticut, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|University of Miami - Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Miami Cancer Institute, Miami, Florida, United States|Orlando Health, Inc., Orlando, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory University - Winship Cancer Institute, Atlanta, Georgia, United States|Northside Hospital, Inc., Atlanta, Georgia, United States|University of Chicago Medical Center, Chicago, Illinois, United States|The University of Kansas Cancer Center, Westwood, Kansas, United States|James Graham Brown Cancer Center, Louisville, Kentucky, United States|Mercy Medical Center, Medical Oncology & Hematology, Baltimore, Maryland, United States|Maryland Oncology Hematology, P.A., Rockville, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Allina Health, Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States|Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States|Saint Luke's Cancer Institute, Kansas City, Missouri, United States|Washington University School of Medicine - Siteman Cancer Center, Saint Louis, Missouri, United States|St. Vincent Frontier Cancer Center, Billings, Montana, United States|Summit Medical Group, Florham Park, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|New York Oncology Hematology, P.C., Albany, New York, United States|Laura and Isaac Perlmutter Cancer Center/NYU Langone Health, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|The Ohio State University, Columbus, Ohio, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States|The West Clinic, PC dba West Cancer Center, Germantown, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|University of Texas Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas, United States|Texas Oncology-Denton South, Denton, Texas, United States|Houston Methodist Hospital/Houston Methodist Cancer Center, Houston, Texas, United States|Texas Oncology-Longview Cancer Center, Longview, Texas, United States|UT Health San Antonio - Mays Cancer Center, San Antonio, Texas, United States|Virginia Cancer Specialists, Arlington, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Oncology & Hematology Associates of Southwest Virginia, Inc. DBA Blue Ridge Cancer Care, Salem, Virginia, United States|Northwest Medical Specialties, PLLC, Tacoma, Washington, United States|Chirec Cancer Institute, Brussels, Belgium|Institut Jules Bordet, Brussels, Belgium|Universitair Ziekenhuis Leuven, Leuven, Belgium|CHU UCL Namur/Site Sainte Elisabeth, Namur, Belgium|Nova Scotia Cancer Centre, Halifax, Nova Scotia, Canada|Hopital de Mercy, Ars-Laquenexy, France|Institut Sainte Catherine, Avignon, France|Hôpital Jean-Minjoz, Besançon, France|Centre Georges-Francois Leclerc, Dijon, France|Centre Leon Berard, Lyon, France|Institut Régional du Cancer de Montpellier, Montpellier, France|Institut Curie, Paris, France|Hospices Civils de Lyon, Pierre-Bénite, France|Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France|Institut Claudius Regaud, Toulouse, France|HELIOS Klinikum Berlin-Buch, Berlin, Germany|Gynakologisches Zentrum Bonn, Bonn, Germany|Marienhospital Bottrop, Bottrop, Germany|Städtisches Klinikum Dessau, Dessau, Germany|Universitätsklinikum Erlangen, Erlangen, Germany|Kliniken Essen-Mitte, Essen, Germany|Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Germany|Onkologische Schwerpunktpraxis Eppendorf, Hamburg, Germany|Gynakologisch-Onkologische Praxis Hannover, Hannover, Germany|Nationales Centrum für Tumorerkrankungen - Heidelberg, Heidelberg, Germany|Praxisklinik für Hämatologie und Onkologie Koblenz, Koblenz, Germany|Universitätsmedizin Mannheim, Mannheim, Germany|Ospedale di Desio, Desio, Italy|Ospedale San Raffaele, Milano, Italy|Azienda Unità Sanitaria Locale di Piacenza-Ospedale Guglielmo da Saliceto, Piacenza, Italy|IFO Istituto Nazionale dei Tumori Regina Elena, Rome, Italy|Antoni van Leeuwenhoekziekenhuis, Amsterdam, Netherlands|Maastricht UMC+, Maastricht, Netherlands|Complejo Hospitalario Universitario A Coruna, A Coruña, Spain|Hospital Quirónsalud Barcelona Instituto Oncologico Baselga, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital de la Santa Creu I Sant Pau, Barcelona, Spain|Hospital Provincial de Castellón, Castillón, Spain|Hospital Universitari Arnau de Vilanova, Lleida, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Instituto Oncologico Bureau (IOB), Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Clinico Universitario de Santiago de Compostela, Santiago De Compostela, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Royal Cornwall Hospital NHS Trust, Cornwell, United Kingdom|Royal Surrey County Hospital, Guildford, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|Barts Health NHS Trust, London, United Kingdom|The Royal Marsden NHS Foundation Trust, London, United Kingdom|The Royal Marsden NHS Trust, London, United Kingdom",4808614.0,C07D317/30,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,14.0,20.8628513932524,1700.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.14,263.1981,108.38,6.0,3.0,2.0,21.45,53.25,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
CCCCCCCCCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]1C(=O)NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@@H]([C@H](C)CC(=O)O)C(=O)N[C@@H](CC(=O)c2ccccc2N)C(=O)O[C@@H]1C,ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTION,_DAPTOMYCIN,NCT04298463,,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry|Other,Observational Model: Cohort|Time Perspective: Retrospective,"University Hospital of Alexandroupolis, Alexandroupolis, Greece|Attikon University Hospital, Rimini 1, Chaidari, 124 62, Athens, Greece|University Hospital of Heraklion, Heraklion, Greece|University General Hospital of Thessaloniki AHEPA /, Thessaloníki, Greece|AO Sant'Orsola Malpighi Unità Operativa di Malattie Infettive, Bologna, Italy|Azienda Ospedaliera per l'Emergenza Cannizzaro Unità Operativa Complessa di Malattie Infettive, Catania, Italy|A.O.U. Careggi SOD Malattie Infettive e Tropicali, Firenze, Italy|Ospedale Policlinico San Martino - IRCCS Genova Clinica Malattie Infettive, Genova, Italy|ASST MANTOVA Ospedale Carlo Poma di Mantova S.C. Malattie Infettive, Mantova, Italy|A.S.S.T. GRANDE OSPEDALE METROPOLITANO NIGUARDA S.C. Malattie Infettive Dipartimento Medico Polispecialistico, Milan, Italy|AOU Federico II di Napoli Dipartimento di Medicina clinica e Chirurgia UOC Malattie Infettive, Napoli, Italy|Azienda Ospedaliera di Padova U.O.C. Malattie Infettive e Tropicali, Padova, Italy|Ospedale S. Maria della Misericordia Clinica Malattie Infettive Dipartimento di Medicina, Università Studi di Perugia, Perugia, Italy|A.O.U. Pisana Stabilimento di Cisanello U.O Malattie Infettive, Pisa, Italy|A.O.R. San Carlo Struttura Interaziendale Complessa di Malattie Infettive, Potenza, Italy|AOU Città della Salute e Scienza - Presidio Molinette SC Malattie Infettive, Torino, Italy",6468967.0,A61K38/12,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,45.0,36.9288897102609,8.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.47,1620.693,702.02,27.0,22.0,4.0,158.96,393.57,35.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O,ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTION,_VANCOMYCIN,NCT04298463,,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry|Other,Observational Model: Cohort|Time Perspective: Retrospective,"University Hospital of Alexandroupolis, Alexandroupolis, Greece|Attikon University Hospital, Rimini 1, Chaidari, 124 62, Athens, Greece|University Hospital of Heraklion, Heraklion, Greece|University General Hospital of Thessaloniki AHEPA /, Thessaloníki, Greece|AO Sant'Orsola Malpighi Unità Operativa di Malattie Infettive, Bologna, Italy|Azienda Ospedaliera per l'Emergenza Cannizzaro Unità Operativa Complessa di Malattie Infettive, Catania, Italy|A.O.U. Careggi SOD Malattie Infettive e Tropicali, Firenze, Italy|Ospedale Policlinico San Martino - IRCCS Genova Clinica Malattie Infettive, Genova, Italy|ASST MANTOVA Ospedale Carlo Poma di Mantova S.C. Malattie Infettive, Mantova, Italy|A.S.S.T. GRANDE OSPEDALE METROPOLITANO NIGUARDA S.C. Malattie Infettive Dipartimento Medico Polispecialistico, Milan, Italy|AOU Federico II di Napoli Dipartimento di Medicina clinica e Chirurgia UOC Malattie Infettive, Napoli, Italy|Azienda Ospedaliera di Padova U.O.C. Malattie Infettive e Tropicali, Padova, Italy|Ospedale S. Maria della Misericordia Clinica Malattie Infettive Dipartimento di Medicina, Università Studi di Perugia, Perugia, Italy|A.O.U. Pisana Stabilimento di Cisanello U.O Malattie Infettive, Pisa, Italy|A.O.R. San Carlo Struttura Interaziendale Complessa di Malattie Infettive, Potenza, Italy|AOU Città della Salute e Scienza - Presidio Molinette SC Malattie Infettive, Torino, Italy",10188697,A61K9/08,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,26.0,38.768763218957204,1648.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.11,1449.254,530.49,24.0,19.0,10.0,138.7,346.61,13.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
CC(=O)N[C@@H]1[C@H](Oc2c3cc4cc2Oc2ccc(cc2Cl)[C@@H](O[C@@H]2O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]2NC(C)=O)[C@@H]2NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H]4NC(=O)[C@@H](Cc5ccc(c(Cl)c5)O3)NC(=O)[C@H](N)c3ccc(O)c(c3)Oc3cc(O)cc4c3)c3ccc(O)c(c3)-c3c(O[C@H]4O[C@H](CO)[C@@H](O)[C@@H](O)[C@@H]4O)cc(O)cc3[C@@H](C(=O)O)NC2=O)O[C@@H](CO)[C@@H](O)[C@@H]1O,ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTION,_TEICOPLANIN,NCT04298463,,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry|Other,Observational Model: Cohort|Time Perspective: Retrospective,"University Hospital of Alexandroupolis, Alexandroupolis, Greece|Attikon University Hospital, Rimini 1, Chaidari, 124 62, Athens, Greece|University Hospital of Heraklion, Heraklion, Greece|University General Hospital of Thessaloniki AHEPA /, Thessaloníki, Greece|AO Sant'Orsola Malpighi Unità Operativa di Malattie Infettive, Bologna, Italy|Azienda Ospedaliera per l'Emergenza Cannizzaro Unità Operativa Complessa di Malattie Infettive, Catania, Italy|A.O.U. Careggi SOD Malattie Infettive e Tropicali, Firenze, Italy|Ospedale Policlinico San Martino - IRCCS Genova Clinica Malattie Infettive, Genova, Italy|ASST MANTOVA Ospedale Carlo Poma di Mantova S.C. Malattie Infettive, Mantova, Italy|A.S.S.T. GRANDE OSPEDALE METROPOLITANO NIGUARDA S.C. Malattie Infettive Dipartimento Medico Polispecialistico, Milan, Italy|AOU Federico II di Napoli Dipartimento di Medicina clinica e Chirurgia UOC Malattie Infettive, Napoli, Italy|Azienda Ospedaliera di Padova U.O.C. Malattie Infettive e Tropicali, Padova, Italy|Ospedale S. Maria della Misericordia Clinica Malattie Infettive Dipartimento di Medicina, Università Studi di Perugia, Perugia, Italy|A.O.U. Pisana Stabilimento di Cisanello U.O Malattie Infettive, Pisa, Italy|A.O.R. San Carlo Struttura Interaziendale Complessa di Malattie Infettive, Potenza, Italy|AOU Città della Salute e Scienza - Presidio Molinette SC Malattie Infettive, Torino, Italy",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,VITILIGO,_DEXAMETHASONE,NCT04030988,Phase 1,Recruiting,All,"6 Years to 60 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment,"Ain Shams University, Cairo, Abbaseya, Egypt",6284804,4,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,METASTATIC BREAST CANCER,_DOXORUBICIN,NCT04159818,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Antoni van Leeuwenhoek, Amsterdam, Netherlands",5013556,C07F9/5537,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,33.0,18.5301546232982,5989.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.41,543.5193,206.07,12.0,6.0,5.0,53.87,134.59,5.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,ATOPIC DERMATITIS,_CHOLECALCIFEROL,NCT02537509,Phase 2,Recruiting,All,"15 Years and older   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CHU d'Angers, Angers, France|Hôpital Saint André, Bordeaux, France|Hôpital Morvan, Brest, France|Hôpital Femme-Mère-Enfant - Hospices Civils de Lyon, Bron, France|Hôpital Trousseau, Chambray Les Tours, France|CHD Vendée, La Roche sur Yon, France|Centre Hospitalier, Le Mans, France|Hôpital Claude Huriez, Lille, France|CHU de Nantes - Hôtel Dieu, Nantes, France|APHP - Hôpital Tenon, Paris, France|Centre Hospitalier, Perigueux, France|Hôpital Laënnec, Quimper, France|Hôpital Pontchaillou, Rennes, France|CHR St Brieuc, Saint Brieuc, France|Centre Hospitalier, Valence, France|Centre Hospitalier, Valenciennes, France",5994329.0,6,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,44.0,15.540360171666698,1534.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,7.98,384.6377,20.23,1.0,1.0,3.0,49.6,123.22,6.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,INTUBATION COMPLICATION,_BUDESONIDE,NCT03250975,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","Vanderbilt University Medical Center, Nashville, Tennessee, United States",6123924,A61K9/008,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,INTUBATION COMPLICATION,_AZITHROMYCIN,NCT03250975,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","Vanderbilt University Medical Center, Nashville, Tennessee, United States",5192535.0,A61K9/0048,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0
CC(C)Cn1cnc2c(N)nc3ccccc3c21,METASTATIC BREAST CANCER,_IMIQUIMOD,NCT03982004,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Washington University School of Medicine, Saint Louis, Missouri, United States",4689338,C07D471/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,22.0,21.289964886342602,122.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.83,240.3036,56.73,3.0,1.0,3.0,26.67,72.54,2.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0
CCN(CC)C(=S)SSC(=S)N(CC)CC,METASTATIC BREAST CANCER,_DISULFIRAM,NCT04265274,Phase 2,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Cancer Institute, Bratislava, Slovakia",3932346,C08F2/50,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,17.0,7.523768455204411,392.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.88,296.539,6.48,0.0,0.0,0.0,31.6,88.24,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
[N-]=[N+]=O,ABSCESS,_NITROUS_OXIDE,NCT03127371,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Einstein Medical Center Philadelphia, Philadelphia, Pennsylvania, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-0.45,44.0128,51.21,2.0,0.0,0.0,2.55,27.67,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1,ATOPIC DERMATITIS,_BARICITINIB,NCT03952559,Phase 3,Recruiting,All,2 Years to 17 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Centro de Investigaciones Metabólicas (CINME), Caba, Buenos Aires, Argentina|Centro Medico Dra. De Salvo, Capital Federal, Argentina|Fundacion CIDEA, Ciudad Autonoma Buenos Aires, Argentina|Instituto de Neumonología y Dermatología, Ciudad Autonoma Buenos Aires, Argentina|The Sydney Children's Hospitals Network, Westmead, New South Wales, Australia|Veracity Clinical Research Pty Ltd, Woolloongabba, Queensland, Australia|Royal Childrens Hospital Melbourne, Parkville, Victoria, Australia|Universitätsklinikum Graz, Graz, Steiermark, Austria|Medizinische Universität Wien, Wien, Vienna, Austria|Sozialmedizinisches Zentrum Ost/Donauspital, Vienna, Wien, Austria|IDERJ - Instituto de Dermatologia e Estética do Brasil, Rio de Janeiro, RJ, Brazil|Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil|Fundação Faculdade de Medicina do ABC, Santo André, Sao Paulo, Brazil|Instituto Brasil de Pesquisa Clínica - IBPCLIN, Rio de Janeiro, Brazil|Hospital de Servidor Publico Estadual, São Paulo, Brazil|Fakultni Nemocnice v Motole, Praha 5, Hl. M. Praha, Czechia|Nemocnice Na Bulovce, Praha 8, Hl. M. Praha, Czechia|Kozni oddeleni, Novy Jicin, Moravskoslezsky Kraj, Czechia|Fakultni nemocnice Hradec Kralove, Hradec Kralove, Czechia|Sanatorium profesora Arenbergera, Praha 1, Czechia|Centre Hospitalier Victor Dupouy Argenteuil, Argenteuil, Cedex, France|CHRU de Brest - Hôpital Morvan, Brest, France|Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu, Nantes Cedex 1, France|CHU de Nice Hopital de L'Archet, Nice, France|Hopital Larrey, Toulouse, France|Centre Hospitalier de Valence, Valence, France|Klinikum der Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt am Main, Hessen, Germany|Universitätsklinikum Münster, Münster, Nordrhein-Westfalen, Germany|Universitätsklinikum Carl Gustav Carus, Dresden, Sachsen, Germany|Katholisches Kinderkrankenhaus Wilhelmstift, Hamburg, Germany|Oroshaza Varosi Onkormanyzat Korhaza, Oroshaza, Bekes, Hungary|SZTE AOK Borgyogyaszati es Allergologiai Klinika, Szeged, Csongrad, Hungary|Allergo-Derm Bakos Kft, Szolnok, Jasz-Nagykun-Szolnok, Hungary|All India Institute of Medical Sciences, New Delhi, Delhi, India|Sir Ganga Ram Hospital, New Delhi, Delhi, India|B. J. Medical College & Civil Hospital, Ahmedabad, Gujarat, India|GMERS Medical College & Hospital, Vadodara, Gujarat, India|Dr. D. Y. Patil Medical College & Hospital, Navi Mumbai, Maharashtra, India|Seth GS Medical College & KEM Hospital, Mumbai, Maharshtra, India|Lifepoint Multispecialty Hsptl, Wakad, Pune, India|Post Graduate Institute of Medical Education & Research, Chandigarh, Punjab, India|Maulana Azad Medical College & LNJP, GB Pant Hospitals, New Delhi, India|Aakash Healthcare Super Speciality Hospital, New Delhi, India|Ha'Emek Medical Center, Afula, Israel|Soroka Medical Center, Beer Sheva, Israel|Sheba Medical Center, Ramat Gan, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Nagoya Medical Center, Nagoya, Aichi, Japan|Fukuyama City Hospital, Fukuyama-shi, Hiroshima, Japan|Takeda Derm Skin Care Clin, Sapporo-city, Hokkaido, Japan|National Sagamihara Hospital, Sagamihara, Kanagawa, Japan|Japan National Hospital Organization Mie Hospital, Tsu-shi, Mie, Japan|Kume Clinic, Sakai City, Osaka, Japan|Senri-Chuo Hanafusa Dermatology Clinic, Toyonaka-shi, Osaka, Japan|Dokkyo Medical University Hospital, Shimotsuga-Gun, Tochigi, Japan|Tokyo Rosai Hospital, Ota-Ku, Tokyo, Japan|Shinjuku Minamiguchi Dermatology, Shinjuku-ku, Tokyo, Japan|Matsuda Tomoko Dermatological Clinic, Fukuoka, Japan|Consultorio Privado de la Dra. Villanueva, Guadalajara, Jalisco, Mexico|Hospital Universitario Dr. Jose Eleuterio Gonzalez, Monterrey, NL, Mexico|Instituto de Investigaciones Aplicadas a la Neurociencia A.C, Durango, Mexico|CRI Centro Regiomontano de Investigación, Monterrey, Mexico|Arke Estudios Clinicos S.A. de C.V., Veracruz, Mexico|Dermed Centrum Medyczne Sp. z o.o., Lodz, Lodzkie, Poland|Diamond Clinic, Krakow, Malopolskie, Poland|Centrum Badan Klinicznych PI-House sp. z o.o., Gdansk, Pomorskie, Poland|GBUZ Clinical dermatology and venereological dispensary, Krasnodar, Krasnodarskiy Kray, Russian Federation|State Healthcare Instit Tula Reg Dermatov Dispensary, Tula, Tul'skaja Oblast, Russian Federation|Pirogov Russian National Research Medical University, Moscow, Russian Federation|Scientific Center of Children's Health, Moscow, Russian Federation|Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology, Moscow, Russian Federation|Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain|Hospital Univ. Puerta de Hierro, Majadahonda, Madrid, Spain|Clinica Universitaria De Navarra, Pamplona, Navarra, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Infantil Universitario Niño Jesús, Madrid, Spain|Clinica Universidad Navarra-Sede Madrid, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Centro de Especialidades Mollabao, Pontevedra, Spain|Universitäts-Kinderspital beider Basel UKBB, Basel, Basel Stadt, Switzerland|Universitäts-Kinderspital Zürich, Zürich, Switzerland|Chang Gung Memorial Hospital - Kaohsiung Branch, Kaohsiung City, Taiwan|Taipei Medical University- Shuang Ho Hospital, New Taipei City, Taiwan|Chung Shan Medical University Hospital, Taichung City, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan|Chang Gung Memorial Hospital - Taipei, Taipei, Taiwan|Chang Gung Memorial Hospital - Linkou, Taoyuan City, Taiwan|St Thomas's Hospital, Waterloo, London, United Kingdom|Queen's Medical Centre, Nottingham University Hospitals, Nottingham, Nottinghamshire, United Kingdom|Royal Hospital for Children, Glasgow, United Kingdom",8158616,C07D487/04,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,3.0,37.257438551099604,12.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.08,371.42,120.56,6.0,1.0,4.0,36.72,105.55,4.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
CCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2C#N)c(=O)n1,BREAST CANCER,_SAPACITABINE,NCT03641755,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dana Farber Cancer Institute, Boston, Massachusetts, United States|Broad Institute of MIT, Cambridge, Massachusetts, United States",US-20050014716-A1,7,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,20.0,32.7488,2.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,4.83,490.645,135.25,7.0,3.0,2.0,56.94,132.29,17.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
COc1cc(OC)cc(N(CCNC(C)C)c2ccc3ncc(-c4cnn(C)c4)nc3c2)c1,METASTATIC BREAST CANCER,_ERDAFITINIB,NCT03238196,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama, Birmingham, Alabama, United States|University of California San Francicso, San Francisco, California, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Baptist Memorial Hospital MEMPHIS, Memphis, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|University of Texas Southwestern Simmons Comprehensive Cancer Center, Dallas, Texas, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,45.0,24.31261422205795,3.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.57,446.555,77.33,7.0,1.0,4.0,51.0,139.32,9.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0
CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12,ATOPIC DERMATITIS,_UPADACITINIB,NCT03569293,Phase 3,Recruiting,All,"12 Years to 75 Years   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Alliance Dermatology and MOHs /ID# 200375, Phoenix, Arizona, United States|Investigate MD /ID# 201256, Scottsdale, Arizona, United States|Bakersfield Derma & Skin Cance /ID# 200433, Bakersfield, California, United States|Tien Q Nguyen MD, Inc /ID# 201910, Fountain Valley, California, United States|California Allergy and Asthma Medical Group /ID# 200727, Los Angeles, California, United States|Allergy & Asthma Associates of Southern California /ID# 200733, Mission Viejo, California, United States|Dermatology Clinical Trials /ID# 205876, Newport Beach, California, United States|UC Davis /ID# 203622, Sacramento, California, United States|Synergy Dermatology /ID# 200842, San Francisco, California, United States|San Luis Derm and Laser Clinic /ID# 200372, San Luis Obispo, California, United States|Stanford University /ID# 200440, Stanford, California, United States|Care Access Research /ID# 200940, Walnut Creek, California, United States|Dermatology Physicians of CT /ID# 200928, Shelton, Connecticut, United States|Foxhall Research Center /ID# 213682, Washington, District of Columbia, United States|George Washington Univ Med /ID# 200364, Washington, District of Columbia, United States|Clearlyderm Dermatology /ID# 208371, Boca Raton, Florida, United States|Skin Care Research, LLC /ID# 200811, Boca Raton, Florida, United States|Olympian Clinical Research /ID# 202914, Clearwater, Florida, United States|Multi-Speciality Research Associates /ID# 213254, Lake City, Florida, United States|GSI Clinical Research, LLC /ID# 200849, Margate, Florida, United States|Florida International Rsrch cr /ID# 218507, Miami, Florida, United States|Tory P Sullivan, MD PA /ID# 200671, North Miami Beach, Florida, United States|Leavitt Medical Associates of Florida /ID# 200880, Ormond Beach, Florida, United States|Precision Clinical Research /ID# 209002, Sunrise, Florida, United States|Integrated Clinical Research LLC /ID# 200900, West Palm Beach, Florida, United States|Christie Clinic, LLC /ID# 200427, Champaign, Illinois, United States|Northwestern University Feinberg School of Medicine /ID# 201644, Chicago, Illinois, United States|Dawes Fretzin, LLC /ID# 200366, Indianapolis, Indiana, United States|The South Bend Clinic Center /ID# 200371, South Bend, Indiana, United States|Clinical Trials Management, LLC - Covington /ID# 212658, Covington, Louisiana, United States|Clinical Trials Management, LLC - Metairie /ID# 212659, Metairie, Louisiana, United States|Northeast Dermatology /ID# 201338, Beverly, Massachusetts, United States|Massachusetts General Hospital /ID# 200474, Boston, Massachusetts, United States|Integrated Dermatology of Massachusetts, LLC /ID# 209468, Quincy, Massachusetts, United States|Clin Res Inst of Michigan, LLC /ID# 208019, Chesterfield, Michigan, United States|Henry Ford Medical Center /ID# 204191, Detroit, Michigan, United States|Cleaver Dermatology /ID# 202825, Kirksville, Missouri, United States|Advanced Dermatology of the Midlands /ID# 201689, Omaha, Nebraska, United States|Clinical Research Consortium /ID# 200734, Las Vegas, Nevada, United States|AllCutis Research Inc /ID# 200981, Portsmouth, New Hampshire, United States|Forest Hills Dermatology Group /ID# 209244, Kew Gardens, New York, United States|The Mount Sinai Hospital /ID# 200370, New York, New York, United States|New York Presbyterian Hospital - Weill Cornell Medical Center /ID# 200456, New York, New York, United States|Joseph Schwartz MD Medical Cosmetic Derm /ID# 202121, Troy, New York, United States|Rapid Medical Research, INC /ID# 202653, Cleveland, Ohio, United States|Lynn Health Science Institute (LHSI) /ID# 212676, Oklahoma City, Oklahoma, United States|Newton Clinical Research /ID# 204169, Oklahoma City, Oklahoma, United States|Oregon Medical Res Center PC /ID# 200428, Portland, Oregon, United States|Oregon Health and Science University /ID# 200992, Portland, Oregon, United States|Dermdox Center for Dermatology /ID# 213782, Hazleton, Pennsylvania, United States|Clinical Partners, LLC /ID# 200460, Johnston, Rhode Island, United States|Derm & Laser Ctr of Charleston /ID# 200402, Charleston, South Carolina, United States|Arlington Research Center, Inc /ID# 200391, Arlington, Texas, United States|Orion Clinical Research /ID# 204703, Austin, Texas, United States|Modern Research Associates, PL /ID# 200705, Dallas, Texas, United States|Menter Dermatology Res Inst /ID# 200390, Dallas, Texas, United States|Center for Clinical Studies - Webster TX /ID# 203185, Webster, Texas, United States|Dermatology Specialists of Spo /ID# 202068, Spokane, Washington, United States|Instituto de Neumonología y Dermatología /ID# 203444, Ciudad Autonoma Buenos Aires, Buenos Aires, Argentina|Framingham Centro Medico /ID# 202688, La Plata, Buenos Aires, Argentina|Psoriahue Med Interdisciplinar /ID# 202451, Buenos Aires, Argentina|Woden Dermatology /ID# 205799, Phillip, Australian Capital Territory, Australia|Holdsworth House Medical Practice /ID# 211236, Sydney, New South Wales, Australia|North Eastern Health Specialis /ID# 205802, Hectorville, South Australia, Australia|Skin Health Institute Inc /ID# 204791, Carlton, Victoria, Australia|Fremantle Dermatology /ID# 205305, Fremantle, Western Australia, Australia|University Clinical Centre of the Republic of Srpska /ID# 202666, Banja Luka, Republika Srpska, Bosnia and Herzegovina|University Clinical Centre of the Republic of Srpska /ID# 202667, Banja Luka, Republika Srpska, Bosnia and Herzegovina|Clinical Center University of Sarajevo /ID# 202668, Sarajevo, Bosnia and Herzegovina|Clinical Center University of Sarajevo /ID# 202669, Sarajevo, Bosnia and Herzegovina|UMHAT Dr Georgi Stranski EAD /ID# 201521, Pleven, Bulgaria|UMHAT Aleksandrovska /ID# 201519, Sofia, Bulgaria|UMHAT Stoyan Kirkovich /ID# 201522, Stara Zagora, Bulgaria|Dermatology Research Institute Inc. /ID# 200318, Calgary, Alberta, Canada|Kirk Barber Research, CA /ID# 200324, Calgary, Alberta, Canada|Dr. Chih-ho Hong Medical Inc. /ID# 200311, Surrey, British Columbia, Canada|Enverus Medical Research /ID# 200307, Surrey, British Columbia, Canada|Wiseman Dermatology Research /ID# 200323, Winnipeg, Manitoba, Canada|Dr. Irina Turchin PC Inc. /ID# 200322, Fredericton, New Brunswick, Canada|Karma Clinical Trials /ID# 200316, St. John's, Newfoundland and Labrador, Canada|McMaster University Med Cent /ID# 200313, Hamilton, Ontario, Canada|Dr. Wei Jing Loo Medicine Prof /ID# 206051, London, Ontario, Canada|Lynderm Research Inc. /ID# 200315, Markham, Ontario, Canada|Dermatology Ottawa Research Centre /ID# 200319, Ottawa, Ontario, Canada|K. Papp Clinical Research /ID# 200317, Waterloo, Ontario, Canada|Dr. David Gratton Dermat Inc. /ID# 200309, Montreal, Quebec, Canada|Innovaderm Research Inc. /ID# 200320, Montréal, Quebec, Canada|Dre Angelique Gagne-Henley M.D. inc. /ID# 200326, St-Jerome, Quebec, Canada|Peking Univ Peoples Hospital /ID# 202549, Beijing, Beijing, China|Sun Yat-sen Memorial Hospital of Sun Yat-sen University /ID# 208597, Guangzhou, Guangdong, China|The Third Affiliated Hospital Of Sun Yat-Sen University /ID# 202548, Guangzhou, Guangdong, China|First Hospital of China Medical University /ID# 202615, Shenyang, Liaoning, China|Ruijin Hospital, Shanghai Jiaotong /ID# 202554, Shanghai, Shanghai, China|Huashan Hospital of Fudan University /ID# 205760, Shanghai, Shanghai, China|The Second Affiliated Hospital /ID# 202608, Hangzhou, Zhejiang, China|Beijing Friendship Hospital /ID# 202601, Beijing, China|Peking University 3rd Hospital /ID# 202612, Beijing, China|Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 208598, Wuhan, China|Fundacion Hospital San Vicente de Paul - Rionegro /ID# 202043, Rionegro, Antioquia, Colombia|Fundacion Centro de Excelencia en Enfermedades Cronicas no Transmisibles - FUNCE /ID# 201905, Monteria, Cordoba, Colombia|Ctr Int de Reum del Caribe SAS /ID# 201620, Barranquilla, Colombia|Clinisalud del sur /ID# 218100, Medellin, Colombia|Klinicki bolnicki centar Zagreb /ID# 201879, Zagreb, Grad Zagreb, Croatia|Klinika za dječje bolesti Zagreb /ID# 203151, Zagreb, Grad Zagreb, Croatia|Klinicki bolnicki centar Osijek /ID# 201523, Osijek, Osjecko-baranjska Zupanija, Croatia|Klinicki bolnicki centar Rijeka /ID# 217423, Rijeka, Primorsko-goranska Zupanija, Croatia|Klinicki bolnicki centar Split /ID# 201527, Split, Croatia|Bispebjerg Hospital /ID# 200979, Copenhagen NV, Hovedstaden, Denmark|Gentofte Hospital /ID# 200736, Hellerup, Hovedstaden, Denmark|Aarhus University Hospital /ID# 200737, Aarhus N, Midtjylland, Denmark|East Tallinn Central Hospital /ID# 200846, Tallinn, Estonia|North Estonian Medical Centre /ID# 200951, Tallinn, Estonia|Tartu University Clinic /ID# 200847, Tartu, Estonia|Mehiläinen Neo /ID# 201116, Turku, Varsinais-Suomi, Finland|Kuopio University Hospital /ID# 202449, Kuopio, Finland|Terveystalo Tampere /ID# 201117, Tampere, Finland|CHU Hotel Dieu /ID# 206377, Nantes CEDEX 1, Pays-de-la-Loire, France|Centre Hospitalier Le Mans /ID# 205991, Le Mans CEDEX 9, Sarthe, France|Charles Nicolle CHU Rouen /ID# 201525, Rouen CEDEX, Seine-Maritime, France|Hopital Saint Vincent de Paul /ID# 218253, Lille Cedex, France|Le Bateau BLanc /ID# 206833, Martigues, France|Hospitalier Necker /ID# 218364, Paris, France|Chu Lyon Sud /Id# 201529, Pierre Benite, France|Hopital Larrey /ID# 201528, Toulouse, France|CMS3 Company for Medical Study /ID# 205193, Selters (Westerwald), Rheinland-Pfalz, Germany|Universitaets-Hautklinik Kiel /ID# 202255, Kiel, Schleswig-Holstein, Germany|Universitaetsklinikum Bonn /ID# 202086, Bonn, Germany|Universitaetsklinikum Frankfurt /ID# 202089, Frankfurt, Germany|TFS Trial Form Support GmbH /ID# 202083, Hamburg, Germany|Med Hochschule Hanover /ID# 202091, Hannover, Germany|Univ Johannes Gutenberg /ID# 205192, Mainz, Germany|Universitatsklinikum Munster /ID# 202085, Muenster, Germany|TU Uniklinik Munchen /ID# 202087, Munich, Germany|AOU Federico II /ID# 200750, Naples, Campania, Italy|Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona /ID# 200692, Ancona, Italy|A.O. Policlinico Sant'Orsola Malpighi /ID# 200746, Bologna, Italy|Universita di Catania /ID# 200741, Catania, Italy|Ospedale Santa Chiara - Università di Pisa /ID# 200695, Pisa, Italy|Policlinico Univ Tor Vergata /ID# 201136, Rome, Italy|Aichi Medical University Hospital /ID# 202833, Nagakute-shi, Aichi, Japan|Fukuoka University Hospital /ID# 201309, Fukuoka-shi, Fukuoka, Japan|Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers /ID# 202891, Fukuoka-shi, Fukuoka, Japan|Gifu University Hospital /ID# 201760, Gifu-shi, Gifu, Japan|Ogaki Municipal Hospital /ID# 203463, Ogaki-shi, Gifu, Japan|Takagi Dermatological Clinic /ID# 201238, Obihiro-shi, Hokkaido, Japan|Medical Cooperation Kojinkai Sapporo Skin Clinic /ID# 201239, Sapporo-shi, Hokkaido, Japan|University Hospital Kyoto Prefectural University of Medicine /ID# 201876, Kyoto-shi, Kyoto, Japan|Kume Clinic /ID# 201912, Sakai-shi, Osaka, Japan|NTT Medical Center Tokyo /ID# 201759, Shinagawa-ku, Tokyo, Japan|University of Yamanashi Hospital /ID# 204174, Chuo-shi, Yamanashi, Japan|Hospital Raja Permaisuri Bainun /ID# 204375, Ipoh, Perak, Malaysia|Hospital Selayang /ID# 204378, Batu Caves, Malaysia|Hospital Queen Elizabeth /ID# 204379, Kota Kinabalu, Malaysia|Clinical Trials NZ /ID# 205335, Hamilton, New Zealand|Cruz-Santana, Carolina, PR /ID# 201096, Carolina, Puerto Rico|Ponce Medical School Foundatio /ID# 201821, Ponce, Puerto Rico|Clinical Research Puerto Rico /ID# 203309, San Juan, Puerto Rico|Colentina Clinical Hospital /ID# 205860, Bucharest, Romania|Cabinet Medical de Dermatovenerologie Dr. Remus Orasan /ID# 205862, Cluj Napoca, Romania|Chelyabinsk Regional Clinical Dermatovenerologic Dispensary /ID# 201996, Chelyabinsk, Chelyabinskaya Oblast, Russian Federation|GBUZ Clinical Dermatovenerology Dispensary of MoH of Krasnodar region /ID# 203439, Krasnodar, Krasnodarskiy Kray, Russian Federation|National Medical Research Center of Children's Health /ID# 203440, Moscow, Moskovskaya Oblast, Russian Federation|Saratov State Medical University n.a. V.I. Razumovskiy /ID# 201595, Saratov, Saratovskaya Oblast, Russian Federation|Ural Research Institute of dermatovenerology and immunopathology /ID# 201593, Ekaterinburg, Sverdlovskaya Oblast, Russian Federation|Hopitaux Universitaires de Geneve /ID# 201600, Genève, Geneve, Switzerland|CHUV - Hopital de l'Enfance /ID# 206505, Lausanne, Vaud, Switzerland|CHUV: Centre Hospitalier Universitaire Vaudois /ID# 200910, Lausanne, Vaud, Switzerland|Universitaetsspital Basel /ID# 201599, Basel, Switzerland|Inselspital, Universitaetsklinik /ID# 201598, Bern, Switzerland|Erciyes University Medical Fac /ID# 204098, Melikgazi, Kayseri, Turkey|Hacettepe University Medical Faculty /ID# 204099, Ankara, Turkey|Gazi Universitesi Tip Fakultes /ID# 204176, Ankara, Turkey|Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty /ID# 204100, Istanbul, Turkey|CI Zaporizhzhya Regional Skin and Venereal Clinical Dispensary /ID# 201962, Zaporizhzhya, Zaporizka Oblast, Ukraine|ME ""Rivne Regional Dermatology and Venereology Dispensary"" of RRC /ID# 210504, Rivne, Ukraine|West Middlesex University Hospital /ID# 202273, Isleworth, London, City Of, United Kingdom|Whipps Cross Univ Hospital /ID# 201043, London, London, City Of, United Kingdom|Guy's and St Thomas' NHS Found /ID# 201192, London, London, City Of, United Kingdom|Chelsea and Westminster Hosp /ID# 201971, London, United Kingdom|The University of Manchester /ID# 201194, Salford, United Kingdom",,,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,53.0,68.53528819893633,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.57,380.375,78.32,3.0,2.0,4.0,36.09,93.03,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0
Nc1cc(F)ccc1NC(=O)c1ccc(CNC(=O)/C=C/c2cccnc2)cc1,BREAST CANCER,_TUCIDINOSTAT,NCT04465097,Phase 2,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The first affiliated hospital of Sun Yat-Sen university, Guangzhou, Guangdong, China",,,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.55,390.418,97.11,4.0,3.0,3.0,41.27,112.68,6.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0
CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1,UVEITIS,_BARICITINIB,NCT04088409,Phase 3,Recruiting,All,2 Years to 17 Years   (Child),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospices Civils de Lyon - Hôpital Femme Mère Enfant, Bron, France|Hôpitaux Universitaires Paris Sud - Hôpital Bicêtre, Le Kremlin Bicetre, France|Centre Hospitalier Universitaire de Nîmes - Hôpital Universitaire Carémeau, Nîmes, France|GH Necker - Enfants Malades, Paris Cedex 15, France|CHU Poitiers - Hopital Jean Bernard, Poitiers Cedex, France|Asklepios Klinik Sankt Augustin, Saint Augustin, Nordrhein-Westfalen, Germany|HELIOS Klinikum Berlin-Buch, Berlin, Germany|Charité Campus Virchow-Klinikum, Berlin, Germany|Hamburger Zentrum für Kinder und Jugendrheumatologie, Hamburg, Germany|Ospedale Pediatrico Gaslini - Istituto Giannina Gaslini, Genova, Liguria, Italy|Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Lombardia, Italy|Azienda Ospedaliero Universitaria Meyer, Firenze, Italy|Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain|Hospital Infantil Universitario Niño Jesús, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario La Fe de Valencia, Valencia, Spain|Cambridge Clinical Research Facility, Cambridge, Cambridgeshire, United Kingdom|University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, United Kingdom|Royal Victoria Infirmary, Newcastle, N'castle-upon-tyne, United Kingdom|Sheffield Children's Hospital, Sheffield, South Yorkshire, United Kingdom|Bristol Royal Hospital for Children, Bristol, United Kingdom|Alder Hey Children's Hospital, Liverpool, United Kingdom|Great Ormond Street Hospital For Children NHS Foundation Trust, London, United Kingdom",8158616,C07D487/04,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,3.0,37.257438551099604,12.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.08,371.42,120.56,6.0,1.0,4.0,36.72,105.55,4.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,PARKINSON'S DISEASE,_PREDNISONE,NCT04127578,Phase 1|Phase 2,Recruiting,All,"35 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"PPD, 100 West Gore Street, Suite 202, Orlando, Florida, United States|Northwestern University Feinberg School of Medicine, Dept. of Neurology, Parkinson's Disease & Movement Disorders Center, 710 N. Lake Shore Drive, 11th Floor, Chicago, Illinois, United States|Mount Sinai Beth Israel, 10 Union Square East, Suite 5H, New York, New York, United States|NYU Langone Health, The Marlene and Paolo Fresco institute for Parkinson's and Movement Disorders, 222 East 41st Street, 13th Floor, New York, New York, United States|Joan and Sanford I. Weill Department of Medicine, 525 E 68th Street, New York, New York, United States",6488960,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,PARKINSON'S DISEASE,_METHYLPREDNISOLONE,NCT04127578,Phase 1|Phase 2,Recruiting,All,"35 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"PPD, 100 West Gore Street, Suite 202, Orlando, Florida, United States|Northwestern University Feinberg School of Medicine, Dept. of Neurology, Parkinson's Disease & Movement Disorders Center, 710 N. Lake Shore Drive, 11th Floor, Chicago, Illinois, United States|Mount Sinai Beth Israel, 10 Union Square East, Suite 5H, New York, New York, United States|NYU Langone Health, The Marlene and Paolo Fresco institute for Parkinson's and Movement Disorders, 222 East 41st Street, 13th Floor, New York, New York, United States|Joan and Sanford I. Weill Department of Medicine, 525 E 68th Street, New York, New York, United States",3962414,A61F9/0017,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,PARKINSON'S DISEASE,_SIROLIMUS,NCT04127578,Phase 1|Phase 2,Recruiting,All,"35 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"PPD, 100 West Gore Street, Suite 202, Orlando, Florida, United States|Northwestern University Feinberg School of Medicine, Dept. of Neurology, Parkinson's Disease & Movement Disorders Center, 710 N. Lake Shore Drive, 11th Floor, Chicago, Illinois, United States|Mount Sinai Beth Israel, 10 Union Square East, Suite 5H, New York, New York, United States|NYU Langone Health, The Marlene and Paolo Fresco institute for Parkinson's and Movement Disorders, 222 East 41st Street, 13th Floor, New York, New York, United States|Joan and Sanford I. Weill Department of Medicine, 525 E 68th Street, New York, New York, United States",5212155,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,10.0,21.5856588430973,1254.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.85,914.187,195.43,12.0,3.0,4.0,101.74,250.66,6.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0
O=P1(N(CCCl)CCCl)NCCCO1,ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS,_CYCLOPHOSPHAMIDE,NCT02953184,Phase 2,Recruiting,Female,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"First Hospital of Jilin University, Changchun, Jilin, China",3987166,7,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS,_DOXORUBICIN,NCT02953184,Phase 2,Recruiting,Female,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"First Hospital of Jilin University, Changchun, Jilin, China",5013556,C07F9/5537,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,33.0,18.5301546232982,5989.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.41,543.5193,206.07,12.0,6.0,5.0,53.87,134.59,5.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0
O=P1(N(CCCl)CCCl)NCCCO1,OSTEOSARCOMA,_CYCLOPHOSPHAMIDE,NCT03063983,Phase 2,Recruiting,All,"up to 30 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Grupo de Apoio ao Adolescente e a Criança com Câncer, Sao Paulo, Brazil",3987166,7,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,OSTEOSARCOMA,_METHOTREXATE,NCT03063983,Phase 2,Recruiting,All,"up to 30 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Grupo de Apoio ao Adolescente e a Criança com Câncer, Sao Paulo, Brazil",6746429,A61M5/2425,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,BREAST NEOPLASM MALIGNANT FEMALE,_CAPECITABINE,NCT04198727,Not Applicable,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Clinique Saint Jean, Cagnes-sur-Mer, France|Centre Azuréen de Cancérologie, Mougins, France|Clinique St Georges, Nice, France|Centre Antoine Lacassagne, Nice, France|Hôpital Princesse Grâce, Monaco, Monaco",4966891,C07H19/06,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,23.688371424464503,1258.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.17,359.3501,120.69,6.0,3.0,2.0,35.81,82.75,7.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,FEMALE BREAST CARCINOMA,_PALBOCICLIB,NCT02942355,Phase 2,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Levine Cancer Institute, Charlotte, North Carolina, United States",6936612,5,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,2.0,31.442124068256,23.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.12,447.5328,103.35,8.0,2.0,5.0,49.69,127.47,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0
CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1,FEMALE BREAST CARCINOMA,_ANASTROZOLE,NCT02942355,Phase 2,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Levine Cancer Institute, Charlotte, North Carolina, United States",RE36617,C07D239/26,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,10.0,47.3438879648452,907.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.31,293.3663,78.29,4.0,0.0,2.0,31.97,97.47,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,BREAST NEOPLASM,_OLAPARIB,NCT03740893,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Royal Bournemouth Hospital, Bournemouth, Dorset, United Kingdom|Bristol Haematology and Oncology Centre, Bristol, England, United Kingdom|King's College Hospital, London, England, United Kingdom|Christie Hospital NHS Trust, Manchester, England, United Kingdom|Belfast City Hospital, Belfast, Northern Ireland, United Kingdom|Velindre Cancer Center at Velinde Hospital, Cardiff, Wales, United Kingdom|Queen Elizabeth Hospital, University Hospitals Birmingham NHS Trust, Birmingham, United Kingdom|Guy's and St Thomas' Hospital NHS Foundation Trust, London, United Kingdom|Weston Park Hospital, Sheffield, United Kingdom",7151102,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,0.0,1.0,0.0,0.0,8.0,61.63576254132521,26.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.72,434.4628,82.08,4.0,1.0,5.0,43.81,117.53,4.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,NON SMALL CELL LUNG CANCER,_METHYLPREDNISOLONE,NCT03661567,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sun yat-sen University Cancer Center, Guangzhou, Guangdong, China",3962414,A61F9/0017,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
CCN(CC)CC(=O)Nc1c(C)cccc1C,SCAR,_LIDOCAINE,NCT02234193,Early Phase 1,Recruiting,All,18 Years to 50 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, Massachusetts, United States",5234957.0,1,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
CNC[C@H](O)c1ccc(O)c(O)c1,SCAR,_EPINEPHRINE,NCT02234193,Early Phase 1,Recruiting,All,18 Years to 50 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, Massachusetts, United States",5665071,A61M5/31511,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,4.0,14.4561489968993,1353.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.82,183.2044,72.72,4.0,4.0,1.0,19.04,49.23,3.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CCN(CC)CC(=O)Nc1c(C)cccc1C,POST-DURAL PUNCTURE HEADACHE,_LIDOCAINE,NCT03560349,Phase 2,Enrolling by invitation,Female,18 Years to 50 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","University of Utah, Salt Lake City, Utah, United States",5234957.0,1,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,OSTEOSARCOMA,_ETOPOSIDE,NCT04154189,Phase 2,Recruiting,All,"2 Years to 25 Years   (Child, Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's of Alabama, Birmingham, Alabama, United States|Children's National Medical Center, Washington, District of Columbia, United States|Riley Hospital For Children, Indianapolis, Indiana, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cook Children's Health Care System, Fort Worth, Texas, United States|Chris O'Brien Lifehouse Hospital, Camperdown, Australia|Perth Childrens Hospital, Nedlands, Australia|Queensland Children's Hospital, South Brisbane, Australia|Children's Hospital at Westmead, Westmead, Australia|St. Anna Kinderspital, Wien, Austria|UZ Gent, Gent, Belgium|Tampereen yliopistollinen sairaala, Tampere, Länsi-Suomen Lääni, Finland|Centre Hospitalier Universitaire de Bordeaux, Hopital Pellegrin, Bordeaux, France|Centre Oscar Lambret, Lille, France|Centre Léon Berard, Lyon, France|Hopitaux de La Timone, Marseille, France|Hôpital de La Mère Et de L'enfant, Nantes, France|Hôpital Armand Trousseau, Paris, France|Institut Curie, Paris, France|Hopital de Hautepierre, Strasbourg, France|Hôpital Des Enfants, Toulouse, France|CHRU Nancy, Vandœuvre-lès-Nancy, France|Institut Gustave Roussy, Villejuif, France|Children's Health Ireland at Crumlin, Dublin, Ireland|Schneider Children's Medical Center of Israel, Petach Tikva, Israel|National Cancer Center, Goyang-si, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Starship Children's Hospital, Auckland, New Zealand|KK Women's and Children's Hospital, Singapore, Singapore|National University Hospital, Singapore, Singapore|Hospital Universitario de Cruces, Barakaldo, Spain|Hospital Sant Joan de Deu, Barcelona, Spain|Hospital Universitario Vall d'Hebrón, Barcelona, Spain|Hospital Infantil Universitario Niño Jesus, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain|Drottning Silvias Barn Och Ungdomssjukhus, Göteborg, Sweden|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|Kinderspital Zürich - Eleonorenstiftung, Zürich, Switzerland|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|UCL Cancer Institute, London, United Kingdom",4701327,7,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,3.0,29.569395675475803,8681.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.73,588.5566,160.83,12.0,3.0,7.0,58.77,139.02,5.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0
O=P1(NCCCl)OCCCN1CCCl,OSTEOSARCOMA,_IFOSFAMIDE,NCT04154189,Phase 2,Recruiting,All,"2 Years to 25 Years   (Child, Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's of Alabama, Birmingham, Alabama, United States|Children's National Medical Center, Washington, District of Columbia, United States|Riley Hospital For Children, Indianapolis, Indiana, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cook Children's Health Care System, Fort Worth, Texas, United States|Chris O'Brien Lifehouse Hospital, Camperdown, Australia|Perth Childrens Hospital, Nedlands, Australia|Queensland Children's Hospital, South Brisbane, Australia|Children's Hospital at Westmead, Westmead, Australia|St. Anna Kinderspital, Wien, Austria|UZ Gent, Gent, Belgium|Tampereen yliopistollinen sairaala, Tampere, Länsi-Suomen Lääni, Finland|Centre Hospitalier Universitaire de Bordeaux, Hopital Pellegrin, Bordeaux, France|Centre Oscar Lambret, Lille, France|Centre Léon Berard, Lyon, France|Hopitaux de La Timone, Marseille, France|Hôpital de La Mère Et de L'enfant, Nantes, France|Hôpital Armand Trousseau, Paris, France|Institut Curie, Paris, France|Hopital de Hautepierre, Strasbourg, France|Hôpital Des Enfants, Toulouse, France|CHRU Nancy, Vandœuvre-lès-Nancy, France|Institut Gustave Roussy, Villejuif, France|Children's Health Ireland at Crumlin, Dublin, Ireland|Schneider Children's Medical Center of Israel, Petach Tikva, Israel|National Cancer Center, Goyang-si, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Starship Children's Hospital, Auckland, New Zealand|KK Women's and Children's Hospital, Singapore, Singapore|National University Hospital, Singapore, Singapore|Hospital Universitario de Cruces, Barakaldo, Spain|Hospital Sant Joan de Deu, Barcelona, Spain|Hospital Universitario Vall d'Hebrón, Barcelona, Spain|Hospital Infantil Universitario Niño Jesus, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain|Drottning Silvias Barn Och Ungdomssjukhus, Göteborg, Sweden|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|Kinderspital Zürich - Eleonorenstiftung, Zürich, Switzerland|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|UCL Cancer Institute, London, United Kingdom",5252341,1,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,10.0,13.831906199305902,2428.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.57,261.086,41.57,2.0,1.0,1.0,23.94,58.48,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0
COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,OSTEOSARCOMA,_LENVATINIB,NCT04154189,Phase 2,Recruiting,All,"2 Years to 25 Years   (Child, Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's of Alabama, Birmingham, Alabama, United States|Children's National Medical Center, Washington, District of Columbia, United States|Riley Hospital For Children, Indianapolis, Indiana, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cook Children's Health Care System, Fort Worth, Texas, United States|Chris O'Brien Lifehouse Hospital, Camperdown, Australia|Perth Childrens Hospital, Nedlands, Australia|Queensland Children's Hospital, South Brisbane, Australia|Children's Hospital at Westmead, Westmead, Australia|St. Anna Kinderspital, Wien, Austria|UZ Gent, Gent, Belgium|Tampereen yliopistollinen sairaala, Tampere, Länsi-Suomen Lääni, Finland|Centre Hospitalier Universitaire de Bordeaux, Hopital Pellegrin, Bordeaux, France|Centre Oscar Lambret, Lille, France|Centre Léon Berard, Lyon, France|Hopitaux de La Timone, Marseille, France|Hôpital de La Mère Et de L'enfant, Nantes, France|Hôpital Armand Trousseau, Paris, France|Institut Curie, Paris, France|Hopital de Hautepierre, Strasbourg, France|Hôpital Des Enfants, Toulouse, France|CHRU Nancy, Vandœuvre-lès-Nancy, France|Institut Gustave Roussy, Villejuif, France|Children's Health Ireland at Crumlin, Dublin, Ireland|Schneider Children's Medical Center of Israel, Petach Tikva, Israel|National Cancer Center, Goyang-si, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Starship Children's Hospital, Auckland, New Zealand|KK Women's and Children's Hospital, Singapore, Singapore|National University Hospital, Singapore, Singapore|Hospital Universitario de Cruces, Barakaldo, Spain|Hospital Sant Joan de Deu, Barcelona, Spain|Hospital Universitario Vall d'Hebrón, Barcelona, Spain|Hospital Infantil Universitario Niño Jesus, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain|Drottning Silvias Barn Och Ungdomssjukhus, Göteborg, Sweden|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|Kinderspital Zürich - Eleonorenstiftung, Zürich, Switzerland|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|UCL Cancer Institute, London, United Kingdom",7253286,4,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,51.6478777798312,65.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.03,426.86,115.57,4.0,3.0,4.0,42.29,112.21,6.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O,OSTEO ARTHRITIS OF THE KNEES,_DEXTROSE,NCT03400631,Not Applicable,Recruiting,All,"21 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","Gaston Topol, M.D.. Private Office, Rosario, Santa Fe, Argentina",3964974,C12Q1/54,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,33.380562229203804,1910.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-2.6,180.1559,110.38,6.0,5.0,1.0,16.43,35.92,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0
CNC[C@H](O)c1cccc(O)c1,"STRESS DISORDERS, POST-TRAUMATIC",_PHENYLEPHRINE,NCT02560805,Phase 2,Recruiting,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Atlanta VA Medical Center, Decatur, Georgia, United States",8173707.0,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,11.0,24.1154849175547,908.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-0.69,167.205,52.49,3.0,3.0,1.0,18.2,47.25,3.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,"STRESS DISORDERS, POST-TRAUMATIC",_LOSARTAN,NCT02560805,Phase 2,Recruiting,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Atlanta VA Medical Center, Decatur, Georgia, United States",5210079,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,31.0,15.0803917944927,357.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.5,422.911,92.51,5.0,2.0,4.0,44.86,131.85,8.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0
CC(C)NCC(O)COc1ccc(CC(N)=O)cc1,"STRESS DISORDERS, POST-TRAUMATIC",_ATENOLOL,NCT02560805,Phase 2,Recruiting,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Atlanta VA Medical Center, Decatur, Georgia, United States",4256108.0,A61F9/0017,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,66.0,21.8813527998521,533.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.57,266.3361,84.58,4.0,3.0,1.0,29.98,73.51,8.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
N#C[Fe-2](C#N)(C#N)(C#N)(C#N)N=O,"STRESS DISORDERS, POST-TRAUMATIC",_NITROPRUSSIDE,NCT02560805,Phase 2,Recruiting,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Atlanta VA Medical Center, Decatur, Georgia, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.071,215.938,148.38,6.0,0.0,0.0,16.52,39.44,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,OSTEOSARCOMA,_SUNITINIB,NCT03900793,Phase 1,Recruiting,All,"10 Years to 40 Years   (Child, Adult)",Other|NIH,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital Colorado, Aurora, Colorado, United States|Children's Hospital of Atlanta, Atlanta, Georgia, United States",6573293,C07D403/06,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,29.0,27.532392862276396,773.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.24,398.4738,77.23,3.0,3.0,3.0,44.32,116.27,7.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,OSTEOSARCOMA,_LOSARTAN,NCT03900793,Phase 1,Recruiting,All,"10 Years to 40 Years   (Child, Adult)",Other|NIH,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital Colorado, Aurora, Colorado, United States|Children's Hospital of Atlanta, Atlanta, Georgia, United States",5210079,4,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,31.0,15.0803917944927,357.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.5,422.911,92.51,5.0,2.0,4.0,44.86,131.85,8.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0
C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@]5(C)[C@H]6C[C@@H](O)[C@]7(C)[C@@H](C8=CC(=O)OC8)CC[C@]7(O)[C@@H]6CC[C@@H]5C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O,ACTINIC KERATOSIS,_DIGOXIN,NCT03684772,Phase 2,Recruiting,All,"18 Years to 100 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Centre for Human Drug Research, Leiden, Netherlands",3933997.0,G01N31/16,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,7.0,22.6698700178648,1774.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.04,780.9385,203.06,13.0,6.0,8.0,84.8,193.23,7.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0
NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl,ACTINIC KERATOSIS,_FUROSEMIDE,NCT03684772,Phase 2,Recruiting,All,"18 Years to 100 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Centre for Human Drug Research, Leiden, Netherlands",3939713,G01N30/18,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,9.0,11.8606131542742,1299.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.71,330.744,122.63,5.0,3.0,2.0,30.55,77.47,5.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,POST TRAUMATIC STRESS DISORDER,_MIDAZOLAM,NCT02727998,Phase 2,Recruiting,All,21 Years to 55 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Yale University School of Medicine, New Haven, Connecticut, United States",8217033,5,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,21.0,37.68455204418978,189.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.89,325.767,30.18,2.0,0.0,4.0,32.7,99.43,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0
CNC1(c2ccccc2Cl)CCCCC1=O,POST TRAUMATIC STRESS DISORDER,_KETAMINE,NCT02727998,Phase 2,Recruiting,All,21 Years to 55 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Yale University School of Medicine, New Haven, Connecticut, United States",3966793,C07D307/52,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,13.0,33.0848682724491,249.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,237.725,29.1,2.0,1.0,2.0,24.97,65.55,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,PARKINSON'S DISEASE,_CLARITHROMYCIN,NCT03440112,Phase 1|Phase 2,Recruiting,All,"50 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other","University of Michigan Health System Functional Neuroimaging, Cognitive and Mobility Laboratory, Ann Arbor, Michigan, United States",6010718,7,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,16.0,32.7891743156943,721.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,3.18,747.9534,182.91,13.0,4.0,3.0,82.03,190.79,8.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,PARKINSON'S DISEASE,_EXENATIDE,NCT04305002,Phase 2,Recruiting,All,"25 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Academic Specialist Center, Center for Neurology, SLSO, Stockholm, Sweden",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,PARKINSON'S DISEASE,_MOXIFLOXACIN,NCT04342273,Phase 1,Completed,All,20 Years to 54 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Medical Co. LTA Sumida Hospital, Sumida-ku, Tokyo, Japan|Medical Co. LTA Fukuoka Mirai Hospital Clinical Research Center, Fukuoka, Japan",4990517.0,C07D401/04,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,14.0,19.220107189059306,175.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.01,401.4314,82.11,7.0,2.0,5.0,41.24,106.22,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
O=C(O)Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1,POST-DURAL PUNCTURE HEADACHE,_TETRAC,NCT02813655,Phase 2,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hospices Civils de Lyon - Hôpital Femme Mère Enfant, Bron, France|Hospices Civils de Lyon / hôpital de la Croix rousse, Lyon, France",4490221,C07C51/377,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,16.0,19.9429146389042,24.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.99,747.8288,66.76,3.0,2.0,2.0,45.76,119.04,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,OSTEO ARTHRITIS OF THE KNEES,_DULOXETINE,NCT04224584,Phase 2,Recruiting,All,"40 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","Mech-Sense, Aalborg, Denmark",5023269.0,C07D333/20,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,51.0,14.4890038809831,220.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.72,297.415,21.26,2.0,1.0,3.0,33.15,87.73,6.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0
COc1cc(CNC(=O)CCCC/C=C/C(C)C)ccc1O,PARKINSON'S DISEASE,_CAPSAICIN,NCT03321019,,Recruiting,All,"45 Years to 85 Years   (Adult, Older Adult)",Other|NIH,Observational Model: Case-Control|Time Perspective: Prospective,"University of Florida Center for Movement Disorders and Neurorestoration, Gainesville, Florida, United States",6239180,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,5.0,41.4300088297501,241.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.8,305.4119,58.56,3.0,2.0,1.0,36.32,90.32,9.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0
Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2,HUNTINGTON'S DISEASE,_RISPERIDONE,NCT04071639,Phase 1,Recruiting,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Second Affiliated Hospital,Zhejiang University School of Medicine, Hangzhou, Zhejiang, China",5792477,5,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,52.0,15.310375983079698,156.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.27,410.4845,61.94,4.0,0.0,5.0,45.27,114.55,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0
Cc1nc2n(c(=O)c1CCN1CCC(C3NOc4cc(F)ccc43)CC1)CCCC2,HUNTINGTON'S DISEASE,_RISPERIDON,NCT04071639,Phase 1,Recruiting,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Second Affiliated Hospital,Zhejiang University School of Medicine, Hangzhou, Zhejiang, China",,,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
COC1=C(OC)C(=O)C(CC=C(C)C)=C(C)C1=O,HUNTINGTON'S DISEASE,_COENZYME_Q1,NCT04071639,Phase 1,Recruiting,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Second Affiliated Hospital,Zhejiang University School of Medicine, Hangzhou, Zhejiang, China",,,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.2,250.2903,52.6,4.0,0.0,1.0,26.94,72.38,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0
O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1,HUNTINGTON'S DISEASE,_HALOPERIDOL,NCT04071639,Phase 1,Recruiting,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Second Affiliated Hospital,Zhejiang University School of Medicine, Hangzhou, Zhejiang, China",3947579,5,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,21.8813527998521,629.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.7,375.864,40.54,3.0,1.0,3.0,39.15,102.59,6.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0
O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1,TOURETTE SYNDROME,_ARIPIPRAZOLE,NCT03487783,Phase 3,Enrolling by invitation,All,6 Years to 17 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Beijing Anding Hospital of Capital Medical University, Beijing, Beijing, China",5006528,C07D215/227,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,21.0,17.61021786895,56.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.21,448.385,44.81,4.0,1.0,4.0,49.23,124.34,7.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,UTERINE FIBROIDS,_BUPIVACAINE,NCT04068766,Not Applicable,Recruiting,Female,18 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Kangbuk Samsung Hospital, Seoul, Korea, Republic of|Wonju Severance Christian Hospital, Wonju, Korea, Republic of",8182835.0,1,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314,PARKINSON'S DISEASE,_OXYCODONE,NCT02601586,Phase 2|Phase 3,Recruiting,All,"40 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Hospital of Aix-en-Provence, Aix-en-Provence, France|CHU Amiens, Amiens, France|University Hospital of Bordeaux, Bordeaux, France|University Hospital of Clermont-Ferrand, Clermont-Ferrand, France|Henri Mondor Hospital, Créteil, France|University Hospital of Lille, Lille, France|University Hospital of Limoges, Limoges, France|Hospital Pierre Wertheimer, Lyon, France|University Hospital of Marseille, Marseille, France|University Hospital of Nancy, Nancy, France|University Hospital of Nantes, Nantes, France|University Hospital of Nîmes - Caremeau, Nîmes, France|Pitié-Salpêtrière Hospital, Paris, France|University Hospital of Poitiers, Poitiers, France|University Hospital of Rennes, Rennes, France|University Hospital of Rouen, Rouen, France|University Hospital of Strasbourg, Strasbourg, France|Chu Toulouse, Toulouse, France",5508042,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,2.0,10.3492884864165,1114.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.04,315.3636,59.0,5.0,1.0,5.0,32.79,84.04,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0
CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,HEMANGIOMA,_TIMOLOL,NCT01873131,Not Applicable,Recruiting,All,up to 3 Months   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Massachusetts General Hospital, Boston, Massachusetts, United States",5231095.0,C07D285/10,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,2.0,27.2695537896055,870.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.44,316.42,79.74,7.0,2.0,2.0,33.86,83.92,7.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0
CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1.O=C(O)/C=C\C(=O)O,HEMANGIOMA,_TIMOLOL_MALEATE,NCT01873131,Not Applicable,Recruiting,All,up to 3 Months   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Massachusetts General Hospital, Boston, Massachusetts, United States",4281654,A61K9/0051,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,23.0,15.901763896589198,234.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0
C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)c1,METASTATIC BREAST CANCER,_ICOTINIB,NCT02362230,Phase 2,Recruiting,Female,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sun Yat-sen University, Cancer Center, Guangzhou, Guangdong, China",US-20040048883-A1,A61P35/00,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,21.0,39.754409741473104,2.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.88,391.42699999999996,74.73,7.0,1.0,4.0,42.08,105.82,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1,PARKINSON'S DISEASE,_QUETIAPINE,NCT04164758,Phase 2,Recruiting,All,"50 Years to 85 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Movement Disorders Center of Arizona, Scottsdale, Arizona, United States|Tucson Neuroscience Research, Tucson, Arizona, United States|SC3 Research, Pasadena, California, United States|SC3 Research, Reseda, California, United States|Sutter Institute for Medical Research, Sacramento, California, United States|Galiz Research, Hialeah, Florida, United States|Charter Research, LLC, Lady Lake, Florida, United States|Premier Clinical Research Institute, Inc., Miami, Florida, United States|Collier Neurologic Specialists, Naples, Florida, United States|Infinity Clinical Research, LLC, Sunrise, Florida, United States|Vero Beach Neurology and Research Institute, Vero Beach, Florida, United States|Charter Research, LLC, Winter Park, Florida, United States|Meridian Clinical Research, Savannah, Georgia, United States|Hawaii Pacific Neuroscience, LLC., Honolulu, Hawaii, United States|University of lowa Hospital and Clinics, Iowa City, Iowa, United States|SRI International, Plymouth, Michigan, United States|The NeuroCognitive Institute, Mount Arlington, New Jersey, United States|Bio Behavioral Health, Toms River, New Jersey, United States|M3 Wake Research, Inc., Raleigh, North Carolina, United States|Dayton Center for Neurological Disorders, Centerville, Ohio, United States|Prisma Health-Upstate, Greenville, South Carolina, United States|Inland Northwest Research, Spokane, Washington, United States",4879288,C07D281/16,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,8.0,31.639253372759104,163.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.93,383.50699999999995,48.3,5.0,1.0,4.0,42.78,114.09,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0
CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1,PARKINSON'S DISEASE,_PIMAVANSERIN,NCT04164758,Phase 2,Recruiting,All,"50 Years to 85 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Movement Disorders Center of Arizona, Scottsdale, Arizona, United States|Tucson Neuroscience Research, Tucson, Arizona, United States|SC3 Research, Pasadena, California, United States|SC3 Research, Reseda, California, United States|Sutter Institute for Medical Research, Sacramento, California, United States|Galiz Research, Hialeah, Florida, United States|Charter Research, LLC, Lady Lake, Florida, United States|Premier Clinical Research Institute, Inc., Miami, Florida, United States|Collier Neurologic Specialists, Naples, Florida, United States|Infinity Clinical Research, LLC, Sunrise, Florida, United States|Vero Beach Neurology and Research Institute, Vero Beach, Florida, United States|Charter Research, LLC, Winter Park, Florida, United States|Meridian Clinical Research, Savannah, Georgia, United States|Hawaii Pacific Neuroscience, LLC., Honolulu, Hawaii, United States|University of lowa Hospital and Clinics, Iowa City, Iowa, United States|SRI International, Plymouth, Michigan, United States|The NeuroCognitive Institute, Mount Arlington, New Jersey, United States|Bio Behavioral Health, Toms River, New Jersey, United States|M3 Wake Research, Inc., Raleigh, North Carolina, United States|Dayton Center for Neurological Disorders, Centerville, Ohio, United States|Prisma Health-Upstate, Greenville, South Carolina, United States|Inland Northwest Research, Spokane, Washington, United States",7115634,C07D417/14,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,10.0,69.6523542577876,22.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.19,427.564,44.81,3.0,1.0,3.0,47.76,122.93,8.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0
OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1,POST TRAUMATIC STRESS DISORDER,_QUETIAPINE,NCT04280965,Early Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UT Health San Antonio, San Antonio, Texas, United States",4879288,C07D281/16,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,31.639253372759104,163.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.93,383.50699999999995,48.3,5.0,1.0,4.0,42.78,114.09,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0
O=C(O)/C=C/C(=O)O.OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1,POST TRAUMATIC STRESS DISORDER,_QUETIAPINE_FUMARATE,NCT04280965,Early Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UT Health San Antonio, San Antonio, Texas, United States",WO-2000072827-A2,A61K9/16 ,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,32.0,32.7488,22.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0
C[C@@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,NON SMALL CELL LUNG CANCER,_APREPITANT,NCT02646020,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Cancer Center of Sun-Yat Sen University (CCSYSU), GuangZhou, Guangdong, China",5145684,B82Y5/00,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,20.0,19.450091377646306,11.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.44,534.4267,75.19,5.0,2.0,4.0,45.56,116.93,8.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1,NON SMALL CELL LUNG CANCER,_DESLORATADINE,NCT02646020,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Cancer Center of Sun-Yat Sen University (CCSYSU), GuangZhou, Guangdong, China",5178878,A61K9/0056,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,100.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.48,310.821,24.92,2.0,1.0,4.0,34.35,101.04,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0
CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/[C@H]1CCCN1C,METASTATIC BREAST CANCER,_PYROTINIB,NCT04034589,Phase 2,Recruiting,Female,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sun Yat-Sen University Cancer Center, Guangyuan, China|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, China",US-20130338190-A1,4,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,23.0,32.7488,2.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.1,583.09,112.4,8.0,2.0,5.0,60.8,164.5,10.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0
CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21,OSTEO ARTHRITIS OF THE KNEES,_DRONABINOL,NCT04298528,Phase 3,Recruiting,All,"21 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Colorado Joint Replacement, Denver, Colorado, United States",6703418.0,3,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,17.0,141.17743690835502,1151.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,7.29,314.4617,29.46,2.0,1.0,3.0,38.96,96.73,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
CCCCCCC(C)(C)c1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(=O)C[C@@H]21,PARKINSON'S DISEASE,_NABILONE,NCT03773796,Phase 3,Recruiting,All,"30 Years to 100 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Neurology - Medical University Innsbruck, Innsbruck, Tyrol, Austria",3944673.0,C07C49/747,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,9.7907554569909,97.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.5,372.5408,46.53,3.0,1.0,3.0,44.91,110.2,6.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c5c(nc6cc(C)ccn65)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,PARKINSON'S DISEASE,_RIFAXIMIN,NCT03575195,Phase 1|Phase 2,Recruiting,All,"30 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of California San Francisco, San Francisco, California, United States",6861053,6,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,31.0,66.6625598061561,159.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,4.94,785.8785,198.38,11.0,5.0,6.0,82.26,216.69,3.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0
COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl,DEMENTIA WITH LEWY BODIES,_BOSUTINIB,NCT03888222,Phase 2,Recruiting,All,"25 Years to 90 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MedStar Georgetown University Hospital, Washington, District of Columbia, United States",6002008,C07D401/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,29.0,20.600012320581502,40.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.87,530.446,82.88,8.0,1.0,4.0,56.14,142.12,9.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,DEMENTIA WITH LEWY BODIES,_NILOTINIB,NCT04002674,Phase 2,Recruiting,All,"25 Years to 90 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MedStar Georgetown University Hospital, Washington, District of Columbia, United States",7169791,C07D405/14,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,11.0,42.9084786135238,336.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.51,529.5158,97.62,6.0,2.0,5.0,52.35,152.85,7.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0
Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,HUNTINGTON'S DISEASE,_NILOTINIB,NCT03764215,Phase 1,Recruiting,All,"25 Years to 90 Years   (Adult, Older Adult)",Other,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Georgetown University Medical Center, Washington, District of Columbia, United States",7169791,C07D405/14,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,11.0,42.9084786135238,336.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.51,529.5158,97.62,6.0,2.0,5.0,52.35,152.85,7.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0
O=C(O[C@H]1CN2CCC1CC2)N1CCc2ccccc2[C@@H]1c1ccccc1,OVERACTIVE BLADDER|PARKINSON DISEASE,_SOLIFENACIN,NCT03149809,Phase 3,Recruiting,All,"Child, Adult, Older Adult",U.S. Fed,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Birmingham VA Medical Center, Birmingham, AL, Birmingham, Alabama, United States|Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia, United States|Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia, Pennsylvania, United States|Hunter Holmes McGuire VA Medical Center, Richmond, VA, Richmond, Virginia, United States",6017927,C07D453/02,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,7.0,28.9122979937986,2.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.9,362.473,32.78,2.0,0.0,5.0,40.13,106.06,3.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0
O=C(O)c1cccnc1,POST TRAUMATIC STRESS DISORDER,_NIACIN,NCT03752918,Phase 1,Recruiting,All,21 Years to 55 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Connecticut Mental Health Center, New Haven, Connecticut, United States",6080428,4,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,13.0,65.4140742109694,3424.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.29,123.1094,50.19,3.0,1.0,1.0,11.3,31.16,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0
CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,BREAST CANCER,_MIFEPRISTONE,NCT02788981,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Alabama - Birmingham, Birmingham, Alabama, United States|University of Chicago, Chicago, Illinois, United States",10500216,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,4.0,85.0,242.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.33,429.5937,40.54,3.0,1.0,5.0,50.69,132.58,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC,PARKINSON'S DISEASE,_TERAZOSIN,NCT03905811,Phase 1|Phase 2,Enrolling by invitation,All,"40 Years to 90 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States",5212176,C07D405/12,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,34.629047824390604,855.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.12,387.4329,103.04,8.0,1.0,4.0,41.26,105.18,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
CCOC(=O)c1ncn2c1CN(C)C(=O)c1cc(F)ccc1-2,PARKINSON'S DISEASE,_FLUMAZENIL,NCT03462641,Phase 1|Phase 2,Recruiting,All,"50 Years to 99 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other","University of Michigan Functional Neuroimaging, Cognitive and Mobility Laboratory, Ann Arbor, Michigan, United States",4316839,C07D333/42,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,17.0,16.690281114601902,263.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.54,303.2884,64.43,3.0,0.0,3.0,29.97,87.93,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1,PARKINSON DISEASE PSYCHOSIS,_SARACATINIB,NCT03661125,Early Phase 1,Recruiting,All,"40 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","Mitul Mehta, London, Camberwell, United Kingdom",WO-2003045395-A1,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,0.0,1.0,0.0,0.0,13.0,32.7488,21.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.53,542.026,90.44,10.0,1.0,6.0,57.31,143.64,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,TRAUMATIC BRAIN INJURY,_PROGESTERONE,NCT04426487,Early Phase 1,Recruiting,All,"20 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment,"ElMinia University, Minya, Abohelal, Egypt",5543150.0,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,23.0,34.694757592558304,3548.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.58,314.4617,34.14,2.0,0.0,4.0,37.26,92.71,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
O=P1(N(CCCl)CCCl)NCCCO1,EPIDERMOLYSIS BULLOSA,_CYCLOPHOSPHAMIDE,NCT01033552,Phase 2,Recruiting,All,"up to 25 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Minnesota Masonic Cancer Center and Medical Center, Minneapolis, Minnesota, United States",3987166,7,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,EPIDERMOLYSIS BULLOSA,_FLUDARABINE,NCT01033552,Phase 2,Recruiting,All,"up to 25 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Minnesota Masonic Cancer Center and Medical Center, Minneapolis, Minnesota, United States",7547776,C07H19/16,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,EPIDERMOLYSIS BULLOSA,_CYCLOSPORINE,NCT01033552,Phase 2,Recruiting,All,"up to 25 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Minnesota Masonic Cancer Center and Medical Center, Minneapolis, Minnesota, United States",4839342.0,A61K38/13,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,18.0,21.3228197704265,3200.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.64,1202.635,278.8,12.0,5.0,1.0,133.6,327.14,15.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,EPIDERMOLYSIS BULLOSA,_MYCOPHENOLATE_MOFETIL,NCT01033552,Phase 2,Recruiting,All,"up to 25 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Minnesota Masonic Cancer Center and Medical Center, Minneapolis, Minnesota, United States",5543408,C07D307/88,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,20.041479291155802,259.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.17,433.4947,94.53,6.0,1.0,3.0,45.54,117.1,10.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,EPIDERMOLYSIS BULLOSA,_TACROLIMUS,NCT02582775,Phase 2,Recruiting,All,"up to 25 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Minnesota Masonic Cancer Center and Medical Center, Minneapolis, Minnesota, United States",5260301,4,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0
CS(=O)(=O)OCCCCOS(C)(=O)=O,EPIDERMOLYSIS BULLOSA,_BUSULFAN,NCT02582775,Phase 2,Recruiting,All,"up to 25 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Minnesota Masonic Cancer Center and Medical Center, Minneapolis, Minnesota, United States",5430057,2,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,31.0,21.0928355818394,3071.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,-0.9,246.302,86.74,4.0,0.0,0.0,23.64,49.57,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0
CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1,EARLY BREAST CANCER,_RIBOCICLIB,NCT03701334,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry|Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama at Birmingham/ Kirklin Clinic, Birmingham, Alabama, United States|Cancer Treatment Centers of America, Goodyear, Arizona, United States|St Bernards Medical Center, Jonesboro, Arkansas, United States|Comprehensive Blood and Cancer Center SC-2, Bakersfield, California, United States|UCLA Beverly Hills, Beverly Hills, California, United States|UCLA Burbank, Burbank, California, United States|Encino Research Center, Encino, California, United States|UCLA Hematology Oncology, Laguna Hills, California, United States|Southern California Oncology Research Alliance SCORA, Los Angeles, California, United States|UCLA Central Regulatory, Los Angeles, California, United States|Valley Breast Care and Women s Health Center, Los Angeles, California, United States|Stanford University Medical Center, Palo Alto, California, United States|UCLA Pasadena Health Care Hematology Oncology, Pasadena, California, United States|UCLA Porter Ranch Hematology and Oncology, Porter Ranch, California, United States|Cancer Care Associates Medical Group, Redondo Beach, California, United States|Sharp Memorial Hospital Regulatory, San Diego, California, United States|University of California San Francisco Gynecologic Oncology, San Francisco, California, United States|Central Coast Medical Oncology Corporation Onc Dept, Santa Maria, California, United States|UCLA Santa Monica Hematology / Oncology Regulatory-2, Santa Monica, California, United States|Lundquist Inst BioMed at Harbor, Torrance, California, United States|Gene Upshaw Memorial Tahoe Forest Cancer Cntr, Truckee, California, United States|UCLA Valencia, Valencia, California, United States|Wellness Oncology Hematology TRM, West Hills, California, United States|UCLA Cancer Center, Westlake Village, Westlake Village, California, United States|St. Jude Heritage Medical Group Dept.of Virginia K Crosson Ctr, Yorba Linda, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|Rocky Mountain Cancer Centers, Greenwood Village, Colorado, United States|Hospital of Central Connecticut, New Britain, Connecticut, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Norwalk Hospital Pulmonary Medicine, Norwalk, Connecticut, United States|Eastern Connecticut Hematology and Oncology Associates Regulatory, Norwich, Connecticut, United States|Holy Cross Hospital - Ft. Lauderdale CLCZ696BUS01, Fort Lauderdale, Florida, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Memorial Cancer Institute, Hollywood, Florida, United States|University of Miami, Miami, Florida, United States|Orlando Health, Clinical Trials Orlando Health Inc, Orlando, Florida, United States|Florida Cancer Specialists - North, Saint Petersburg, Florida, United States|Florida Cancer Specialists Panhandle, Tallahassee, Florida, United States|Florida Cancer Specialists- East Region, West Palm Beach, Florida, United States|Southeastern Regional Medical Center, Newnan, Georgia, United States|Cancer Treatment Centers of America, Zion, Illinois, United States|Fort Wayne Medical Oncology/Hematology, Inc., Fort Wayne, Indiana, United States|Cancer Care Center, New Albany, Indiana, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|Cancer Center of Kansas, Wichita, Kansas, United States|Mercy Medical Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Michigan Cancer Center, Ann Arbor, Michigan, United States|Fairview Health Services, Maple Grove, Minnesota, United States|Metro Minnesota CCOP Metro Minneapolis CCOP, Saint Louis Park, Minnesota, United States|Park Nicollet Institute, Saint Louis Park, Minnesota, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|HCA Midwest Division, Kansas City, Missouri, United States|David C Pratt Cancer Center, Saint Louis, Missouri, United States|St Vincent Frontier Cancer Center, Billings, Montana, United States|Saint Francis Medical Center, Grand Island, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Saint Barnabas Medical Center, Livingston, New Jersey, United States|Perlmutter Cancer Centre, New York, New York, United States|Randolph Medical Associates, Asheboro, North Carolina, United States|Alamance Regional Medical Cancer Center, Burlington, North Carolina, United States|Cone Health Cancer Center, Greensboro, North Carolina, United States|Kaiser Permanente NW Region, Clackamas, Oregon, United States|Penn State Hershey Cancer Institute, Hershey, Pennsylvania, United States|Cancer Treatment Centers of America Eastern Regional Medical Center, Philadelphia, Pennsylvania, United States|The West Clinic, Germantown, Tennessee, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|Center for Cancer and Blood Disorders Research Department, Fort Worth, Texas, United States|MD Anderson Cancer Center/University of Texas, Houston, Texas, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Virginia Cancer Specialists, Fairfax, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Seattle Cancer Care Alliance Medical Oncology, Seattle, Washington, United States|University of Wisconsin / Paul P. Carbone Comp Cancer Center, Madison, Wisconsin, United States|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Rosario, Sante Fe, Argentina|Novartis Investigative Site, San Miguel De Tucuman, Tucuman, Argentina|Novartis Investigative Site, Rio Negro, Viedma, Argentina|Novartis Investigative Site, Caba, Argentina|Novartis Investigative Site, Jujuy, Argentina|Novartis Investigative Site, La Rioja, Argentina|Novartis Investigative Site, Santa Fe, Argentina|Novartis Investigative Site, Campbelltown, New South Wales, Australia|Novartis Investigative Site, Coffs Harbour, New South Wales, Australia|Novartis Investigative Site, Darlinghurst, New South Wales, Australia|Novartis Investigative Site, Kingswood, New South Wales, Australia|Novartis Investigative Site, Kogarah, New South Wales, Australia|Novartis Investigative Site, Liverpool, New South Wales, Australia|Novartis Investigative Site, North Ryde, New South Wales, Australia|Novartis Investigative Site, St Leonards, New South Wales, Australia|Novartis Investigative Site, Wahroonga, New South Wales, Australia|Novartis Investigative Site, Westmead, New South Wales, Australia|Novartis Investigative Site, Auchenflower, Queensland, Australia|Novartis Investigative Site, Birtinya, Queensland, Australia|Novartis Investigative Site, Wooloongabba, Queensland, Australia|Novartis Investigative Site, Bedford Park, South Australia, Australia|Novartis Investigative Site, Bendigo, Victoria, Australia|Novartis Investigative Site, East Melbourne, Victoria, Australia|Novartis Investigative Site, Epping, Victoria, Australia|Novartis Investigative Site, Fitzroy, Victoria, Australia|Novartis Investigative Site, Franston, Victoria, Australia|Novartis Investigative Site, Heidelberg, Victoria, Australia|Novartis Investigative Site, Melbourne, Victoria, Australia|Novartis Investigative Site, Shepparton, Victoria, Australia|Novartis Investigative Site, Murdoch, Western Australia, Australia|Novartis Investigative Site, Nedlands, Western Australia, Australia|Novartis Investigative Site, Graz, Styria, Austria|Novartis Investigative Site, Innsbruck, Tyrol, Austria|Novartis Investigative Site, Linz, Austria|Novartis Investigative Site, Salzburg, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Edegem, Antwerpen, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Charleroi, Belgium|Novartis Investigative Site, Hasselt, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Libramont, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Namur, Belgium|Novartis Investigative Site, Wilrijk, Belgium|Novartis Investigative Site, Yvoir, Belgium|Novartis Investigative Site, Londrina, PR, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Barretos, Sao Paulo, Brazil|Novartis Investigative Site, Santo Andre, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Caxias do Sul, Brazil|Novartis Investigative Site, Ijui, Brazil|Novartis Investigative Site, Passo Fundo, Brazil|Novartis Investigative Site, Piracicaba, Brazil|Novartis Investigative Site, Recife, Brazil|Novartis Investigative Site, Rio De Janeiro, Brazil|Novartis Investigative Site, Salvador, Brazil|Novartis Investigative Site, Sao Paulo, Brazil|Novartis Investigative Site, Calgary, Alberta, Canada|Novartis Investigative Site, Edmonton, Alberta, Canada|Novartis Investigative Site, Kelowna, British Columbia, Canada|Novartis Investigative Site, North Vancouver, British Columbia, Canada|Novartis Investigative Site, Surrey, British Columbia, Canada|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Halifax, Nova Scotia, Canada|Novartis Investigative Site, Kitchener, Ontario, Canada|Novartis Investigative Site, London, Ontario, Canada|Novartis Investigative Site, Newmarket, Ontario, Canada|Novartis Investigative Site, Oshawa, Ontario, Canada|Novartis Investigative Site, Sault Ste Marie, Ontario, Canada|Novartis Investigative Site, Sudbury, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Windsor, Ontario, Canada|Novartis Investigative Site, Greenfield Park, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Sherbrooke, Quebec, Canada|Novartis Investigative Site, St-Jerome, Quebec, Canada|Novartis Investigative Site, Quebec, Canada|Novartis Investigative Site, Chang Chun, Jilin, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Nice Cedex 2, Alpes Maritimes, France|Novartis Investigative Site, Dijon Cedex, Cote D Or, France|Novartis Investigative Site, Limoges cedex, Haute Vienne, France|Novartis Investigative Site, Saint-Cloud, Hauts De Seine, France|Novartis Investigative Site, Rennes Cedex, Ille Et Vilaine, France|Novartis Investigative Site, Amiens, France|Novartis Investigative Site, Angers Cedex 02, France|Novartis Investigative Site, Argenteuil, France|Novartis Investigative Site, Avignon Cedex, France|Novartis Investigative Site, Besancon cedex, France|Novartis Investigative Site, Bobigny Cedex, France|Novartis Investigative Site, Bordeaux Cedex, France|Novartis Investigative Site, Caen Cedex, France|Novartis Investigative Site, Grenoble cedex, France|Novartis Investigative Site, Le Mans, France|Novartis Investigative Site, Lyon, France|Novartis Investigative Site, Lyon, France|Novartis Investigative Site, Marseille, France|Novartis Investigative Site, Montpellier Cedex 5, France|Novartis Investigative Site, Montpellier, France|Novartis Investigative Site, Nantes cedex 2, France|Novartis Investigative Site, Paris Cedex 13, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Pierre Benite Cedex, France|Novartis Investigative Site, Rouen Cedex 1, France|Novartis Investigative Site, Saint Herblain cedex, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Toulouse Cedex 9, France|Novartis Investigative Site, Vandoeuvre-les-Nancy cedex, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Ravensburg, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Muenchen, Bavaria, Germany|Novartis Investigative Site, Georgsmarienhuette, Lower Saxony, Germany|Novartis Investigative Site, Hannover, Niedersachsen, Germany|Novartis Investigative Site, Duesseldorf, Nordrhein Westfalen, Germany|Novartis Investigative Site, Essen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Velbert, North Rhine-westphalia, Germany|Novartis Investigative Site, Augsburg, Germany|Novartis Investigative Site, Augsburg, Germany|Novartis Investigative Site, Bad Liebenwerda, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Bonn, Germany|Novartis Investigative Site, Bottrop, Germany|Novartis Investigative Site, Cottbus, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Esslingen, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Halle S, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Kiel, Germany|Novartis Investigative Site, Lüneburg, Germany|Novartis Investigative Site, Mainz, Germany|Novartis Investigative Site, Mannheim, Germany|Novartis Investigative Site, Moenchengladbach, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Muenster, Germany|Novartis Investigative Site, Munchen, Germany|Novartis Investigative Site, Regensburg, Germany|Novartis Investigative Site, Rostock, Germany|Novartis Investigative Site, Schweinfurt, Germany|Novartis Investigative Site, Tübingen, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Wuerzburg, Germany|Novartis Investigative Site, Zalaegerszeg, Zala, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Kecskemet, Hungary|Novartis Investigative Site, Pecs, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, Szekszard, Hungary|Novartis Investigative Site, Szombathely, Hungary|Novartis Investigative Site, Tatabanya, Hungary|Novartis Investigative Site, Wilton, Cork, Ireland|Novartis Investigative Site, Dublin 9, D9, Ireland|Novartis Investigative Site, County Limerick, Ireland|Novartis Investigative Site, Dublin 4, Ireland|Novartis Investigative Site, Dublin 7, Ireland|Novartis Investigative Site, Dublin, Ireland|Novartis Investigative Site, Waterford, Ireland|Novartis Investigative Site, Torrette AN, Ancona, Italy|Novartis Investigative Site, Bergamo, BG, Italy|Novartis Investigative Site, Brindisi, BR, Italy|Novartis Investigative Site, Catania, CT, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Rozzano, MI, Italy|Novartis Investigative Site, Palermo, PA, Italy|Novartis Investigative Site, Aviano, PN, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Candiolo, TO, Italy|Novartis Investigative Site, Bologna, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Cheongju si, Chungcheongbuk Do, Korea, Republic of|Novartis Investigative Site, Seoul, Daegu, Korea, Republic of|Novartis Investigative Site, Wonju-si, Gangwon-do, Korea, Republic of|Novartis Investigative Site, Bundang Gu, Gyeonggi Do, Korea, Republic of|Novartis Investigative Site, Gyeonggi do, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Suwon, Kyonggi Do, Korea, Republic of|Novartis Investigative Site, Seoul, Seocho Gu, Korea, Republic of|Novartis Investigative Site, Incheon, Korea, Republic of|Novartis Investigative Site, Incheon, Korea, Republic of|Novartis Investigative Site, Seongnam Si Gyeonggi Do, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Ulsan, Korea, Republic of|Novartis Investigative Site, Warsaw, Ul Roentgena 5, Poland|Novartis Investigative Site, Bialystok, Poland|Novartis Investigative Site, Gdynia, Poland|Novartis Investigative Site, Gliwice, Poland|Novartis Investigative Site, Grudziadz, Poland|Novartis Investigative Site, Krakow, Poland|Novartis Investigative Site, Lodz, Poland|Novartis Investigative Site, Lublin, Poland|Novartis Investigative Site, Opole, Poland|Novartis Investigative Site, Ostroleka, Poland|Novartis Investigative Site, Otwock, Poland|Novartis Investigative Site, Wieliszew, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Craiova, Dolj, Romania|Novartis Investigative Site, Bucuresti, Romania|Novartis Investigative Site, Bucuresti, Romania|Novartis Investigative Site, Cluj-Napoca, Romania|Novartis Investigative Site, Iasi, Romania|Novartis Investigative Site, Timisoara, Romania|Novartis Investigative Site, Leningrad Region, Russia, Russian Federation|Novartis Investigative Site, St Petersburg, Saint Petersburg, Russian Federation|Novartis Investigative Site, Chelyabinsk, Russian Federation|Novartis Investigative Site, Kazan, Russian Federation|Novartis Investigative Site, Kostroma, Russian Federation|Novartis Investigative Site, Krasnoyarsk, Russian Federation|Novartis Investigative Site, Kursk, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Nizhny Novgorod, Russian Federation|Novartis Investigative Site, Novosibirsk, Russian Federation|Novartis Investigative Site, Obninsk, Russian Federation|Novartis Investigative Site, Omsk, Russian Federation|Novartis Investigative Site, Orenburg, Russian Federation|Novartis Investigative Site, Rostov-na-Donu, Russian Federation|Novartis Investigative Site, Ryazan, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, St- Petersburg, Russian Federation|Novartis Investigative Site, Tyumen, Russian Federation|Novartis Investigative Site, Ufa, Russian Federation|Novartis Investigative Site, Yaroslavl, Russian Federation|Novartis Investigative Site, Elche, Alicante, Spain|Novartis Investigative Site, Cordoba, Andalucia, Spain|Novartis Investigative Site, Granada, Andalucia, Spain|Novartis Investigative Site, Huelva, Andalucia, Spain|Novartis Investigative Site, Jaen, Andalucia, Spain|Novartis Investigative Site, Malaga, Andalucia, Spain|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Avila, Castilla Y Leon, Spain|Novartis Investigative Site, Burgos, Castilla Y Leon, Spain|Novartis Investigative Site, Salamanca, Castilla Y Leon, Spain|Novartis Investigative Site, Badalona, Cataluna, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Manresa, Catalunya, Spain|Novartis Investigative Site, Barcelona, Cataluña, Spain|Novartis Investigative Site, Alicante, Comunidad Valenciana, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Badajoz, Extremadura, Spain|Novartis Investigative Site, Caceres, Extremadura, Spain|Novartis Investigative Site, A Coruna, Galicia, Spain|Novartis Investigative Site, La Coruna, Galicia, Spain|Novartis Investigative Site, Lugo, Galicia, Spain|Novartis Investigative Site, Fuenlabrada, Madrid, Spain|Novartis Investigative Site, El Palmar, Murcia, Spain|Novartis Investigative Site, Madrid, N Ap, Spain|Novartis Investigative Site, San Sebastian, Pais Vasco, Spain|Novartis Investigative Site, Vitoria-Gasteiz, País Vasco, Spain|Novartis Investigative Site, Vigo, Pontevedra, Spain|Novartis Investigative Site, La Laguna, Santa Cruz De Tenerife, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Bilbao, Spain|Novartis Investigative Site, Castellon, Spain|Novartis Investigative Site, Girona, Spain|Novartis Investigative Site, Granada, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Murcia, Spain|Novartis Investigative Site, Navarra, Spain|Novartis Investigative Site, Sabadell, Spain|Novartis Investigative Site, Valencia, Spain|Novartis Investigative Site, Zaragoza, Spain|Novartis Investigative Site, Changhua, Taiwan|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Tainan, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taoyuan, Taiwan|Novartis Investigative Site, Truro, Cornwall, United Kingdom|Novartis Investigative Site, Maidstone, Kent, United Kingdom|Novartis Investigative Site, Cardiff, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Nottingham, United Kingdom|Novartis Investigative Site, Oxford, United Kingdom|Novartis Investigative Site, Preston, United Kingdom|Novartis Investigative Site, Stoke-on-Trent, United Kingdom",8324225,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,0.0,0.0,0.0,1.0,9.0,66.3997207334852,15.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.5,434.548,91.21,7.0,2.0,5.0,49.13,125.59,5.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,POLYMYALGIA RHEUMATICA,_PREDNISOLONE,NCT03576794,Phase 3,Recruiting,All,"50 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","ZGT Almelo, Almelo, Netherlands|University Medical Center Groningen, Groningen, Netherlands",5178878,A61K9/0056,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1,POLYMYALGIA RHEUMATICA,_LEFLUNOMIDE,NCT03576794,Phase 3,Recruiting,All,"50 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","ZGT Almelo, Almelo, Netherlands|University Medical Center Groningen, Groningen, Netherlands",5504084,2,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,16.0,24.345469106141802,1785.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.52,270.2073,55.13,2.0,1.0,2.0,23.11,64.16,3.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0
OC[C@@H]1O[C@@](O)(CO)[C@H](O)[C@H]1O,ACUTE KIDNEY INJURY,_FRUCTOSE,NCT04310514,Not Applicable,Recruiting,All,18 Years to 40 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Diagnostic,"Medical University of Gdansk, Gdańsk, Poland",WO-2006138705-A1,A23L7/1963 ,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,25.0,32.7488,3.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-2.4,180.1559,110.38,6.0,5.0,1.0,16.29,36.36,2.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0
[C-]#[O+],ACUTE RESPIRATORY DISTRESS SYNDROME,_CARBON_MONOXIDE,NCT03799874,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|U.S. Fed,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|New York-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States|Weill Cornell Medical College, New York, New York, United States|Duke Regional Hospital, Durham, North Carolina, United States|Duke University Hospital, Durham, North Carolina, United States|Durham VA Medical Center, Durham, North Carolina, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,TRAUMATIC BRAIN INJURY,_SILDENAFIL,NCT04058132,Phase 2,Recruiting,All,18 Years to 55 Years   (Adult),U.S. Fed,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Walter Reed National Military Medical Center, Bethesda, Maryland, United States",5250534.0,C07D487/04,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.8,474.576,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12.O=C(O)CC(O)(CC(=O)O)C(=O)O,TRAUMATIC BRAIN INJURY,_SILDENAFIL_CITRATE,NCT04058132,Phase 2,Recruiting,All,18 Years to 55 Years   (Adult),U.S. Fed,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Walter Reed National Military Medical Center, Bethesda, Maryland, United States",WO-1999030688-A1,A61K9/19,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,45.0,32.7488,208.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,BIRTH ASPHYXIA,_SILDENAFIL,NCT04169191,Phase 1,Recruiting,All,up to 2 Days   (Child),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Montreal Children's Hospital, Montréal, Quebec, Canada",5250534.0,C07D487/04,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.8,474.576,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12.O=C(O)CC(O)(CC(=O)O)C(=O)O,BIRTH ASPHYXIA,_SILDENAFIL_CITRATE,NCT04169191,Phase 1,Recruiting,All,up to 2 Days   (Child),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Montreal Children's Hospital, Montréal, Quebec, Canada",WO-1999030688-A1,A61K9/19,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,45.0,32.7488,208.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,BRONCHOPULMONARY DYSPLASIA,_SILDENAFIL,NCT03142568,Phase 2,Recruiting,All,up to 28 Days   (Child),Other|NIH|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Riley Hospital for Children at IU Health, Indianapolis, Indiana, United States|Wesley Medical Center, Wichita, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|Ochsner Baptist Medical Center, New Orleans, Louisiana, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|Children's Hospital of Nevada at UMC, Las Vegas, Nevada, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Kings County Hospital Center, Brooklyn, New York, United States|Cohen Children's Medical Center of NY, New Hyde Park, New York, United States|Golisano Children's Hospital - University of Rochester Medical Center, Rochester, New York, United States|WakeMed Health and Hospitals, Raleigh, North Carolina, United States|New Hanover Regional Medical Center, Wilmington, North Carolina, United States|Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States|University of Oklahoma, Oklahoma City, Oklahoma, United States",5250534.0,C07D487/04,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.8,474.576,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0
NS(=O)(=O)Cc1noc2ccccc12,PARKINSON'S DISEASE,_ZONISAMIDE,NCT04182399,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Department of Neurology, Ain Shams University Hospital, Cairo, Abbasia, Egypt|Ain Shams Univeristy, Cairo, Egypt",4172896,C07D261/20,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,24.0,16.8217006509373,29.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.67,212.226,86.19,3.0,1.0,2.0,19.48,50.3,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0
C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(CCCCC)cc1O,PARKINSON'S DISEASE,_CANNABIDIOL,NCT03582137,Phase 2,Recruiting,All,"40 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Colorado hospital, Aurora, Colorado, United States",10195159,0,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,5.0,46.2268219059939,452.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,6.1,314.469,40.46,2.0,2.0,2.0,38.35,98.53,6.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0
CNC1(c2ccccc2Cl)CCCCC1=O,POST-TRAUMATIC STRESS DISORDER,_KETAMINE,NCT03960658,Phase 1|Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",U.S. Fed,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Minneapolis VA Medical Center, Minneapolis, Minnesota, United States",3966793,C07D307/52,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,13.0,33.0848682724491,249.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,237.725,29.1,2.0,1.0,2.0,24.97,65.55,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,PREMATURE BIRTH,_BETAMETHASONE,NCT02469519,Phase 2|Phase 3,Recruiting,Female,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of South Alabama Medical Center, Mobile, Alabama, United States|Phoenix Perinatal Associates, Phoenix, Arizona, United States|Long Beach Memorial Medical Center, Long Beach, California, United States|Good Samaritan Hospital, San Jose, California, United States|Presbyterian/St Luke's Hospital, Denver, Colorado, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Lousiana State University Health Science, Shreveport, Louisiana, United States|University of Tennessee Medical Center, Knoxville, Tennessee, United States|Harris Methodist Hospital - Fort Worth, Fort Worth, Texas, United States|Swedish Medical Center, Seattle, Washington, United States",6126920.0,5,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.6906096634427,1325.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.81,102.49,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)/C=C/[C@@H](O)C2CC2)C[C@@H](O)C[C@@H]1O,BREAST CANCER,_CALCIPOTRIENE,NCT03596073,Phase 1,Recruiting,All,"45 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Massachusetts General Hospital, Boston, Massachusetts, United States",5763426,C07C5/321,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,34.8590320129776,581.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.63,412.6047,60.69,3.0,3.0,4.0,49.59,125.45,5.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1,ALOPECIA AREATA,_BARICITINIB,NCT03899259,Phase 3,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Total Skin and Beauty Dermatology Center, PC, Birmingham, Alabama, United States|Investigate MD, Scottsdale, Arizona, United States|First OC Dermatology, Fountain Valley, California, United States|Center For Dermatology Clinical Research, Inc., Fremont, California, United States|Quest Dermatology Research, Northridge, California, United States|Kaiser Permanente Hospital, San Francisco, California, United States|New England Research Associates, Bridgeport, Connecticut, United States|Florida Academic Centers Research and Education, LLC, Coral Gables, Florida, United States|New Horizon Research Center, Miami, Florida, United States|ForCare Clinical Research, Tampa, Florida, United States|Qualmedica Research, LLC, Evansville, Indiana, United States|Dawes Fretzin Clinical Research Group, LLC, Indianapolis, Indiana, United States|The South Bend Clinic Center for Research, South Bend, Indiana, United States|Dermatology and Skin Cancer Specialists, Rockville, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Great Lakes Research Group, Inc., Bay City, Michigan, United States|Clinical Research Institute of Michigan, LLC, Chesterfield, Michigan, United States|Hamzavi Dermatology, Fort Gratiot, Michigan, United States|Associated Skin Care Specialists, New Brighton, Minnesota, United States|MediSearch Clinical Trials, Saint Joseph, Missouri, United States|Joseph J. Schwartz, M.D., Troy, New York, United States|University of North Carolina Dermatology and Skin Cancer Cen, Chapel Hill, North Carolina, United States|Dermatology Specialists of Charlotte, Charlotte, North Carolina, United States|Wake Research Associates, Raleigh, North Carolina, United States|Bexley Dermatology Research, Bexley, Ohio, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Dermatologists of Southwest Ohio, Mason, Ohio, United States|Vital Prospects Clinical Research Institute, P.C., Tulsa, Oklahoma, United States|NW Dermatology & Research Center, LLC, Portland, Oregon, United States|Oregon Dermatology and Research Center, Portland, Oregon, United States|Center for Medical Research, LLC, Providence, Rhode Island, United States|Omega Medical Research, Warwick, Rhode Island, United States|Suzanne Bruce and Associates, PA, Houston, Texas, United States|Progressive Clinical Research, San Antonio, Texas, United States|Virginia Clinical Research, Inc., Norfolk, Virginia, United States|Stat Research, Caba, Buenos Aires, Argentina|Centro Medico Privado de Reumatologia, SAN M. DE Tucuman, Tucuman, Argentina|Centro de Investigaciones Metabólicas (CINME), Buenos Aires, Argentina|Fundacion Respirar, Buenos Aires, Argentina|Buenos Aires Skin, Ciudad Autonoma Buenos Aires, Argentina|Instituto de Neumonología y Dermatología, Ciudad Autonoma Buenos Aires, Argentina|Parra Dermatología, Mendoza, Argentina|Woden Dermatology, Phillip, Australian Capital Territory, Australia|Skin & Cancer Foundation Australia, Westmead, New South Wales, Australia|Veracity Clinical Research Pty Ltd, Woolloongabba, Queensland, Australia|Clinical Trials SA Pty Ltd, Adelaide, South Australia, Australia|Skin Health Institute Inc., Carlton, Victoria, Australia|Fremantle Dermatology, Perth, Western Australia, Australia|Sinclair Dermatology, Victoria, Australia|Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|IDERJ - Instituto de Dermatologia e Estética do Brasil, Rio de Janeiro, RJ, Brazil|Faculdade de Ciências Médicas - UNICAMP, Campinas, Sao Paulo, Brazil|Fundação Faculdade de Medicina do ABC, Santo André, Sao Paulo, Brazil|Hospital PUC-CAMPINAS, Campinas, São Paulo, Brazil|Instituto Brasil de Pesquisa Clínica - IBPCLIN, Rio de Janeiro, Brazil|Santa Casa Da Misericórdia De São Paulo, São Paulo, Brazil|Hospital de Servidor Publico Estadual, São Paulo, Brazil|Beijing Chao Yang Hospital, Beijing, Beijing, China|Beijing Friendship Hospital Affiliate of Capital University, Beijing, Beijing, China|Peking University Third Hospital, Beijing, Beijing, China|Dermatology Hospital of Southern Medical University (Guangdong Provincial Dermatology Hospital), Guangzhou, Guangdong, China|Xiangya Hospital Central South University, Changsha, Hunan, China|Jiangsu Province Hospital, Nanjing, Jiangsu, China|Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'An, Shaanxi, China|1st affiliated Hospital of Shanxi Medical University, Tai Yuan, Shan XI, China|HuaShan Hospital Affiliated To Fudan University, Shanghai, Shanghai, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China|Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China|Chinese PLA General Hospital, Beijing, China|Shanghai Dermatology Hospital, Shanghai, China|Tianjin Medical University General Hospital, Tianjin, China|Ha'Emek Medical Center, Afula, Israel|Soroka Medical Center, Beer Sheva, Israel|Rambam Medical Center, Haifa, Israel|Hadassah Medical Center, Jerusalem, Israel|Rabin Medical Center, Petach Tikva, Israel|Sheba Medical Center, Ramat Gan, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan|Hamamatsu University School of Medicine, University Hospital, Hamamatsu, Shizuoka, Japan|Juntendo University Hospital, Bunkyo-ku, Tokyo, Japan|Kyorin University Hospital, Mitaka, Tokyo, Japan|Tokyo Medical Univ. Hospital, Shinjuku-ku, Tokyo, Japan|Yamaguchi University Hospital, Ube, Yamaguchi, Japan|Osaka City University Hospital, Osaka, Japan|Juntendo Tokyo Koto Geriatric Medical Center, Tokyo, Japan|Dankook University Hospital, Cheonan, Chungcheongnam-do, Korea, Republic of|Soonchunhyang University Bucheon Hospital, Bucheon, Gyeonggi-do, Korea, Republic of|Ajou University Hospital, Suwon, Gyeonggi-do, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Kyunghee University Hospital at Gangdong, Seoul, Korea, Republic of|Seoul National University Boramae Medical Center, Seoul, Korea, Republic of|Clinical Research Puerto Rico, San Juan, Puerto Rico|Chung Shan Medical University Hospital, Taichung City (r.o.c), Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan|Chang Gung Memorial Hospital - Taipei, Taipei, Taiwan",8158616,C07D487/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,3.0,37.257438551099604,12.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.08,371.42,120.56,6.0,1.0,4.0,36.72,105.55,4.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
CC(C)(C)CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C,OSTEO ARTHRITIS OF THE KNEES,_TRIAMCINOLONE_HEXACETONIDE,NCT04231318,Phase 3,Recruiting,All,"40 Years to 75 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Tucson Orthopaedic Institute, Tucson, Arizona, United States|Ascension Research LLC, Pinellas Park, Florida, United States",4279900,C07J71/0031,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,67.0,23.8197909608,351.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
CCCCNc1cc(C(=O)O)cc(S(N)(=O)=O)c1Oc1ccccc1,PARKINSON'S DISEASE,_BUMETANIDE,NCT03899324,Phase 2,Recruiting,All,"40 Years to 80 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Chu Nantes, Nantes, France",4110445,C07D233/88,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,9.0,16.296022505595502,672.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.44,364.416,118.72,5.0,3.0,2.0,37.21,95.78,8.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0
CC#CCC(C)[C@H](O)/C=C/[C@@H]1[C@H]2C/C(=C/CCCC(=O)O)C[C@H]2C[C@H]1O,"RESPIRATORY DISTRESS SYNDROME, ADULT",_ILOPROST,NCT03111212,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital Tuebingen, Tuebingen, Germany",EP-1089970-B1,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,57.5289020308425,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.22,360.494,77.76,4.0,3.0,2.0,42.68,105.18,9.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0
C[C@@H](O[C@H]1CC[C@@H]2CN(C3=CC(=O)CC3)C[C@H]2[C@@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,EPIDERMOLYSIS BULLOSA,_SERLOPITANT,NCT03836001,Phase 2,Recruiting,All,"13 Years and older   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Stanford University, Redwood City, California, United States",US-20100209496-A1,4,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,37.0,32.7488,3.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.29,555.5369999999998,29.54,3.0,0.0,5.0,51.54,134.58,7.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0
NC(=O)c1cccnc1,PARKINSON'S DISEASE,_NICOTINAMIDE,NCT03568968,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Arendal Hospital, Arendal, Norway|Haukeland University Hospital, Bergen, Norway|Vestre Viken Hospital, Drammen, Norway|Førde sykehus, Førde, Norway|Haugesund Hospital, Haugesund, Norway|Akershus university hospital, Oslo, Norway|Oslo University Hospital, Oslo, Norway|St. Olavs Hospital, Trondheim, Norway",3931207,C07D207/44,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,24.7397277151481,6368.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.39,122.1246,55.98,2.0,1.0,1.0,11.71,32.98,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,PRURITIS,_FENTANYL,NCT04518618,Not Applicable,Recruiting,Female,21 Years to 30 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","Faculty of Medicine, Tanta, Algharbia, Egypt|Tanta University hospitals, Tanta, Egypt",6169920,A61N1/303,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,58.0,74.7448612907862,622.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.12,336.4705,23.55,2.0,0.0,3.0,40.03,103.48,6.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0
C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5,PRURITIS,_NALOXONE,NCT04518618,Not Applicable,Recruiting,Female,21 Years to 30 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","Faculty of Medicine, Tanta, Algharbia, Egypt|Tanta University hospitals, Tanta, Egypt",6159498,5,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,27.0,27.3681184418571,1213.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.47,327.3743,70.0,5.0,2.0,5.0,33.83,88.72,2.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-],PRETERM PREMATURE RUPTURE OF MEMBRANE,_NIFEDIPINE,NCT03976063,Phase 3,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Trousseau University Hospital, Paris, France",5264446,A61K9/14,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,17.7416374052855,1857.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.49,346.3346,110.45,5.0,1.0,2.0,33.85,92.16,6.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1,PRETERM PREMATURE RUPTURE OF MEMBRANE,_CHLORHEXIDINE,NCT04516226,Not Applicable,Recruiting,Female,18 Years to 50 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Albany Medical Center, Albany, New York, United States",5538353,A45D34/04,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,20.0,10.940676399926,1621.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.71,505.44699999999995,167.58,10.0,10.0,2.0,54.6,181.71,9.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1.O=C(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,PRETERM PREMATURE RUPTURE OF MEMBRANE,_CHLORHEXIDINE_GLUCONATE,NCT04516226,Not Applicable,Recruiting,Female,18 Years to 50 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Albany Medical Center, Albany, New York, United States",4199567,1,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,4.0,15.6389248239183,476.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,JUVENILE IDIOPATHIC ARTHRITIS,_METHOTREXATE,NCT04169828,Not Applicable,Recruiting,All,4 Years to 16 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Calgary / Alberta Children's Hospital, Calgary, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada|BC Children's Hospital, Vancouver, British Columbia, Canada|University of Manitoba/Children's hospital research institute, Winnipeg, Manitoba, Canada|Memorial University/Janeway Childrens Health and Rehabilitation Centre, St. John's, Newfoundland and Labrador, Canada|IWK Health Centre, Halifax, Nova Scotia, Canada|McMaster University/McMaster Children's Hospital, Hamilton, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|Hospital for Sick Children, Toronto, Ontario, Canada|McGill University Health Centre, Montréal, Quebec, Canada|Université de Montréal, Montréal, Quebec, Canada|University of Sherbrooke, Sherbrooke, Quebec, Canada|Royal University Hospital, Saskatoon, Saskatchewan, Canada",6746429,A61M5/2425,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O,JUVENILE IDIOPATHIC ARTHRITIS,_ONDANSETRON,NCT04169828,Not Applicable,Recruiting,All,4 Years to 16 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Calgary / Alberta Children's Hospital, Calgary, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada|BC Children's Hospital, Vancouver, British Columbia, Canada|University of Manitoba/Children's hospital research institute, Winnipeg, Manitoba, Canada|Memorial University/Janeway Childrens Health and Rehabilitation Centre, St. John's, Newfoundland and Labrador, Canada|IWK Health Centre, Halifax, Nova Scotia, Canada|McMaster University/McMaster Children's Hospital, Hamilton, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|Hospital for Sick Children, Toronto, Ontario, Canada|McGill University Health Centre, Montréal, Quebec, Canada|Université de Montréal, Montréal, Quebec, Canada|University of Sherbrooke, Sherbrooke, Quebec, Canada|Royal University Hospital, Saskatoon, Saskatchewan, Canada",5344658,C07D403/06,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,10.0,19.5486560298979,384.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.56,293.363,39.82,2.0,0.0,4.0,33.16,86.78,2.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0
OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O,CHRONIC SHOULDER PAIN,_DEXTROSE,NCT03000205,Not Applicable,Recruiting,All,"20 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Shuang Ho Hospital, New taipei city, Zhonghe Dist, Taiwan|Shuang Ho Hospital, New taipei city, Zhonghe Dist, Taiwan",3964974,C12Q1/54,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,33.380562229203804,1910.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-2.6,180.1559,110.38,6.0,5.0,1.0,16.43,35.92,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0
CN(C)C(=N)NC(=N)N,RHEUMATOID ARTHRITIS|CARDIOVASCULAR DISEASES,_METFORMIN,NCT02246257,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Department of Rheumathology, Frederiksberg and Bispebjerg univeristy Hospital, Frederiksberg, Region Of Copenhagen, Denmark",6288095.0,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,RHEUMATOID ARTHRITIS|CARDIOVASCULAR DISEASES,_SIMVASTATIN,NCT02246257,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Department of Rheumathology, Frederiksberg and Bispebjerg univeristy Hospital, Frederiksberg, Region Of Copenhagen, Denmark",RE42461,C07D205/08 ,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,200.973325940984,1639.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.51,418.5662,72.83,3.0,1.0,3.0,47.88,117.68,7.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,RHEUMATOID ARTHRITIS|CARDIOVASCULAR DISEASES,_LOSARTAN,NCT02246257,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Department of Rheumathology, Frederiksberg and Bispebjerg univeristy Hospital, Frederiksberg, Region Of Copenhagen, Denmark",5210079,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,31.0,15.0803917944927,357.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.5,422.911,92.51,5.0,2.0,4.0,44.86,131.85,8.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0
CC#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C,HAND OSTEOARTHRITIS,_ESTROGEN,NCT04036929,Not Applicable,Recruiting,Female,"40 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","White Horse Medical Practice, Faringdon Medical Centre, Faringdon, Oxfordshire, United Kingdom|Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom|Nuffield Orthopaedic Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom",,,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0
C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,JUVENILE IDIOPATHIC ARTHRITIS,_TOFACITINIB,NCT01500551,Phase 3,Recruiting,All,"2 Years to 18 Years   (Child, Adult)",Industry,Masking: None (Open Label)|Primary Purpose: Treatment,"Phoenix Children's Hospital- Inpatient Pharmacy, Phoenix, Arizona, United States|Phoenix Children's Hospital, Phoenix, Arizona, United States|Arkansas Children's Hospital- Attention: Jill Hernandez, Little Rock, Arkansas, United States|Arkansas Children's Hospital, Little Rock, Arkansas, United States|Loma Linda University Children'S Hospital, Loma Linda, California, United States|Loma Linda University Clinical Trials Center, Loma Linda, California, United States|Loma Linda University Eye Institute, Loma Linda, California, United States|Loma Linda University General Pediatric Clinic - Meridian, Loma Linda, California, United States|Pediatric Speciality Team Centers of LLU Children's Hospital (Rheumatology), Loma Linda, California, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Pediatric Speciality Team Centers of LLU Children's Hospital (Rheumatology), San Bernardino, California, United States|Rady Children's Hospital Center for Pediatric Clinical Research, San Diego, California, United States|Rady Children's Hospital Education and Office Building, San Diego, California, United States|Rady Children's Hospital Research Pharmacy, San Diego, California, United States|Rady Children's Hospital Rheumatology Clinic, San Diego, California, United States|Rady Children's Hospital San Diego, San Diego, California, United States|Connecticut Children's Medical Center Pharmacy, Hartford, Connecticut, United States|Connecticut Children's Medical Center, Hartford, Connecticut, United States|Children's National Medical Center, Washington, District of Columbia, United States|IDS Pharmacy, Washington, District of Columbia, United States|Nicklaus Children's Hospital, Miami, Florida, United States|Johns Hopkins All Children's Hospital, Saint Pertersburg, Florida, United States|All Children's Hospital Speciality Physicians, Saint Petersburg, Florida, United States|Children's Healthcare of Atlanta-Pediatric Research Center, Atlanta, Georgia, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Children's Specialty Services, Atlanta, Georgia, United States|Augusta University Health Pharmacy, Augusta, Georgia, United States|Augusta University, Augusta, Georgia, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Lurie Children's Investigational Drug Pharmacy, Chicago, Illinois, United States|Lurie Rheumatology Offices, Chicago, Illinois, United States|The University of Chicago Medical Center, Chicago, Illinois, United States|IU Health Investigational Drug Services, Indianapolis, Indiana, United States|Riley Hospital for Children at IU Health, Indianapolis, Indiana, United States|Tufts Medical Center - Floating Hospital for Children, Boston, Massachusetts, United States|Explorer Clinic, University of Minnesota Children's Hospital, Minneapolis, Minnesota, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|Pharmacy Department, Bronx, New York, United States|Cohen Children's Medical Center of New York, Lake Success, New York, United States|Cohen Children's Medical Center of New York, New Hyde Park, New York, United States|Columbia University Medical Center-Herbert Irving Pavillion, New York, New York, United States|Pediatric Research, Charlotte, North Carolina, United States|Levine Children's Specialty Center, Charlotte, North Carolina, United States|Atrium Health- Investigational Drug Services, Charlotte, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Legacy Emanuel Medical Center - Inpatient Pharmacy, Portland, Oregon, United States|Randall Children's Hospital at Legacy Emanuel, Portland, Oregon, United States|The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|Dell Children's Medical Group, Dell Children's Medical Center, Austin, Texas, United States|Texas Children's Hospital- Clinical Care Center, Houston, Texas, United States|Texas Children's Hospital- Clinical Research Center, Houston, Texas, United States|Texas Children's Hospital- Investigational Pharmacy, Houston, Texas, United States|Texas Children's Hospital- Main Hospital, Houston, Texas, United States|Texas Children's Hospital/Baylor College of Medicine- Feigin Center, Houston, Texas, United States|Primary Children's Hospital, Salt Lake City, Utah, United States|Seattle Children's Hospital, Seattle, Washington, United States|Instituto CAICI SRL, Rosario, Santa FE, Argentina|Centro Medico Privado de Reumatologia, San Miguel de Tucuman, Tucuman, Argentina|Hospital Britanico de Buenos Aires, Caba, Argentina|The Children's Hospital at Westmead, Westmead, New South Wales, Australia|The Royal Children's Hospital, Parkville, Victoria, Australia|UZ Leuven - Gasthuisberg, Leuven, Belgium|SER - Serviços Especializados em Reumatologia, Salvador, Bahia, Brazil|CMIP - Centro Mineiro de Pesquisa Ltda, Juiz de Fora, Minas Gerais, Brazil|Hospital Pequeno Príncipe/, Curitiba, Parana, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, RIO Grande DO SUL, Brazil|Faculdade de Medicina da UNESP, Botucatu, SAO Paulo, Brazil|Hospital de Clinicas da UNICAMP-Laboratorio de Reumatologia-L06, Campinas, SAO Paulo, Brazil|Hospital de Clinicas da UNICAMP, Campinas, SAO Paulo, Brazil|Instituto de Puericultura e Pediatria Martagao Gesteira (IPPMG), Rio de Janeiro, Brazil|SPDM - Associacao Paulista para o Desenvolvimento da Medicina, Sao Paulo, Brazil|Instituto da Crianca do Hospital das Clinicas da FMUSP, Sao Paulo, Brazil|Alberta Children's Hospital, Calgary, Alberta, Canada|Teck Acute Care Centre, Vancouver, British Columbia, Canada|C & W Health Centre of BC, Vancouver, British Columbia, Canada|British Columbia Children's Hospital, Vancouver, British Columbia, Canada|The Hospital for Sick Children, Toronto, Ontario, Canada|McGill University Health Center, Glen Site, Central Pharmacy, Montreal, Quebec, Canada|McGill University Health Center, Glen Site, Montreal, Quebec, Canada|Bioreuma, Concepcion, Chile|Children's Hospital of Chongqing Medical University, Chongqing, Chongqing, China|Children's Hospital Affiliated to Capital Institute of Pediatrics/Rheumatology Immunology, Beijing, China|Children's Hospital of Fudan University, Shanghai, China|PRI - Pediatric Rheumatology Research Institute GmbH, Bad Bramstedt, Germany|Klinikum Bremen-Mitte, Prof. Hess-Kinderklinik, Bremen, Germany|Hamburger Zentrum fur Kinder und Jugendrheumatologie, Hamburg, Germany|Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany|Rambam Health Care, Haifa, Israel|Meir Medical Center, Kfar Saba, Israel|Chaim Sheba M.C Tel hashomer, Ramat Gan, Israel|Clínica de Investigacion en Reumatologia y Obesidad, S.C., Guadalajara, Jalisco, Mexico|Hospital Universitario ""Dr. Jose Eleuterio Gonzalez"", Monterrey, Nuevo LEON, Mexico|Hospital Central ""Dr. Ignacio Morones Prieto"", San Luis Potosi, Mexico|Unidad de Investigaciones Reumatologicas A.C., San Luis Potosi, Mexico|Centro de Alta Especialidad en Reumatología e Investigación del Potosí, S.C., San Luis Potosí, Mexico|Wojewodzki Szpital Dzieciecy im. J. Brudzinskiego, Bydgoszcz, Poland|Wojewodzki Specjalistyczny Szpital Dzieciecy im. Sw. Ludwika w Krakowie, Krakow, Poland|Klinika Kardiologii i Reumatologii Dzieciecej, Lodz, Poland|Centrum Pediatrii im. Jana Pawla II w Sosnowcu Sp. z o.o., Sosnowiec, Poland|FSBEI HE BSMU MoH RF, Ufa, Republic OF Bashkortostan, Russian Federation|Clinic of FSBEI HE BSMU MoH RF, Ufa, Republic OF Bashkortostan, Russian Federation|FSBEI HE ""Kazan SMU"" MoH RF, Kazan, Russian Federation|SAHI CRCH MoH TR, Kazan, Russian Federation|Federal State Budgetary Scientific Institution, Moscow, Russian Federation|FSAEI HE I.M. Sechenov First MSMU of Minzdrav of Russia (Sechenovskiy University), Moscow, Russian Federation|FSAEI HE I.M. Sechenov First MSMU of Minzdrav of Russia (Sechenovskiy University),, Moscow, Russian Federation|FSAI ""NMRCCH"" of MOH Russia, Moscow, Russian Federation|FSBEI HE ""St. Petersburg State Pediatric Medical University"" of the Ministry of Healthcare, Saint-Petersburg, Russian Federation|FSBEI HE Saratov SMU n.a. V.I.Razumovskiy MoH RF, Saratov, Russian Federation|FSBEI HE Saratov SMU n.a. V.I.Razumovskiy MoH RF, Saratov, Russian Federation|State Budgetary Healthcare Institution of Samara Region ""Tolyatti City Clinical Hospital #5"", Tolyatti, Russian Federation|State Budgetary Healthcare Institution of Sverdlovsk Region, Yekaterinburg, Russian Federation|Narodny ustav reumatickych chorob, Piestany, Slovakia|Panorama Medical Centre, Panorama, Cape Town, South Africa|Emmed Research, Pretoria, Gauteng, South Africa|Enhancing Care Foundation, Durban, Kwa-zulu Natal, South Africa|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario y Politecnico La Fe, Valencia, Spain|Hacettepe University Ihsan Dogramaci Children Hospital, Ankara, Turkey|Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey|Istanbul Medeniyet University Medical Faculty, Istanbul, Turkey|Umraniye Training and Research Hospital, Istanbul, Turkey|Erciyes University Medical Faculty, Kayseri, Turkey|Communal Institution ""Dnipropetrovsk Specialized Clinical Medical Center of Mother and Child n.a., Dnipro, Ukraine|Municipal non-Profit Enterprise, Ivano-Frankivsk, Ukraine|Communal Institution of Lviv Regional Council, Lviv, Ukraine|Vinnytsia Regional Children's Clinical Hospital, Vinnitsya, Ukraine|Birmingham Woman's and Children's NHS Foundation Trust, Birmingham, WEST Midlands, United Kingdom",7301023,C07D487/04,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,1.0,66.1697365448982,52.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.58,312.3696,88.91,5.0,1.0,3.0,32.65,87.8,3.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1,JUVENILE IDIOPATHIC ARTHRITIS,_BARICITINIB,NCT03773978,Phase 3,Recruiting,All,2 Years to 17 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Instituto CAICI SRL, Rosario, Santa Fe, Argentina|Centro Medico Privado de Reumatologia, SAN M. DE Tucuman, Tucuman, Argentina|Hospital General de Niños Dr. Pedro de Elizalde, Buenos Aires, Argentina|The Sydney Children's Hospitals Network, Westmead, New South Wales, Australia|Royal Childrens Hospital Melbourne, Parkville, Victoria, Australia|Perth Children's Hospital, Nedlands, Western Australia, Australia|LKH Bregenz, Bregenz, Vorarlberg, Austria|AKH, Wien, Austria|UCL- Saint Luc, Brussels, Brussels-Capital, Belgium|UZ Gent-Reuma, Gent, East Flanders, Belgium|Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven, Belgium|CMIP - Centro Mineiro de Pesquisa, Juiz de Fora, Minas Gerais, Brazil|Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil|Faculdade de Medicina de Botucatu, Botucatu, Sao Paulo, Brazil|Faculdade de Ciências Médicas - UNICAMP, Campinas, Sao Paulo, Brazil|Universidade Federal de São Paulo - Escola Paulista de Medicina, São Paulo, Brazil|Children's hospital of Nanjing, Nanjing, Jiangsu, China|Children's Hospital of Chongqing Medical University, Chongqing, Tianjin City, China|Capitol Institute of Pediatrics Children'S Hospital, Beijing, China|Beijing Children's hospital, Capital Medical University, Beijing, China|Children's Hospital of Soochow University, Suzhou, China|Centrum detske revmatologie VFN, Klinika detskeho a dorostoveho lekarstvi 1.LFUK a VFN v Praze, Prague, Czechia|Fakultni Nemocnice v Motole, Praha 5, Czechia|Aarhus Universitetshospital, Skejby, Aarhus, Denmark|Paediatric rheumatology Unit, København Ø, Denmark|Hospices Civils de Lyon - Hôpital Femme Mère Enfant, Bron, France|Hôpitaux Universitaires Paris Sud - Hôpital Bicêtre, Le Kremlin Bicetre, France|Centre Hospitalier Universitaire de Nîmes - Hôpital Universitaire Carémeau, Nîmes, France|GH Necker - Enfants Malades, Paris Cedex 15, France|CHU la Miletrie, Poitiers, France|Universitätsklinikum Heidelberg, Heidelberg, Baden-Württemberg, Germany|Universitätsklinikum Tübingen, Tübingen, Baden-Württemberg, Germany|Asklepios Klinik Sankt Augustin, Saint Augustin, Nordrhein-Westfalen, Germany|HELIOS Klinikum Berlin-Buch, Berlin, Germany|Charité Campus Virchow-Klinikum, Berlin, Germany|Schön Klinik Hamburg Eilbek, Hamburg, Germany|Sri Ramachandra MedicaL College & Research Institute, Porur, Chennai, India|Sir Ganga Ram Hospital, New Delhi, Delhi, India|Christian Medical College Vellore, Vellore, Tamil Nadu, India|Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India|Rambam Medical Center, Haifa, Israel|Meir Medical Center, Kfar Saba, Israel|Schneider Children's Medical Center, Petah Tiqva, Israel|Sheba Medical Center, Ramat Gan, Israel|A.O.U. Ospedali Riuniti- Presidio ""G. Salesi"" -Reumatologia Pediatrica, Ancona, Italy|ASST Spedali Civili - Università degli Studi, Brescia, Italy|Ospedale SS. Annunziata, Chieti, Italy|Azienda Ospedaliero Universitaria Meyer, Firenze, Italy|Ospedale Pediatrico Gaslini - Istituto Giannina Gaslini, Genova, Italy|Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico, Milano, Italy|Azienda Ospedaliera Universitaria Federico II, Napoli, Italy|Azienda Ospedaliera - Universitaria Pisana, Pisa, Italy|Ospedale Infantile Burlo Garofolo, Trieste, Italy|Kanazawa University Hospital, Kanazawa, Ishikawa, Japan|Kanagawa Children's Medical Center, Yokohama, Kanagawa, Japan|Yokohama City University Hospital, Yokohama, Kanagawa, Japan|Miyagi Children's Hospital, Sendai, Miyagi, Japan|Osaka Medical College Hospital, Takatsuki, Osaka, Japan|Saitama Children's Medical Center, Saitama-shi, Saitama, Japan|Tokyo Medical And Dental University Medical Hospital, Bunkyō, Tokyo, Japan|St. Lukes International Hospital, Chuo-Ku, Tokyo, Japan|Tokyo Women's Medical University Hospital, Shinjuku-ku, Tokyo, Japan|Kagoshima University Hospital, Kagoshima, Japan|Niigata University Medical & Dental Hospital, Niigata, Japan|Clinstile, S.A. de C.V., Cuauhtemoc, Federal District, Mexico|CREA de Guadalajara, S.C., Guadalajara, Jalisco, Mexico|Hospital Univ. ""Dr. José Eleuterio González"", Monterrey, Nuevo León, Mexico|Investigacion y Biomedicina de Chihuahua, Chihuahua, Mexico|Instituto de Investigaciones Aplicadas a la Neurociencia A.C, Durango, Mexico|Wojewódzki Specjalistyczny Szpital Dziecięcy im. św. Ludwika w Krakowie, Krakow, Poland|CSK, Uniwersyteckie Centrum Pediatrii im.M.Konopnickiej,Klinika Kardiologii i Reumatologii Dzieciecej, Lodz, Poland|Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji, Warszawa, Poland|V.A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation|Morozovsky Children's City Clinical Hospital, Moscow, Russian Federation|First Moscow State Medical University n.a. Sechenov, Moscow, Russian Federation|Scientific Center of Children's Health, Moscow, Russian Federation|Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russian Federation|Hospital Sant Joan de Deu, Barcelona, Cataluna, Spain|Complexo Hospitalario Universitario A Coruña, CHUAC, La Coruña, Spain|Hospital Infantil Universitario Niño Jesús, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario La Fe de Valencia, Valencia, Spain|Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey|Dokuz Eylul University Hospital, Izmir, Turkey|University College Hospital - London, London, Greater London, United Kingdom|Great Ormond Street Hospital For Children NHS Foundation Trust, Bloomsbury, London, United Kingdom|Sheffield Children's Hospital, Sheffield, South Yorkshire, United Kingdom|Bristol Royal Hospital for Children, Bristol, United Kingdom|Alder Hey Children's Hospital, Liverpool, United Kingdom",8158616,C07D487/04,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,3.0,37.257438551099604,12.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.08,371.42,120.56,6.0,1.0,4.0,36.72,105.55,4.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O,KNEE OSTEOARTHRITIS,_GLUCOSAMINE,NCT04470336,Not Applicable,Recruiting,All,"40 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","Dr. Randive's Knee & Spine Clinic, Mumbai, Mahararashtra, India|Kurla Nursing Home, Mumbai, Maharashtra, India|Rainbow Multispeciality hospital and trauma center, Navi Mumbai, Maharashtra, India",4120954,C07H13/08,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,21.0,18.431589971046602,17.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-2.7,179.1711,116.17,6.0,5.0,1.0,16.87,37.58,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0
Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1,MUSCULOSKELETAL PAIN,_ETORICOXIB,NCT04565600,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Guangdong General Hospital, Guangzhou, Guangdong, China",5861419,C07D213/65,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,19.0,18.300170434711106,383.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.7,358.842,59.92,4.0,0.0,3.0,36.42,95.04,3.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0
O=[O+][O-],KNEE OSTEOARTHRITIS,_OZONE,NCT04426721,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Humanitas Clinical and Research Hospital, Rozzano, Milano, Italy",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-0.21,47.997,74.27,3.0,0.0,0.0,2.31,4.24,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0
CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12,JUVENILE IDIOPATHIC ARTHRITIS,_UPADACITINIB,NCT03725007,Phase 1,Recruiting,All,2 Years to 17 Years   (Child),Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ann & Robert H. Lurie Children's Hospital of Chicago /ID# 211162, Chicago, Illinois, United States|University of Louisville /ID# 202896, Louisville, Kentucky, United States|Boston Childrens Hospital /ID# 202993, Boston, Massachusetts, United States|Cincinnati Childrens Hosp Med /ID# 209697, Cincinnati, Ohio, United States|Randall Children's Hospital /ID# 213609, Portland, Oregon, United States|Children's Hospital of Philadelphia /ID# 209617, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC /ID# 202994, Pittsburgh, Pennsylvania, United States|Seattle Children's Hospital /ID# 203003, Seattle, Washington, United States|PRI - Pediatric Rheumatology Research Institute /ID# 205954, Bad Bramstedt, Germany|Helios Klinikum Berlin Buch /ID# 206859, Berlin, Germany|Kinder- & Jugendrheumatologie /ID# 206571, Hamburg, Germany|Asklepios Klinik St. Augustin /ID# 203264, Sankt Augustin, Germany|Semmelweis Egyetem II. Számú Gyermekgyógyászati Klinika /ID# 208970, Budapest VIII, Pest, Hungary|IRCCS Ospedale Pediatrico Bambino Gesù /ID# 203835, Rome, Lazio, Italy|Azienda Ospedaliero Universitaria Meyer /ID# 215576, Florence, Italy|IRCCS Istituto G. Gaslini /ID# 203648, Genoa, Italy|Centro de Reumatologia Pediatrico de Puerto Rico /Id# 204406, Bayamon, Puerto Rico|GCM Medical Group PSC - Hato Rey /ID# 211702, San Juan, Puerto Rico|Mindful Medical Research /ID# 204488, San Juan, Puerto Rico|Hospital Sant Joan de Deu /ID# 203915, Esplugues de Llobregat, Spain|Hospital Infantil Universitario Nino Jesus /ID# 206466, Madrid, Spain|Hospital Univ Ramon y Cajal /ID# 203917, Madrid, Spain|Hospital Universitario La Paz /ID# 203927, Madrid, Spain|Hospital Universitario La Fe /ID# 203914, Valencia, Spain",,,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,53.0,68.53528819893633,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.57,380.375,78.32,3.0,2.0,4.0,36.09,93.03,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0
CC(=O)O,ATOPIC DERMATITIS|ECZEMA,_ACETIC_ACID,NCT03775590,Not Applicable,Recruiting,All,6 Months to 17 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Mayo Clinic, Rochester, Minnesota, United States|HealthPartners, Saint Paul, Minnesota, United States",,,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-0.12,60.052,37.3,2.0,1.0,0.0,5.34,12.64,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0
COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,"HEMATOMA, SUBDURAL, CHRONIC",_CURCUMIN,NCT03845322,Early Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of New Mexico Health Sciences center, Albuquerque, New Mexico, United States",4138212,C09B61/00,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,14.0,17.905911825704802,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.62,368.3799,93.06,6.0,2.0,2.0,38.12,103.81,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0
CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O,POSTOPERATIVE PAIN,_PIROXICAM,NCT04062591,Early Phase 1,Recruiting,All,"16 Years to 25 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Ain Shams U, Cairo, Egypt",4289879,C07D275/06,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,4.0,11.5320643134355,1236.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.2,331.346,99.6,5.0,2.0,3.0,32.27,87.04,2.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
NC[C@H]1CC[C@H](C(=O)O)CC1,"HEMATOMA, SUBDURAL, CHRONIC",_TRANEXAMIC_ACID,NCT03582293,Phase 3,Recruiting,All,"50 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Academic Medical Center, Amsterdam, Netherlands",8273795.0,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,49.4137456621285,532.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.4,157.2102,63.32,3.0,2.0,1.0,17.28,41.9,2.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0
CCCCC[C@H](O)CC[C@@H]1[C@H]2Cc3cccc(OCC(=O)O)c3C[C@H]2C[C@H]1O,DIABETIC FOOT ULCER,_TREPROSTINIL,NCT03654989,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","CHU Grenoble Alpes, Grenoble, France",5153222.0,3,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,2.0,15.770344360253803,26.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,3.53,390.5131,86.99,5.0,3.0,3.0,45.74,108.0,10.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0
CC(C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCCN1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCCN)C(=O)O,REPERFUSION INJURY,_RIP,NCT03068689,Not Applicable,Recruiting,All,"18 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"University Hospital Basel, Clinic of Urology, Basel, Switzerland",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CN(CC(=O)O)C(=N)N,KNEE OSTEOARTHRITIS,_CREATINE,NCT04423432,Not Applicable,Recruiting,All,"40 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Foundation University Institute of Rehabilitation Sciences, Islamabad, Federal, Pakistan",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-1.6,131.1332,90.41,5.0,3.0,0.0,12.17,42.01,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
Cn1c(=O)c2c(ncn2C)n(C)c1=O,SPINAL CORD INJURIES,_CAFFEINE,NCT02323698,Phase 1|Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Spaulding Rehabilitation Hospital, Cambridge, Massachusetts, United States",5972916.0,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,17.0,20.468592784246,2772.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-0.24,194.1906,58.44,3.0,0.0,2.0,18.95,49.83,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0
C[C@@](Cc1ccc(O)c(O)c1)(NN)C(=O)O,SPINAL CORD INJURIES,_CARBIDOPA,NCT04520178,Phase 2|Phase 3,Recruiting,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science","University of Louisville, Kentucky Spinal Cord Injury Research Centre, Louisville, Kentucky, United States",6500867.0,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,25.0,30.0622189367338,800.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.16,226.2292,115.81,6.0,5.0,1.0,21.81,68.77,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,ORAL LICHEN PLANUS,_CLOBETASOL_PROPIONATE,NCT04364555,Phase 2|Phase 3,Recruiting,All,"40 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Oral surgery, Universityhospital of Scania, Lund, Sweden|Oral Surgery and oral medicine, Malmö University, Malmö, Sweden",6106848,A61K8/062,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,20.0,34.9904515493131,799.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.49,466.97,80.67,4.0,1.0,4.0,48.28,119.32,5.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,ORAL LICHEN PLANUS,_CLOBETASOL,NCT04364555,Phase 2|Phase 3,Recruiting,All,"40 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Oral surgery, Universityhospital of Scania, Lund, Sweden|Oral Surgery and oral medicine, Malmö University, Malmö, Sweden",4333927,6,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,23.0,14.8504076059056,513.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.72,410.907,74.6,4.0,2.0,4.0,41.97,105.54,2.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
COc1cc(CNC(=O)CCCC/C=C/C(C)C)ccc1O,SPINAL CORD INJURIES|NEUROPATHIC PAIN,_CAPSAICIN,NCT02441660,Not Applicable,Recruiting,All,"18 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Audie Lee Murphy VA Hospital, San Antonio, Texas, United States",6239180,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,5.0,41.4300088297501,241.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.8,305.4119,58.56,3.0,2.0,1.0,36.32,90.32,9.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0
C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(CCCCC)cc1O,POST TRAUMATIC STRESS DISORDER,_CANNABIDIOL,NCT04197102,Phase 2,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Laboratory for the Study of Anxiety Disorders, University of Texas at Austin, Austin, Texas, United States",10195159,0,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,5.0,46.2268219059939,452.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,6.1,314.469,40.46,2.0,2.0,2.0,38.35,98.53,6.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0
CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O,LATERAL EPICONDYLITIS,_PIROXICAM,NCT04201249,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Hospital de Santa Maria, Lisboa, Portugal",4289879,C07D275/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,4.0,11.5320643134355,1236.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.2,331.346,99.6,5.0,2.0,3.0,32.27,87.04,2.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
CCN(CC)CC(=O)Nc1c(C)cccc1C,LATERAL EPICONDYLITIS,_LIDOCAINE,NCT04201249,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Hospital de Santa Maria, Lisboa, Portugal",5234957.0,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,ACUTE PAIN DUE TO TRAUMA,_KETOROLAC,NCT04133623,Phase 3,Recruiting,All,"8 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Azienda Ospedaliera Santa Maria degli Angeli, Pordenone, Italy|Institute for Maternal and Child Health - IRCCS Burlo Garofolo-, Trieste, Italy|Ospedale Santa Maria della Misericordia, Udine, Italy",5110493.0,A61K9/0048,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,16.0,16.920265303188902,1024.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.66,255.2686,59.3,3.0,1.0,3.0,26.67,70.19,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0
CC(C)Cc1ccc(C(C)C(=O)O)cc1,ACUTE PAIN DUE TO TRAUMA,_IBUPROFEN,NCT04133623,Phase 3,Recruiting,All,"8 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Azienda Ospedaliera Santa Maria degli Angeli, Pordenone, Italy|Institute for Maternal and Child Health - IRCCS Burlo Garofolo-, Trieste, Italy|Ospedale Santa Maria della Misericordia, Udine, Italy",5215755,A61K9/0056,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,17.0,25.4953900490769,3547.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.5,206.2808,37.3,2.0,1.0,1.0,23.76,60.73,4.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
CN(C)CCCN1c2ccccc2CCc2ccccc21,BREAST CANCER,_IMIPRAMINE,NCT03122444,Early Phase 1,Recruiting,All,"18 Years to 71 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mays Cancer Center, UT Health San Antonio, San Antonio, Texas, United States",3961060.0,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,26.0,24.5754532947288,78.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.53,280.4073,6.48,2.0,0.0,3.0,33.39,90.61,4.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0
CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,POST TRAUMATIC STRESS DISORDER,_PREGNENOLONE,NCT03799562,Phase 2,Recruiting,All,"18 Years to 65 Years   (Adult, Older Adult)",U.S. Fed,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Durham VA Medical Center, Durham, NC, Durham, North Carolina, United States",4189400,G01N33/92,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,43.0,30.0950738208176,298.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.06,316.4776,37.3,2.0,1.0,4.0,38.09,93.76,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1,TRAUMATIC BRAIN INJURY,_BUSPIRONE,NCT01821690,Not Applicable,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Indiana University and Rehabilitation Hospital of Indiana, Indianapolis, Indiana, United States",3976776.0,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,38.0,13.3719378221318,357.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.95,385.5031,69.64,6.0,0.0,4.0,44.12,108.89,6.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1,SPINAL CORD INJURIES,_BUSPIRONE,NCT04105114,Early Phase 1,Recruiting,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","Frazier Rehabilitation and Neuroscience Institute, Louisville, Kentucky, United States",3976776.0,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,38.0,13.3719378221318,357.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.95,385.5031,69.64,6.0,0.0,4.0,44.12,108.89,6.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,SPINAL CORD INJURIES,_TESTOSTERONE,NCT02317640,Phase 1|Phase 2,Recruiting,Male,18 Years to 58 Years   (Adult),Other|U.S. Fed,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Kessler Foundation, West Orange, New Jersey, United States",5152997,A61K9/7084,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,SPINAL CORD INJURIES,_TESTOSTERONE_UNDECANOATE,NCT03576001,Phase 2,Recruiting,All,"19 Years to 70 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Brigham and Women's Hospital, Boston, Massachusetts, United States",7718640,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,14.0,74.1863282613606,77.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.74,456.711,43.37,2.0,0.0,4.0,57.8,135.02,11.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0
CCCCCCCCCCC(=O)O,SPINAL CORD INJURIES,_UNDECANOATE,NCT03576001,Phase 2,Recruiting,All,"19 Years to 70 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Brigham and Women's Hospital, Boston, Massachusetts, United States",3932476,C07C231/02,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,10.0,30.3907677775724,567.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
OC(CCN1CCCCC1)(c1ccccc1)C1CC2C=CC1C2,TRAUMATIC BRAIN INJURY,_BIPERIDEN,NCT01048138,Phase 3,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Federal University of São Paulo, Sao Paulo, Brazil",4863738,A61K9/7053,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,17.0,21.421384422678003,236.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.28,311.4611,23.47,2.0,1.0,4.0,36.88,97.02,5.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0
COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1,ACUTE SPINAL CORD INJURY,_GLYBURIDE,NCT02524379,Phase 1|Phase 2,Recruiting,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The Ohio State University, Columbus, Ohio, United States",6303146,6,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,27.105279369186203,439.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,3.78,494.004,113.6,5.0,3.0,3.0,51.75,126.98,7.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC,ATOPIC DERMATITIS,_APREMILAST,NCT04306965,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tufts Medical Center, Department of Dermatology, Boston, Massachusetts, United States",6020358,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,19.0,15.0803917944927,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.86,460.5,119.08,7.0,1.0,3.0,46.71,119.1,8.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
Oc1ccc(/C=C/c2cc(O)cc(O)c2)cc1,KNEE OSTEOARTHRITIS,_RESVERATROL,NCT02905799,Phase 3,Recruiting,All,"40 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","Rehabilitation department , CHU Clermont-Ferrand, Cebazat, France|Rheumatology Department, Saint Antoine Hospital, Paris, France|Rehabilitation Department, Cochin Hospital, Paris, France",5747536,0,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,20.0,19.05583276864,5538.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.57,228.2433,60.69,3.0,3.0,2.0,24.55,67.46,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
O=C(CCN1CCN(c2cccc(C(F)(F)F)c2)CC1)c1cc(O)c(O)c([N+](=O)[O-])c1,PTSD,_BIA,NCT04228133,Not Applicable,Recruiting,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Tel Aviv University, Tel Aviv, Israel",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,3.7,439.3851,109.83,7.0,2.0,3.0,41.6,108.4,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0
N[C@H](CC(=O)O)C(=O)O,BRAIN INJURIES,_D-ASPARTATE,NCT03228524,Early Phase 1,Recruiting,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"IRCCS Neuromed, Pozzilli, Isernia, Italy",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-3.5,133.1027,100.62,5.0,3.0,0.0,11.35,26.53,3.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
CC(=O)Nc1ccc(O)cc1,ANTERIOR CRUCIATE LIGAMENT INJURY,_ACETAMINOPHEN,NCT03818932,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment,"Henry Ford Health System, Detroit, Michigan, United States",5972916.0,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,17.0,20.468592784246,1703.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.51,151.1626,49.33,2.0,2.0,1.0,15.52,42.9,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,ANTERIOR CRUCIATE LIGAMENT INJURY,_CELECOXIB,NCT03818932,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment,"Henry Ford Health System, Detroit, Michigan, United States",5972986.0,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0
NCC1(CC(=O)O)CCCCC1,ANTERIOR CRUCIATE LIGAMENT INJURY,_GABAPENTIN,NCT03818932,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment,"Henry Ford Health System, Detroit, Michigan, United States",6054482,C07C229/28,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,11.0,62.9828127887636,456.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-1.9,171.2368,63.32,3.0,2.0,1.0,18.92,46.33,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21,ANTERIOR CRUCIATE LIGAMENT INJURY,_DIAZEPAM,NCT03818932,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment,"Henry Ford Health System, Detroit, Michigan, United States",5462740,A61M5/24,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,25.4296802809092,2386.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.63,284.74,32.67,2.0,0.0,3.0,29.39,79.81,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
COc1ccc2c3c1O[C@H]1C(=O)CC[C@H]4[C@@H](C2)N(C)CC[C@]314,ANTERIOR CRUCIATE LIGAMENT INJURY,_HYDROCODONE,NCT03818932,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment,"Henry Ford Health System, Detroit, Michigan, United States",6348216,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,34.0,56.346126203823395,1296.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.13,299.3642,38.77,4.0,0.0,5.0,32.05,82.74,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0
CC(=O)Nc1ccc(O)cc1,MUSCULOSKELETAL INJURY,_ACETAMINOPHEN,NCT03767933,Phase 2,Recruiting,All,6 Years to 17 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Alberta Children's Hospital, Calgary, Alberta, Canada|Stollery Children's Hospital Emergency Department, Edmonton, Alberta, Canada|Children's Hospital of Winnipeg, Winnipeg, Manitoba, Canada|Childrens Hospital at London Health Sciences, London, Ontario, Canada|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|CHU Sainte-Justine, Montréal, Quebec, Canada",5972916.0,5,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,17.0,20.468592784246,1703.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.51,151.1626,49.33,2.0,2.0,1.0,15.52,42.9,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
CC(C)Cc1ccc(C(C)C(=O)O)cc1,MUSCULOSKELETAL INJURY,_IBUPROFEN,NCT03767933,Phase 2,Recruiting,All,6 Years to 17 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Alberta Children's Hospital, Calgary, Alberta, Canada|Stollery Children's Hospital Emergency Department, Edmonton, Alberta, Canada|Children's Hospital of Winnipeg, Winnipeg, Manitoba, Canada|Childrens Hospital at London Health Sciences, London, Ontario, Canada|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|CHU Sainte-Justine, Montréal, Quebec, Canada",5215755,A61K9/0056,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,17.0,25.4953900490769,3547.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.5,206.2808,37.3,2.0,1.0,1.0,23.76,60.73,4.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5,MUSCULOSKELETAL INJURY,_HYDROMORPHONE,NCT03767933,Phase 2,Recruiting,All,6 Years to 17 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Alberta Children's Hospital, Calgary, Alberta, Canada|Stollery Children's Hospital Emergency Department, Edmonton, Alberta, Canada|Children's Hospital of Winnipeg, Winnipeg, Manitoba, Canada|Childrens Hospital at London Health Sciences, London, Ontario, Canada|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|CHU Sainte-Justine, Montréal, Quebec, Canada",5968551.0,4,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,52.0,50.7607959095669,1264.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.69,285.3377,49.77,4.0,1.0,5.0,30.02,78.26,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,"OSTEOARTHRITIS, HIP",_ZOLEDRONIC_ACID,NCT04303026,Phase 3,Recruiting,All,"50 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Martina Hansens Hospital, Sandvika, Norway",4939130.0,C07F9/65031,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0
O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCC2CC2)c1,CHRONIC PLAQUE PSORIASIS,_ROFLUMILAST,NCT04286607,Phase 3,Enrolling by invitation,All,"12 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Arcutis Biotherapeutics Clinical Site 203, Scottsdale, Arizona, United States|Arcutis Biotherapeutics Clinical Site 239, Beverly Hills, California, United States|Arcutis Biotherapeutics Clinical Site 127, Encinitas, California, United States|Arcutis Biotherapeutics Clinical Site 225, Encino, California, United States|Arcutis Biotherapeutics Clinical Site 112, Fremont, California, United States|Arcutis Biotherapeutics Clinical Site 120, Irvine, California, United States|Arcutis Biotherapeutics Clinical Site 123, San Diego, California, United States|Arcutis Biotherapeutics Clinical Site 220, San Diego, California, United States|Arcutis Biotherapeutics Clinical Site 136, San Francisco, California, United States|Arcutis Biotherapeutics Clinical Site 208, Santa Monica, California, United States|Arcutis Biotherapeutics Clinical Site 215, Santa Monica, California, United States|Arcutis Biotherapeutics Clinical Site 223, Boynton Beach, Florida, United States|Arcutis Biotherapeutics Clinical Site 237, DeLand, Florida, United States|Arcutis Biotherapeutics Clinical Site 118, Delray Beach, Florida, United States|Arcutis Biotherapeutics Clinical Site 202, Hialeah, Florida, United States|Arcutis Biotherapeutics Clinical Site 228, Largo, Florida, United States|Arcutis Biotherapeutics Clinical Site 131, Miami, Florida, United States|Arcutis Biotherapeutics Clinical Site 201, North Miami Beach, Florida, United States|Arcutis Biotherapeutics Clinical Site 137, Ocala, Florida, United States|Arcutis Biotherapeutics Clinical Site 105, Sanford, Florida, United States|Arcutis Biotherapeutics Clinical Site 209, Sweetwater, Florida, United States|Arcutis Biotherapeutics Clinical Site 114, Plainfield, Illinois, United States|Arcutis Biotherapeutics Clinical Site 102, Rolling Meadows, Illinois, United States|Arcutis Biotherapeutics Clinical Site 214, Indianapolis, Indiana, United States|Arcutis Biotherapeutics Clinical Site 217, Louisville, Kentucky, United States|Arcutis Biotherapeutics Clinical Site 111, Baton Rouge, Louisiana, United States|Arcutis Biotherapeutics Clinical Site 211, Lake Charles, Louisiana, United States|Arcutis Biotherapeutics Clinical Site 213, Metairie, Louisiana, United States|Arcutis Biotherapeutics Clinical Site 224, New Orleans, Louisiana, United States|Arcutis Biotherapeutics Clinical Site 125, Rockville, Maryland, United States|Arcutis Biotherapeutics Clinical Site 138, Rockville, Maryland, United States|Arcutis Biotherapeutics Clinical Site 101, Brighton, Massachusetts, United States|Arcutis Biotherapeutics Clinical Site 116, Clinton Township, Michigan, United States|Arcutis Biotherapeutics Clinical Site 212, Detroit, Michigan, United States|Arcutis Biotherapeutics Clinical Site 216, Fridley, Minnesota, United States|Arcutis Biotherapeutics Clinical Site 227, Saint Joseph, Missouri, United States|Arcutis Biotherapeutics Clinical Site 219, Las Vegas, Nevada, United States|Arcutis Biotherapeutics Clinical Site 231, Las Vegas, Nevada, United States|Arcutis Biotherapeutics Clinical Site 139, Reno, Nevada, United States|Arcutis Biotherapeutics Clinical Site 240, Reno, Nevada, United States|Arcutis Biotherapeutics Clinical Site 236, Portsmouth, New Hampshire, United States|Arcutis Biotherapeutics Clinical Site 129, East Windsor, New Jersey, United States|Arcutis Biotherapeutics Clinical Site 121, New York, New York, United States|Arcutis Biotherapeutics Clinical Site 130, Rochester, New York, United States|Arcutis Biotherapeutics Clinical Site 108, Stony Brook, New York, United States|Arcutis Biotherapeutics Clinical Site 115, High Point, North Carolina, United States|Arcutis Biotherapeutics Clinical Site 124, Fairborn, Ohio, United States|Arcutis Biotherapeutics Clinical Site 222, Oklahoma City, Oklahoma, United States|Arcutis Biotherapeutics Clinical Site 134, Oklahoma City, Oklahoma, United States|Arcutis Biotherapeutics Clinical Site 229, Broomall, Pennsylvania, United States|Arcutis Biotherapeutics Clinical Site 128, Duncansville, Pennsylvania, United States|Arcutis Biotherapeutics Clinical Site 113, Exton, Pennsylvania, United States|Arcutis Biotherapeutics Clinical Site 135, Pittsburgh, Pennsylvania, United States|Arcutis Biotherapeutics Clinical Site 233, Knoxville, Tennessee, United States|Arcutis Biotherapeutics Clinical Site 221, Murfreesboro, Tennessee, United States|Arcutis Biotherapeutics Clinical Site 206, Arlington, Texas, United States|Arcutis Biotherapeutics Clinical Site 104, College Station, Texas, United States|Arcutis Biotherapeutics Clinical Site 119, Dallas, Texas, United States|Arcutis Biotherapeutics Clinical Site 238, Houston, Texas, United States|Arcutis Biotherapeutics Clinical Site 110, San Antonio, Texas, United States|Arcutis Biotherapeutics Clinical Site 117, San Antonio, Texas, United States|Arcutis Biotherapeutics Clinical Site 210, West Jordan, Utah, United States|Arcutis Biotherapeutics Clinical Site 230, Richmond, Virginia, United States|Arcutis Biotherapeutics Clinical Site 132, Calgary, Alberta, Canada|Arcutis Biotherapeutics Clinical Site 207, Surrey, British Columbia, Canada|Arcutis Biotherapeutics Clinical Site 226, Surrey, British Columbia, Canada|Arcutis Biotherapeutics Clinical Site 232, Winnepeg, Manitoba, Canada|Arcutis Biotherapeutics Clinical Site 234, Fredericton, New Brunswick, Canada|Arcutis Biotherapeutics Clinical Site 205, Ajax, Ontario, Canada|Arcutis Biotherapeutics Clinical Site 218, Barrie, Ontario, Canada|Arcutis Biotherapeutics Clinical Site 103, London, Ontario, Canada|Arcutis Biotherapeutics Clinical Site 133, Mississauga, Ontario, Canada|Arcutis Biotherapeutics Clinical Site 140, Ottawa, Ontario, Canada|Arcutis Biotherapeutics Clinical Site 109, Peterborough, Ontario, Canada|Arcutis Biotherapeutics Clinical Site 235, Toronto, Ontario, Canada|Arcutis Biotherapeutics Clinical Site 106, Waterloo, Ontario, Canada|Arcutis Biotherapeutics Clinical Site 204, Windsor, Ontario, Canada|Arcutis Biotherapeutics Clinical Site 107, Montreal, Quebec, Canada|Arcutis Biotherapeutics Clinical Site 126, Québec, Quebec, Canada",5712298,C07C235/56,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,8.0,25.298260744573803,549.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.47,403.207,60.45,4.0,1.0,3.0,35.9,93.92,7.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314,SPINAL CORD INJURIES,_OXYCODONE,NCT03906721,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Spaulding Rehabilitation Hospital, Charlestown, Massachusetts, United States",5508042,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,2.0,10.3492884864165,1114.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.04,315.3636,59.0,5.0,1.0,5.0,32.79,84.04,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0
OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O,FRACTURES,_LACTOSE,NCT02999022,Phase 2,Recruiting,All,18 Years to 55 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",4001198,C13K5/00,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,21.0,12.813404792706196,54.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-3.0,342.2965,189.53,11.0,8.0,2.0,31.32,68.34,4.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0
O=C([O-])[O-].[Li+].[Li+],FRACTURES,_LITHIUM_CARBONATE,NCT02999022,Phase 2,Recruiting,All,18 Years to 55 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",,,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-0.28,73.89,63.19,3.0,0.0,0.0,3.52,31.17,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c5c(nc6cc(C)ccn65)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,PAPULOPUSTULAR ROSACEA,_RIFAXIMIN,NCT03864978,Phase 2,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Ospedali Riuniti di Ancona, Ancona, Italy|Policlinico di Bari, Bari, Italy|Policlinico Sant'Orsola Malpighi, Bologna, Italy|Spedali Civili, Brescia, Italy|Policlinico Vittorio Emanuele, Catania, Italy|Ospedale Policlinico San Martino, Genova, Italy|Ospedale della Misericordia, Grosseto, Italy|Policlinico di Modena, Modena, Italy|Azienda Ospedaliera Universitaria Federico II, Napoli, Italy|Policlinico Universitario A. Gemelli, Roma, Italy|Azienda Ospedaliera Santa Maria, Terni, Italy|A.O.U. Città della Salute e della Scienza, Torino, Italy",6861053,6,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,31.0,66.6625598061561,159.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,4.94,785.8785,198.38,11.0,5.0,6.0,82.26,216.69,3.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0
CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1,HAND ECZEMA,_ALITRETINOIN,NCT03026946,Phase 3,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"University Medical Center Groningen, Groningen, Netherlands",5932622,2,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,2.0,49.8737140393026,1115.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,5.66,300.4351,37.3,2.0,1.0,1.0,35.95,97.79,5.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
N#Cc1ccc(Oc2ccc3c(c2)COB3O)cc1,ALOPECIA AREATA,_CRISABOROLE,NCT04299503,Phase 2,Recruiting,All,"2 Years and older   (Child, Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Tufts Medical Center, Department of Dermatology, Boston, Massachusetts, United States",8168614,6,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,36.0,62.457134643421796,4.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.6,251.05,62.48,3.0,1.0,3.0,25.9,65.6,2.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
C[C@]12COC(=O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,ROTATOR CUFF TEAR,_OXANDROLONE,NCT03091075,Phase 2,Recruiting,All,"40 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Keck School of Medicine of the University of Southern California, Los Angeles, California, United States",6090799,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,60.8801002073964,57.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.36,306.4397,46.53,2.0,1.0,4.0,35.29,84.75,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,SEBORRHEIC DERMATITIS,_KETOCONAZOLE,NCT03688971,Phase 2,Recruiting,All,"18 Years to 100 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Centre for Human Drug Research, Leiden, Netherlands",5456851,A61K8/49,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,14.0,18.103041130208002,2611.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.3,531.431,69.06,6.0,0.0,5.0,54.83,138.07,7.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0
CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)O)c2ccc3ccccc3c21,ABDOMINAL INJURIES,_INDOCYANINE_GREEN,NCT04534816,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Tygerberg Hospital, Cape Town, South Africa",6915154,A61B5/0261,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,11.0,58.7773876260292,7.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.26,753.99,114.99,7.0,2.0,6.0,87.2,231.13,14.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
NCC(=O)CCC(=O)O,GENITAL WARTS,_AMINOLEVULINIC_ACID,NCT03948321,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Shanghai Dermatology Hospital, Shanghai, Shanghai, Jingan, China, China",5422093,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,21.0,23.261257931374306,8.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.8,131.1299,80.39,4.0,2.0,0.0,12.55,30.45,4.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
Cn1nnc(-c2ccc(-c3ccc(N4C[C@H](CO)OC4=O)cc3F)cn2)n1,ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS,_TEDIZOLID,NCT03176134,Phase 3,Recruiting,All,up to 11 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Rady Children's Hospital-San Diego ( Site 0118), San Diego, California, United States|Ann & Robert H. Lurie Children's Hospital of Chicago ( Site 0129), Chicago, Illinois, United States|Children's Hospital of Michigan ( Site 0100), Detroit, Michigan, United States|William Beaumont Hospital ( Site 0108), Royal Oak, Michigan, United States|St. Louis Children's Hospital ( Site 0127), Saint Louis, Missouri, United States|Cook Children's Medical Center ( Site 0124), Fort Worth, Texas, United States|Baylor College of Medicine - Texas Children's Hospital ( Site 0107), Houston, Texas, United States|Children's Hospital of Richmond at VCU ( Site 0123), Richmond, Virginia, United States|Hospital Pequeno Principe ( Site 0276), Curitiba, Parana, Brazil|Inst de Medicina Integral Professor Fernando Figueira- IMIP ( Site 0277), Recife, Pernambuco, Brazil|MHAT Sv. Nikolay Chudotvorets EOOD ( Site 0338), Lom, Montana, Bulgaria|UMHAT Deva Maria ( Site 0333), Burgas, Bulgaria|MHAT City Clinic Sv. Georgi EOOD ( Site 0334), Montana, Bulgaria|MHAT Dr. Stamen Iliev AD ( Site 0339), Montana, Bulgaria|UMHAT Dr. Georgi Stranski EAD ( Site 0330), Pleven, Bulgaria|UMHAT Sv. Georgi ( Site 0332), Plovdiv, Bulgaria|MBAL Medica Ruse EOOD ( Site 0336), Ruse, Bulgaria|UMHAT Kanev AD ( Site 0337), Ruse, Bulgaria|UMHATEM. N.I.Pirogov. EAD ( Site 0331), Sofia, Bulgaria|Haunersches Kinderspital ( Site 0480), München, Bayern, Germany|Clinica Privada ( Site 0551), Guatemala, Guatemala|Hospital Civil de Guadalajara Fray Antonio Alcalde ( Site 0230), Guadalajara, Jalisco, Mexico|Instituto Nacional de Pediatria ( Site 0231), Mexico City, Mexico|Wojewodzki Szpital Obserwacyjno Zakazny ( Site 0429), Bydgoszcz, Dolnośląskie, Poland|Wojewodzki Szpital Specjalistyczny im. dr. Wladyslawa Bieganskiego ( Site 0427), Lodz, Lodzkie, Poland|City Childrens Clinical Emergency Hospital ( Site 0507), Novosibirsk, Novosibirskaya Oblast, Russian Federation|Smolensk Regional Clinical Hospital ( Site 0511), Smolensk, Smolenskaya Oblast, Russian Federation|Emmed Research Incorporating ( Site 0377), Pretoria, Gauteng, South Africa|Setshaba Research Centre ( Site 0378), Pretoria, Gauteng, South Africa|Enhancing Care Foundation-DICRS ( Site 0381), Durban, Kwazulu-Natal, South Africa|Cukurova Uni Tip Fak Cocuk Saglıgı ve Hasta ABD ( Site 0353), Adana, Turkey|Hacettepe Universitesi Tip Fakultesi Hastanesi ( Site 0351), Ankara, Turkey|Osmangazi UTF ( Site 0357), Eskisehir, Turkey|Istanbul Universitesi Istanbul Tip Fakultesi ( Site 0355), Istanbul, Turkey|Sisli Hamide Etfal Egitim ve Arastirma Hastanesi ( Site 0358), Istanbul, Turkey|Ege UTF ( Site 0356), Izmir, Turkey",WO-2005058886-A1,4,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,16.0,32.7488,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.95,370.344,106.26,7.0,1.0,4.0,36.84,115.06,4.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0
